0001645260 true S-1/A 0001645260 2021-01-01 2021-09-30 0001645260 2020-12-31 0001645260 2019-12-31 0001645260 2021-09-30 0001645260 TOMDF:ILSMember 2020-12-31 0001645260 TOMDF:ILSMember 2019-12-31 0001645260 TOMDF:ILSMember 2021-09-30 0001645260 2020-01-01 2020-12-31 0001645260 2019-01-01 2019-12-31 0001645260 2020-01-01 2020-09-30 0001645260 2021-07-01 2021-09-30 0001645260 2020-07-01 2020-09-30 0001645260 us-gaap:CommonStockMember 2018-12-31 0001645260 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001645260 us-gaap:RetainedEarningsMember 2018-12-31 0001645260 2018-12-31 0001645260 us-gaap:CommonStockMember 2019-12-31 0001645260 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001645260 us-gaap:RetainedEarningsMember 2019-12-31 0001645260 us-gaap:CommonStockMember 2020-03-31 0001645260 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001645260 us-gaap:RetainedEarningsMember 2020-03-31 0001645260 2020-03-31 0001645260 us-gaap:CommonStockMember 2020-06-30 0001645260 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001645260 us-gaap:RetainedEarningsMember 2020-06-30 0001645260 2020-06-30 0001645260 us-gaap:CommonStockMember 2020-12-31 0001645260 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001645260 us-gaap:RetainedEarningsMember 2020-12-31 0001645260 us-gaap:CommonStockMember 2021-03-31 0001645260 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001645260 us-gaap:RetainedEarningsMember 2021-03-31 0001645260 2021-03-31 0001645260 us-gaap:CommonStockMember 2021-06-30 0001645260 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001645260 us-gaap:RetainedEarningsMember 2021-06-30 0001645260 2021-06-30 0001645260 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001645260 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001645260 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001645260 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001645260 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001645260 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001645260 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001645260 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001645260 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001645260 2020-01-01 2020-03-31 0001645260 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001645260 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001645260 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001645260 2020-04-01 2020-06-30 0001645260 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001645260 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001645260 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001645260 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001645260 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001645260 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001645260 2021-01-01 2021-03-31 0001645260 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001645260 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001645260 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001645260 2021-04-01 2021-06-30 0001645260 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001645260 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001645260 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001645260 us-gaap:CommonStockMember 2020-09-30 0001645260 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001645260 us-gaap:RetainedEarningsMember 2020-09-30 0001645260 2020-09-30 0001645260 us-gaap:CommonStockMember 2021-09-30 0001645260 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001645260 us-gaap:RetainedEarningsMember 2021-09-30 0001645260 TOMDF:AssignmentofLicenseAgreementMember TOMDF:BreakthroughDiagnosticsIncMember 2019-02-27 0001645260 TOMDF:AssignmentofLicenseAgreementMember TOMDF:BreakthroughDiagnosticsIncMember 2020-07-27 0001645260 TOMDF:PrivatePlacementTransactionsMember 2019-01-01 2019-12-31 0001645260 TOMDF:ConvertibleBridgeLoansTransactionsMember 2019-01-01 2019-12-31 0001645260 TOMDF:PrivatePlacementTransactionsMember 2020-01-01 2020-12-31 0001645260 TOMDF:StraightLoansMember 2020-01-01 2020-12-31 0001645260 TOMDF:CreditLineMember 2020-01-01 2020-12-31 0001645260 TOMDF:ConvertibleBridgeLoansTransactionsMember 2020-01-01 2020-12-31 0001645260 TOMDF:SharePurchaseAgreementMember TOMDF:ProvistaDiagnosticsIncMember us-gaap:PreferredStockMember 2021-04-17 2021-04-19 0001645260 TOMDF:SharePurchaseAgreementMember TOMDF:ProvistaDiagnosticsIncMember TOMDF:OrdinaryStockMember 2021-04-17 2021-04-19 0001645260 TOMDF:ProvistaDiagnosticsIncMember 2021-04-17 2021-04-19 0001645260 TOMDF:SharePurchaseAgreementMember TOMDF:ProvistaDiagnosticsIncMember 2021-04-17 2021-04-19 0001645260 2021-04-19 0001645260 TOMDF:TodosDepositSharesMember 2021-09-30 0001645260 TOMDF:TodosDepositSharesMember 2021-01-01 2021-09-30 0001645260 2021-07-01 2021-07-02 0001645260 2021-07-13 2021-07-15 0001645260 2021-07-02 0001645260 srt:MinimumMember 2021-07-02 0001645260 TOMDF:SharePurchaseAgreementMember 2021-01-01 2021-09-30 0001645260 2021-04-14 2021-04-19 0001645260 TOMDF:ThirdPartyMember 2021-09-30 0001645260 TOMDF:BreakthroughDiagnosticsIncMember 2019-02-27 0001645260 TOMDF:BreakthroughDiagnosticsIncMember 2020-07-28 0001645260 2020-08-01 2020-08-31 0001645260 TOMDF:AntigenCOVIDTestKillerMember 2020-01-01 2020-12-31 0001645260 TOMDF:BioImageryLtdMember 2020-01-01 2020-12-31 0001645260 us-gaap:EquipmentMember srt:MinimumMember 2020-01-01 2020-12-31 0001645260 us-gaap:EquipmentMember srt:MaximumMember 2020-01-01 2020-12-31 0001645260 us-gaap:FurnitureAndFixturesMember srt:MinimumMember 2020-01-01 2020-12-31 0001645260 us-gaap:FurnitureAndFixturesMember srt:MaximumMember 2020-01-01 2020-12-31 0001645260 TOMDF:ComputersMember 2020-01-01 2020-12-31 0001645260 TOMDF:VehicleMember 2020-01-01 2020-12-31 0001645260 TOMDF:JointVentureAgreementMember TOMDF:AmarantusBioscienceHoldingsIncMember 2019-02-26 2019-02-27 0001645260 TOMDF:JointVentureAgreementMember TOMDF:AmarantusBioscienceHoldingsIncMember 2019-02-27 0001645260 TOMDF:JointVentureAgreementMember TOMDF:SubsidiaryAndAmarantusBioscienceHoldingsIncMember 2019-02-27 0001645260 TOMDF:JointVentureAgreementMember 2019-02-26 2019-02-27 0001645260 TOMDF:JointVentureAgreementMember 2019-02-27 0001645260 TOMDF:JointVentureAgreementMember 2019-01-01 2019-12-31 0001645260 TOMDF:JointVentureAgreementMember TOMDF:AmarantusBioscienceHoldingsIncMember 2020-07-24 2020-07-31 0001645260 TOMDF:JointVentureAgreementMember TOMDF:AmarantusBioscienceHoldingsIncMember 2019-12-31 0001645260 TOMDF:JointVentureAgreementMember TOMDF:AmarantusBioscienceHoldingsIncMember 2020-07-15 2020-07-16 0001645260 TOMDF:LicenseAgreementMember 2020-06-11 2020-06-14 0001645260 TOMDF:JointVentureAgreementMember TOMDF:AmarantusBioscienceHoldingsIncMember 2020-01-01 2020-12-31 0001645260 TOMDF:JointVentureAgreementMember TOMDF:AmarantusBioscienceHoldingsIncMember 2020-12-31 0001645260 TOMDF:DistributionAgreementMember 2020-06-11 2020-06-14 0001645260 TOMDF:AntigenCOVIDTestKillerMember 2020-01-01 2020-12-31 0001645260 TOMDF:NLCPharmaLtdMember 2020-07-11 2020-07-12 0001645260 TOMDF:NLCPharmaLtdMember 2020-06-11 2020-06-14 0001645260 TOMDF:NLCPharmaLtdMember 2020-06-14 0001645260 us-gaap:DistributionRightsMember 2020-06-11 2020-06-14 0001645260 us-gaap:DistributionRightsMember 2020-06-13 0001645260 us-gaap:DistributionRightsMember 2020-06-14 0001645260 TOMDF:AntigenCOVIDTestKillerMember 2020-06-11 2020-06-14 0001645260 TOMDF:AntigenCOVIDTestKillerMember 2020-12-31 0001645260 TOMDF:AntigenCOVIDTestKillerMember us-gaap:InProcessResearchAndDevelopmentMember 2020-12-31 0001645260 TOMDF:BioImageryMember 2020-08-31 0001645260 TOMDF:CareGBMember 2020-08-31 0001645260 TOMDF:BioImageryMember TOMDF:RestrictedOrdinarySharesMember 2020-08-30 2020-08-31 0001645260 TOMDF:OrdinarySharesMember 2020-11-01 2020-11-02 0001645260 TOMDF:BioImageryMember 2020-12-31 0001645260 2019-02-27 0001645260 us-gaap:MeasurementInputPriceVolatilityMember 2019-02-27 0001645260 us-gaap:MeasurementInputRiskFreeInterestRateMember 2019-02-27 0001645260 us-gaap:MeasurementInputExpectedDividendRateMember 2019-02-27 0001645260 2019-02-26 2019-02-27 0001645260 TOMDF:CATKMember us-gaap:InProcessResearchAndDevelopmentMember 2020-12-31 0001645260 TOMDF:CATKMember 2020-07-11 2020-07-12 0001645260 TOMDF:SubscriptionAgreementMember currency:SGD srt:MaximumMember 2020-08-14 0001645260 TOMDF:SubscriptionAgreementMember srt:MaximumMember 2020-08-14 0001645260 TOMDF:PathnovaLaboratoriesPTELtdMember 2020-01-01 2020-12-31 0001645260 TOMDF:PathnovaLaboratoriesPTELtdMember 2020-12-31 0001645260 TOMDF:LaboratoryEquipmentAndOthersMember 2020-12-31 0001645260 TOMDF:LaboratoryEquipmentAndOthersMember 2019-12-31 0001645260 TOMDF:ComputersMember 2020-12-31 0001645260 TOMDF:ComputersMember 2019-12-31 0001645260 us-gaap:VehiclesMember 2020-12-31 0001645260 us-gaap:VehiclesMember 2019-12-31 0001645260 TOMDF:FurnitureAndEquipmentMember 2020-12-31 0001645260 TOMDF:FurnitureAndEquipmentMember 2019-12-31 0001645260 us-gaap:RevolvingCreditFacilityMember TOMDF:ToledoAdvisorLLCMember 2020-06-19 0001645260 us-gaap:RevolvingCreditFacilityMember TOMDF:ToledoAdvisorLLCMember 2020-06-18 2020-06-19 0001645260 2020-07-28 0001645260 2020-07-25 2020-07-28 0001645260 2020-08-03 2020-08-04 0001645260 us-gaap:RevolvingCreditFacilityMember 2020-01-01 2020-12-31 0001645260 2020-11-03 2020-11-04 0001645260 srt:MinimumMember 2020-11-03 2020-11-04 0001645260 TOMDF:SecuredConvertibleEquipmentLoanAgreementMember 2020-11-03 2020-11-04 0001645260 TOMDF:SecuredConvertibleEquipmentLoanAgreementMember 2020-01-01 2020-12-31 0001645260 2020-12-22 0001645260 TOMDF:ConvertibleBridgeLoanMember 2020-01-01 2020-12-31 0001645260 TOMDF:ConvertibleBridgeLoanMember 2019-01-01 2019-12-31 0001645260 TOMDF:AssignmentAgreementMember TOMDF:AssigneesMember 2018-11-20 0001645260 TOMDF:AssignmentAgreementMember TOMDF:AssigneesMember 2018-11-19 2018-11-20 0001645260 TOMDF:AssignmentAgreementMember 2019-04-28 2019-04-29 0001645260 TOMDF:LoanConversionAgreementMember 2020-05-10 0001645260 TOMDF:LoanConversionAgreementMember 2020-05-09 2020-05-10 0001645260 TOMDF:LoanAgreementMember 2019-12-31 0001645260 TOMDF:LoanAgreementMember 2018-12-31 0001645260 TOMDF:LoanAgreementMember 2019-01-01 2019-12-31 0001645260 TOMDF:LoanAgreementMember 2020-01-01 2020-12-31 0001645260 TOMDF:LoanAgreementMember 2018-01-01 2019-12-31 0001645260 TOMDF:ThirdPartyMember TOMDF:FirstWarrantMember 2020-01-01 2020-12-31 0001645260 TOMDF:NotesMember 2020-01-01 2020-12-31 0001645260 TOMDF:SecondWarrantMember 2020-01-01 2020-12-31 0001645260 TOMDF:FirstAmendmentOfTwoThousandNinteenAndTwoThousandEighteenLoanAgreementMember 2019-12-02 0001645260 TOMDF:FirstAmendmentOfTwoThousandNinteenAndTwoThousandEighteenLoanAgreementMember srt:MaximumMember 2019-12-02 0001645260 TOMDF:FirstAmendmentOfTwoThousandNinteenAndTwoThousandEighteenLoanAgreementMember 2019-12-01 2019-12-02 0001645260 TOMDF:ConvertibleNoteExtensionAgreementMember 2019-12-10 0001645260 TOMDF:ConvertibleNoteExtensionAgreementMember 2019-12-09 2019-12-10 0001645260 TOMDF:SecondAmendmentOfTwoThousandNinteenAndTwoThousandEighteenLoanAgreementMember 2020-01-08 2020-01-09 0001645260 TOMDF:SecondAmendmentOfTwoThousandNinteenAndTwoThousandEighteenLoanAgreementMember srt:MinimumMember 2020-01-09 0001645260 TOMDF:SecondAmendmentOfTwoThousandNinteenAndTwoThousandEighteenLoanAgreementMember srt:MaximumMember 2020-01-09 0001645260 TOMDF:SecondAmendmentOfTwoThousandNinteenAndTwoThousandEighteenLoanAgreementMember 2020-01-09 0001645260 TOMDF:ConvertibleNoteExtensionAgreementMember 2020-02-19 2020-02-20 0001645260 TOMDF:ConvertibleNoteExtensionAgreementMember 2020-02-20 0001645260 TOMDF:AmendmentNumberTwoOfTwoThousandNinteenAndTwoThousandEighteenLoanAgreementMember 2020-09-01 2020-09-02 0001645260 TOMDF:AmendmentNumberTwoOfTwoThousandNinteenAndTwoThousandEighteenLoanAgreementMember 2020-09-02 0001645260 TOMDF:ConvertibleBridgeLoanMember 2019-12-31 0001645260 TOMDF:ConvertibleBridgeLoanMember 2020-12-31 0001645260 TOMDF:MarchTwoThousandTwentyLoanAgreementsMember 2020-03-31 0001645260 TOMDF:MarchTwoThousandTwentyLoanAgreementsMember 2020-01-01 2020-03-31 0001645260 TOMDF:ConvertibleBridgeLoanMember 2020-04-01 2020-06-30 0001645260 TOMDF:SecuritiesPurchaseAgreementMember 2020-04-23 2020-04-24 0001645260 TOMDF:SecuritiesPurchaseAgreementMember 2020-04-24 0001645260 TOMDF:SecuritiesPurchaseAgreementMember TOMDF:HostLoanInstrumentMember 2020-04-24 0001645260 TOMDF:SecuritiesPurchaseAgreementMember 2020-06-10 2020-06-12 0001645260 TOMDF:SecuritiesPurchaseAgreementMember 2020-06-12 0001645260 TOMDF:SecuritiesPurchaseAgreementMember 2020-06-11 2020-06-12 0001645260 TOMDF:SecuritiesPurchaseAgreementMember TOMDF:HostLoanInstrumentMember 2020-06-11 2020-06-12 0001645260 TOMDF:SecuritiesPurchaseAgreementMember 2020-06-11 2020-06-15 0001645260 TOMDF:SecuritiesPurchaseAgreementMember 2020-06-15 0001645260 TOMDF:SecuritiesPurchaseAgreementMember 2020-01-01 2020-12-31 0001645260 TOMDF:SecuritiesPurchaseAgreementMember TOMDF:TwoPrivateLendersMember 2020-06-29 2020-06-30 0001645260 TOMDF:SecuritiesPurchaseAgreementMember TOMDF:TwoPrivateLendersMember 2020-06-30 0001645260 TOMDF:SecuritiesPurchaseAgreementMember TOMDF:TwoPrivateLendersMember 2020-07-31 0001645260 TOMDF:SecuritiesPurchaseAgreementMember TOMDF:TwoPrivateLendersMember 2020-07-01 2020-07-31 0001645260 TOMDF:SecuritiesPurchaseAgreementMember TOMDF:TwoPrivateLendersMember 2020-01-01 2020-12-31 0001645260 TOMDF:SecuritiesPurchaseAgreementMember TOMDF:TwoPrivateLendersMember 2020-07-26 2020-07-31 0001645260 TOMDF:SecuritiesPurchaseAgreementMember TOMDF:TwoPrivateLendersMember 2019-01-01 2020-12-31 0001645260 TOMDF:JulyTwoThousandTwentyLoanAgreementMember 2020-07-31 0001645260 TOMDF:JulyTwoThousandTwentyLoanAgreementMember 2020-07-26 2020-07-31 0001645260 TOMDF:JulyTwoThousandTwentyLoanAgreementMember 2020-12-31 0001645260 TOMDF:SecuritiesPurchaseAgreementMember 2020-07-26 2020-07-31 0001645260 TOMDF:SecuritiesPurchaseAgreementMember 2020-08-20 2020-08-21 0001645260 TOMDF:SecuritiesPurchaseAgreementMember 2020-08-21 0001645260 2020-08-20 2020-08-21 0001645260 TOMDF:AmendmentToJulyTwoThousandTwentyLoanAgreementMember 2020-11-03 2020-11-04 0001645260 TOMDF:AmendmentToJulyTwoThousandTwentyLoanAgreementMember 2020-11-04 0001645260 TOMDF:SecuredConvertibleEquipmentLoanAgreementMember 2020-12-31 0001645260 TOMDF:SecuredConvertibleEquipmentLoanAgreementMember 2019-12-30 2019-12-31 0001645260 TOMDF:SecuredConvertibleEquipmentLoanAgreementMember 2020-12-30 2020-12-31 0001645260 2017-12-31 0001645260 2019-01-01 2020-12-31 0001645260 2018-01-01 2019-12-31 0001645260 us-gaap:PrivatePlacementMember 2018-01-01 2018-12-31 0001645260 us-gaap:PrivatePlacementMember 2016-01-01 2016-12-31 0001645260 us-gaap:PrivatePlacementMember 2015-01-01 2015-12-31 0001645260 us-gaap:WarrantMember 2018-01-01 2018-12-31 0001645260 us-gaap:WarrantMember 2016-01-01 2016-12-31 0001645260 us-gaap:WarrantMember 2015-01-01 2015-12-31 0001645260 TOMDF:ConvertibleBridgeLoanTransactionsMember us-gaap:PrivatePlacementMember 2019-01-01 2019-12-31 0001645260 TOMDF:ConvertibleBridgeLoanTransactionsMember us-gaap:PrivatePlacementMember 2019-12-31 0001645260 TOMDF:ConvertibleBridgeLoanTransactionsMember us-gaap:PrivatePlacementMember 2020-12-31 0001645260 TOMDF:IssuanceDateOneMember 2019-12-31 0001645260 TOMDF:IssuanceDateOneMember 2020-12-31 0001645260 TOMDF:IssuanceDateOneMember 2020-01-01 2020-12-31 0001645260 TOMDF:IssuanceDateTwoMember 2019-12-31 0001645260 TOMDF:IssuanceDateTwoMember 2020-12-31 0001645260 TOMDF:IssuanceDateTwoMember 2020-01-01 2020-12-31 0001645260 TOMDF:IssuanceDateThreeMember 2019-12-31 0001645260 TOMDF:IssuanceDateThreeMember 2020-12-31 0001645260 TOMDF:IssuanceDateThreeMember 2020-01-01 2020-12-31 0001645260 TOMDF:IssuanceDateFourMember 2019-12-31 0001645260 TOMDF:IssuanceDateFourMember 2020-12-31 0001645260 TOMDF:IssuanceDateFourMember 2020-01-01 2020-12-31 0001645260 us-gaap:WarrantMember 2019-12-31 0001645260 us-gaap:WarrantMember 2020-12-31 0001645260 TOMDF:IssuanceDateOneMember us-gaap:WarrantMember 2020-12-31 0001645260 TOMDF:IssuanceDateTwoMember us-gaap:WarrantMember 2020-12-31 0001645260 TOMDF:IssuanceDateThreeMember us-gaap:WarrantMember 2020-12-31 0001645260 TOMDF:IssuanceDateOneMember us-gaap:WarrantMember 2019-12-31 0001645260 TOMDF:IssuanceDateTwoMember us-gaap:WarrantMember 2019-12-31 0001645260 TOMDF:IssuanceDateThreeMember us-gaap:WarrantMember 2019-12-31 0001645260 TOMDF:IssuanceDateOneMember us-gaap:WarrantMember us-gaap:MeasurementInputExercisePriceMember 2020-12-31 0001645260 TOMDF:IssuanceDateTwoMember us-gaap:WarrantMember us-gaap:MeasurementInputExercisePriceMember 2020-12-31 0001645260 TOMDF:IssuanceDateThreeMember us-gaap:WarrantMember us-gaap:MeasurementInputExercisePriceMember 2020-12-31 0001645260 TOMDF:IssuanceDateOneMember us-gaap:WarrantMember us-gaap:MeasurementInputExercisePriceMember 2019-12-31 0001645260 TOMDF:IssuanceDateTwoMember us-gaap:WarrantMember us-gaap:MeasurementInputExercisePriceMember 2019-12-31 0001645260 TOMDF:IssuanceDateThreeMember us-gaap:WarrantMember us-gaap:MeasurementInputExercisePriceMember 2019-12-31 0001645260 TOMDF:IssuanceDateOneMember us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember 2020-12-31 0001645260 TOMDF:IssuanceDateTwoMember us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember 2020-12-31 0001645260 TOMDF:IssuanceDateThreeMember us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember 2020-12-31 0001645260 TOMDF:IssuanceDateOneMember us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember 2019-12-31 0001645260 TOMDF:IssuanceDateTwoMember us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember 2019-12-31 0001645260 TOMDF:IssuanceDateThreeMember us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember 2019-12-31 0001645260 TOMDF:IssuanceDateOneMember us-gaap:WarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-12-31 0001645260 TOMDF:IssuanceDateTwoMember us-gaap:WarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-12-31 0001645260 TOMDF:IssuanceDateThreeMember us-gaap:WarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-12-31 0001645260 TOMDF:IssuanceDateOneMember us-gaap:WarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2019-12-31 0001645260 TOMDF:IssuanceDateTwoMember us-gaap:WarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2019-12-31 0001645260 TOMDF:IssuanceDateThreeMember us-gaap:WarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2019-12-31 0001645260 TOMDF:IssuanceDateOneMember us-gaap:WarrantMember us-gaap:MeasurementInputExpectedDividendRateMember 2020-12-31 0001645260 TOMDF:IssuanceDateTwoMember us-gaap:WarrantMember us-gaap:MeasurementInputExpectedDividendRateMember 2020-12-31 0001645260 TOMDF:IssuanceDateThreeMember us-gaap:WarrantMember us-gaap:MeasurementInputExpectedDividendRateMember 2020-12-31 0001645260 TOMDF:IssuanceDateOneMember us-gaap:WarrantMember us-gaap:MeasurementInputExpectedDividendRateMember 2019-12-31 0001645260 TOMDF:IssuanceDateTwoMember us-gaap:WarrantMember us-gaap:MeasurementInputExpectedDividendRateMember 2019-12-31 0001645260 TOMDF:IssuanceDateThreeMember us-gaap:WarrantMember us-gaap:MeasurementInputExpectedDividendRateMember 2019-12-31 0001645260 TOMDF:IssuanceDateOneMember us-gaap:WarrantMember 2020-01-01 2020-12-31 0001645260 TOMDF:IssuanceDateTwoMember us-gaap:WarrantMember 2020-01-01 2020-12-31 0001645260 TOMDF:IssuanceDateThreeMember us-gaap:WarrantMember 2020-01-01 2020-12-31 0001645260 TOMDF:IssuanceDateOneMember us-gaap:WarrantMember 2019-01-01 2019-12-31 0001645260 TOMDF:IssuanceDateTwoMember us-gaap:WarrantMember 2019-01-01 2019-12-31 0001645260 TOMDF:IssuanceDateThreeMember us-gaap:WarrantMember 2019-01-01 2019-12-31 0001645260 TOMDF:ClosingDateMember us-gaap:WarrantMember srt:MinimumMember 2020-12-31 0001645260 TOMDF:ClosingDateMember us-gaap:WarrantMember srt:MaximumMember 2020-12-31 0001645260 TOMDF:ClosingDateMember us-gaap:WarrantMember us-gaap:MeasurementInputExercisePriceMember srt:MinimumMember 2020-12-31 0001645260 TOMDF:ClosingDateMember us-gaap:WarrantMember us-gaap:MeasurementInputExercisePriceMember srt:MaximumMember 2020-12-31 0001645260 us-gaap:WarrantMember us-gaap:MeasurementInputExercisePriceMember 2019-12-31 0001645260 us-gaap:WarrantMember us-gaap:MeasurementInputExercisePriceMember 2020-12-31 0001645260 TOMDF:ClosingDateMember us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember 2020-12-31 0001645260 TOMDF:ClosingDateMember us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember srt:MaximumMember 2020-12-31 0001645260 us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember 2019-12-31 0001645260 us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember srt:MaximumMember 2019-12-31 0001645260 us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember 2020-12-31 0001645260 us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember srt:MaximumMember 2020-12-31 0001645260 TOMDF:ClosingDateMember us-gaap:WarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2020-12-31 0001645260 TOMDF:ClosingDateMember us-gaap:WarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2020-12-31 0001645260 us-gaap:WarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2019-12-31 0001645260 us-gaap:WarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2019-12-31 0001645260 us-gaap:WarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2020-12-31 0001645260 us-gaap:WarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2020-12-31 0001645260 TOMDF:ClosingDateMember us-gaap:WarrantMember us-gaap:MeasurementInputExpectedDividendRateMember 2020-12-31 0001645260 us-gaap:WarrantMember us-gaap:MeasurementInputExpectedDividendRateMember 2019-12-31 0001645260 us-gaap:WarrantMember us-gaap:MeasurementInputExpectedDividendRateMember 2020-12-31 0001645260 TOMDF:ClosingDateMember us-gaap:WarrantMember 2020-01-01 2020-12-31 0001645260 us-gaap:WarrantMember srt:MinimumMember 2019-01-01 2019-12-31 0001645260 us-gaap:WarrantMember srt:MaximumMember 2019-01-01 2019-12-31 0001645260 us-gaap:WarrantMember srt:MinimumMember 2020-01-01 2020-12-31 0001645260 us-gaap:WarrantMember srt:MaximumMember 2020-01-01 2020-12-31 0001645260 TOMDF:ClosingDateMember us-gaap:WarrantMember 2020-12-31 0001645260 TOMDF:SeriesTwoThousandAndFifteenMember 2018-12-31 0001645260 TOMDF:SeriesTwoThousandAndSixteenMember 2018-12-31 0001645260 TOMDF:SeriesTwoThousandAndEighteenMember 2018-12-31 0001645260 TOMDF:TwoThousandNineteenWarrantsMember 2018-12-31 0001645260 TOMDF:PlacementAgentWarrantMember 2018-12-31 0001645260 TOMDF:SeriesTwoThousandAndFifteenMember 2019-01-01 2019-12-31 0001645260 TOMDF:SeriesTwoThousandAndSixteenMember 2019-01-01 2019-12-31 0001645260 TOMDF:SeriesTwoThousandAndEighteenMember 2019-01-01 2019-12-31 0001645260 TOMDF:TwoThousandNineteenWarrantsMember 2019-01-01 2019-12-31 0001645260 TOMDF:PlacementAgentWarrantMember 2019-01-01 2019-12-31 0001645260 TOMDF:SeriesTwoThousandAndFifteenMember 2019-12-31 0001645260 TOMDF:SeriesTwoThousandAndSixteenMember 2019-12-31 0001645260 TOMDF:SeriesTwoThousandAndEighteenMember 2019-12-31 0001645260 TOMDF:TwoThousandNineteenWarrantsMember 2019-12-31 0001645260 TOMDF:PlacementAgentWarrantMember 2019-12-31 0001645260 TOMDF:FirstWarrantMember 2019-12-31 0001645260 TOMDF:SeriesTwoThousandAndFifteenMember 2020-01-01 2020-12-31 0001645260 TOMDF:SeriesTwoThousandAndSixteenMember 2020-01-01 2020-12-31 0001645260 TOMDF:SeriesTwoThousandAndEighteenMember 2020-01-01 2020-12-31 0001645260 TOMDF:FirstWarrantMember 2020-01-01 2020-12-31 0001645260 TOMDF:PlacementAgentWarrantMember 2020-01-01 2020-12-31 0001645260 TOMDF:SeriesTwoThousandAndFifteenMember 2020-12-31 0001645260 TOMDF:SeriesTwoThousandAndSixteenMember 2020-12-31 0001645260 TOMDF:SeriesTwoThousandAndEighteenMember 2020-12-31 0001645260 TOMDF:FirstWarrantMember 2020-12-31 0001645260 TOMDF:PlacementAgentWarrantMember 2020-12-31 0001645260 us-gaap:WarrantMember TOMDF:PlacementAgentMember 2020-12-31 0001645260 TOMDF:ConvertibleBridgeLoanMember us-gaap:MeasurementInputSharePriceMember TOMDF:ClosingDateMember srt:MinimumMember 2020-12-31 0001645260 TOMDF:ConvertibleBridgeLoanMember us-gaap:MeasurementInputSharePriceMember TOMDF:ClosingDateMember srt:MaximumMember 2020-12-31 0001645260 TOMDF:ConvertibleBridgeLoanMember us-gaap:MeasurementInputSharePriceMember 2020-12-31 0001645260 TOMDF:ConvertibleBridgeLoanMember us-gaap:MeasurementInputPriceVolatilityMember TOMDF:ClosingDateMember srt:MinimumMember 2020-12-31 0001645260 TOMDF:ConvertibleBridgeLoanMember us-gaap:MeasurementInputPriceVolatilityMember TOMDF:ClosingDateMember srt:MaximumMember 2020-12-31 0001645260 TOMDF:ConvertibleBridgeLoanMember us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember 2020-12-31 0001645260 TOMDF:ConvertibleBridgeLoanMember us-gaap:MeasurementInputPriceVolatilityMember srt:MaximumMember 2020-12-31 0001645260 TOMDF:ConvertibleBridgeLoanMember us-gaap:MeasurementInputRiskFreeInterestRateMember TOMDF:ClosingDateMember srt:MinimumMember 2020-12-31 0001645260 TOMDF:ConvertibleBridgeLoanMember us-gaap:MeasurementInputRiskFreeInterestRateMember TOMDF:ClosingDateMember srt:MaximumMember 2020-12-31 0001645260 TOMDF:ConvertibleBridgeLoanMember us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2020-12-31 0001645260 TOMDF:ConvertibleBridgeLoanMember us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2020-12-31 0001645260 TOMDF:CareGBPlusLtdMember 2018-12-19 2018-12-20 0001645260 TOMDF:OrotPlusLtdMember TOMDF:DistributionAgreementMember TOMDF:NISMember 2019-03-28 0001645260 TOMDF:OrotPlusLtdMember TOMDF:DistributionAgreementMember 2019-03-26 2019-03-28 0001645260 TOMDF:OrotPlusLtdMember TOMDF:DistributionAgreementMember 2019-03-28 0001645260 TOMDF:OrotPlusLtdMember TOMDF:DistributionAgreementMember 2019-08-31 2019-09-01 0001645260 TOMDF:OrotPlusLtdMember TOMDF:DistributionAgreementMember 2019-10-09 2019-10-10 0001645260 TOMDF:OrotPlusLtdMember TOMDF:DistributionAgreementMember 2019-03-27 2019-03-28 0001645260 TOMDF:OrotPlusLtdMember 2019-01-01 2019-12-31 0001645260 TOMDF:OrotPlusLtdMember 2020-01-08 2020-01-13 0001645260 TOMDF:OrionCapitalAdvisorsLLCMember TOMDF:BusinessDevelopmentAgreementMember 2019-05-15 2019-05-16 0001645260 TOMDF:OrionCapitalAdvisorsLLCMember TOMDF:BusinessDevelopmentAgreementMember TOMDF:ILSMember 2019-05-16 0001645260 TOMDF:OrionCapitalAdvisorsLLCMember TOMDF:BusinessDevelopmentAgreementMember us-gaap:GeneralAndAdministrativeExpenseMember 2019-05-15 2019-05-16 0001645260 TOMDF:OrionCapitalAdvisorsLLCMember TOMDF:BusinessDevelopmentAgreementMember 2019-05-16 0001645260 TOMDF:BusinessDevelopmentAgreementMember TOMDF:OrionCapitalAdvisorsLLCMember us-gaap:RestrictedStockMember 2020-02-09 2020-02-10 0001645260 TOMDF:BusinessDevelopmentAgreementMember TOMDF:OrionCapitalAdvisorsLLCMember TOMDF:NISMember 2020-02-10 0001645260 TOMDF:BusinessDevelopmentAgreementMember TOMDF:OrionCapitalAdvisorsLLCMember us-gaap:RestrictedStockMember 2020-02-10 0001645260 us-gaap:SubsequentEventMember TOMDF:BusinessDevelopmentAgreementMember TOMDF:OrionCapitalAdvisorsLLCMember 2021-01-29 2021-02-01 0001645260 TOMDF:CTOConsultingAgreementMember TOMDF:MrUdiZeligMember TOMDF:ILSMember 2019-11-23 2019-11-24 0001645260 TOMDF:CTOConsultingAgreementMember 2020-01-01 2020-12-31 0001645260 TOMDF:CTOConsultingAgreementMember 2019-01-01 2019-12-31 0001645260 TOMDF:CTOConsultingAgreementMember TOMDF:NISMember 2020-12-31 0001645260 TOMDF:BusinessDevelopmentAgreementMember TOMDF:SteeltownConsultingGroupLLCMember 2019-03-27 2019-03-28 0001645260 TOMDF:BusinessDevelopmentAgreementMember TOMDF:SteeltownConsultingGroupLLCMember TOMDF:ILSMember 2019-03-28 0001645260 us-gaap:ResearchAndDevelopmentArrangementMember TOMDF:SteeltownConsultingGroupLLCMember 2019-01-01 2019-12-31 0001645260 us-gaap:ResearchAndDevelopmentArrangementMember TOMDF:SteeltownConsultingGroupLLCMember TOMDF:ILSMember 2019-12-31 0001645260 us-gaap:ResearchAndDevelopmentArrangementMember TOMDF:SteeltownConsultingGroupLLCMember 2019-12-31 0001645260 TOMDF:BusinessDevelopmentAgreementMember TOMDF:SteeltownConsultingGroupLLCMember us-gaap:RestrictedStockMember 2019-03-27 2019-03-28 0001645260 TOMDF:AlAndJMediaIncMember TOMDF:MediaAdvertisingAgreementMember 2019-01-01 2019-12-31 0001645260 TOMDF:AlAndJMediaIncMember TOMDF:MediaAdvertisingAgreementMember TOMDF:ILSMember 2019-12-31 0001645260 TOMDF:AlAndJMediaIncMember TOMDF:MediaAdvertisingAgreementMember 2019-12-31 0001645260 TOMDF:MediaAdvertisingAgreementMember TOMDF:AlAndJMediaIncMember 2020-06-04 2020-06-05 0001645260 TOMDF:MediaAdvertisingAgreementMember TOMDF:AlAndJMediaIncMember us-gaap:SellingAndMarketingExpenseMember 2020-01-01 2020-12-31 0001645260 TOMDF:MediaAdvertisingAgreementMember TOMDF:AlAndJMediaIncMember us-gaap:SellingAndMarketingExpenseMember TOMDF:NISMember 2020-12-31 0001645260 TOMDF:MediaAdvertisingAgreementMember TOMDF:AlAndJMediaIncMember us-gaap:SubsequentEventMember 2021-03-14 2021-03-15 0001645260 TOMDF:FirstChoiceInternationalCompanyIncMember TOMDF:ConsultingAgreementMember 2019-09-23 2019-09-24 0001645260 TOMDF:FirstChoiceInternationalCompanyIncMember us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-12-31 0001645260 TOMDF:FirstChoiceInternationalCompanyIncMember us-gaap:GeneralAndAdministrativeExpenseMember TOMDF:ILSMember 2019-12-31 0001645260 TOMDF:FirstChoiceInternationalCompanyIncMember us-gaap:GeneralAndAdministrativeExpenseMember 2019-12-31 0001645260 TOMDF:FirstChoiceInternationalCompanyIncMember TOMDF:PerformanceMilestonesMember 2019-01-01 2019-12-31 0001645260 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-12-31 0001645260 us-gaap:GeneralAndAdministrativeExpenseMember 2019-12-31 0001645260 TOMDF:FirstChoiceInternationalCompanyIncMember TOMDF:ConsultingAgreementMember us-gaap:CommonStockMember 2020-02-05 2020-02-06 0001645260 TOMDF:FirstChoiceInternationalCompanyIncMember TOMDF:ConsultingAgreementMember 2020-02-06 0001645260 TOMDF:PRandMediaServiceProviderAgreementMember TOMDF:FinancialBuzzMediaNetworksLLCMember 2019-11-18 2019-12-02 0001645260 TOMDF:PRandMediaServiceProviderAgreementMember TOMDF:FinancialBuzzMediaNetworksLLCMember TOMDF:ILSMember 2019-12-02 0001645260 TOMDF:PRandMediaServiceProviderAgreementMember TOMDF:FinancialBuzzMediaNetworksLLCMember 2019-12-02 0001645260 TOMDF:PRandMediaServiceProviderAgreementMember TOMDF:FinancialBuzzMediaNetworksLLCMember 2020-06-07 2020-06-08 0001645260 TOMDF:PRandMediaServiceProviderAgreementMember TOMDF:FinancialBuzzMediaNetworksLLCMember TOMDF:ILSMember 2020-06-08 0001645260 TOMDF:PRandMediaServiceProviderAgreementMember TOMDF:FinancialBuzzMediaNetworksLLCMember 2020-06-08 0001645260 TOMDF:FinancialBuzzMediaNetworksLLCMember 2020-01-01 2020-12-31 0001645260 TOMDF:FinancialBuzzMediaNetworksLLCMember 2020-12-31 0001645260 TOMDF:FinancialBuzzMediaNetworksLLCMember 2020-05-26 2020-05-27 0001645260 us-gaap:SubsequentEventMember TOMDF:FinancialBuzzMediaNetworksLLCMember 2021-01-30 2021-02-01 0001645260 TOMDF:DistributionAgreementMember TOMDF:ThreeDBiomedicineScienceAndTechnologyCoLimitedMember 2020-03-12 2020-03-13 0001645260 TOMDF:ConsultingAgreementMember TOMDF:ProvistaDiagnosticsIncMember 2020-03-29 2020-04-02 0001645260 TOMDF:ConsultingAgreementMember 2020-01-01 2020-12-31 0001645260 TOMDF:ConsultingAgreementMember TOMDF:AndrewBlumenthalMember 2020-05-23 0001645260 TOMDF:ConsultingAgreementMember TOMDF:AndrewBlumenthalMember 2020-05-22 2020-05-23 0001645260 TOMDF:ConsultingAgreementMember TOMDF:AndrewBlumenthalMember TOMDF:ILSMember 2020-05-23 0001645260 TOMDF:ConsultingAgreementMember TOMDF:AndrewBlumenthalMember 2020-01-01 2020-12-31 0001645260 TOMDF:ConsultingAgreementMember TOMDF:AndrewBlumenthalMember 2020-12-31 0001645260 TOMDF:ConsultingAgreementMember TOMDF:SinghGlobalLLCMember 2020-05-23 0001645260 TOMDF:ConsultingAgreementMember TOMDF:SinghGlobalLLCMember 2020-05-22 2020-05-23 0001645260 TOMDF:ConsultingAgreementMember TOMDF:SinghGlobalLLCMember TOMDF:ILSMember 2020-05-23 0001645260 TOMDF:ConsultingAgreementMember TOMDF:SinghGlobalLLCMember 2020-01-01 2020-12-31 0001645260 TOMDF:MediaAdvertisingAgreementMember TOMDF:AlAndJMediaIncMember us-gaap:SellingAndMarketingExpenseMember 2020-12-31 0001645260 TOMDF:ConsultingAgreementMember TOMDF:PriyankaMisraMember 2020-06-22 0001645260 TOMDF:ConsultingAgreementMember TOMDF:PriyankaMisraMember 2020-06-21 2020-06-22 0001645260 TOMDF:ConsultingAgreementMember TOMDF:PriyankaMisraMember TOMDF:ILSMember 2020-06-22 0001645260 TOMDF:ConsultingAgreementMember TOMDF:PriyankaMisraMember 2020-01-01 2020-12-31 0001645260 TOMDF:ConsultingAgreementMember TOMDF:PriyankaMisraMember 2020-05-22 2020-05-23 0001645260 TOMDF:ConsultingAgreementMember TOMDF:PriyankaMisraMember us-gaap:SellingAndMarketingExpenseMember 2020-01-01 2020-12-31 0001645260 TOMDF:ConsultingAgreementMember TOMDF:PriyankaMisraMember us-gaap:SellingAndMarketingExpenseMember 2020-12-31 0001645260 TOMDF:ConsultingAgreementMember TOMDF:CNCapitalLLCMember 2020-06-23 0001645260 TOMDF:ConsultingAgreementMember TOMDF:CNCapitalLLCMember 2020-06-21 2020-06-23 0001645260 TOMDF:ConsultingAgreementMember TOMDF:CNCapitalLLCMember TOMDF:ILSMember 2020-06-23 0001645260 TOMDF:ConsultingAgreementMember TOMDF:CNCapitalLLCMember us-gaap:SellingAndMarketingExpenseMember 2020-01-01 2020-12-31 0001645260 TOMDF:ConsultingAgreementMember TOMDF:CNCapitalLLCMember us-gaap:SellingAndMarketingExpenseMember 2020-12-31 0001645260 us-gaap:SubsequentEventMember TOMDF:ConsultingAgreementMember TOMDF:CNCapitalLLCMember 2021-02-16 2021-02-17 0001645260 TOMDF:ConsultingAgreementMember TOMDF:LeomicsAssociatesMember 2020-07-22 2020-07-23 0001645260 TOMDF:ConsultingAgreementMember TOMDF:LeomicsAssociatesMember 2020-07-21 2020-07-23 0001645260 TOMDF:ConsultingAgreementMember TOMDF:LeomicsAssociatesMember TOMDF:GeneralAndAdministrativeMember 2020-01-01 2020-12-31 0001645260 TOMDF:ConsultingAgreementMember TOMDF:LeomicsAssociatesMember 2020-12-31 0001645260 TOMDF:ConsultingAgreementMember TOMDF:ExpansionMedicalLLCMember 2020-08-24 2020-08-25 0001645260 TOMDF:ConsultingAgreementMember TOMDF:ExpansionMedicalLLCMember srt:MinimumMember 2020-08-24 2020-08-25 0001645260 TOMDF:ConsultingAgreementMember TOMDF:ExpansionMedicalLLCMember srt:MaximumMember 2020-08-24 2020-08-25 0001645260 TOMDF:ConsultingAgreementMember TOMDF:ExpansionMedicalLLCMember us-gaap:SellingAndMarketingExpenseMember 2020-01-01 2020-12-31 0001645260 TOMDF:ConsultingAgreementMember TOMDF:AIDGenomicsMember 2020-01-01 2020-12-31 0001645260 TOMDF:ConsultingAgreementMember TOMDF:AIDGenomicsMember 2020-09-14 2020-09-15 0001645260 TOMDF:ASIberIsraelLtdMember TOMDF:EngagementAgreementMember 2020-02-11 0001645260 TOMDF:ASIberIsraelLtdMember 2020-02-11 0001645260 TOMDF:ASIberIsraelLtdMember 2020-02-09 2020-02-11 0001645260 TOMDF:DawsonJamesSecuritiesMember 2020-04-05 2020-04-06 0001645260 TOMDF:DawsonJamesSecuritiesMember 2020-04-06 0001645260 TOMDF:DawsonJamesSecuritiesMember TOMDF:InvestorsMember 2020-04-06 0001645260 TOMDF:DawsonJamesSecuritiesMember us-gaap:WarrantMember 2020-04-06 0001645260 TOMDF:DawsonJamesSecuritiesMember us-gaap:WarrantMember 2020-04-05 2020-04-06 0001645260 TOMDF:ZegalAndRossCapitalLLCMember 2020-06-11 2020-06-15 0001645260 TOMDF:ZegalAndRossCapitalLLCMember TOMDF:VestedMember 2020-06-11 2020-06-15 0001645260 TOMDF:ZegalAndRossCapitalLLCMember TOMDF:NonVestedMember 2020-06-11 2020-06-15 0001645260 TOMDF:ZegalAndRossCapitalLLCMember 2020-01-01 2020-12-31 0001645260 TOMDF:ZegalAndRossCapitalLLCMember 2020-12-31 0001645260 TOMDF:BuckmanAndReidIncMember TOMDF:EquityTransactionMember 2020-10-06 0001645260 TOMDF:BuckmanAndReidIncMember TOMDF:EquityTransactionMember us-gaap:RestrictedStockMember 2020-10-06 0001645260 TOMDF:BuckmanAndReidIncMember TOMDF:DebtTransactionMember 2020-10-06 0001645260 TOMDF:BuckmanAndReidIncMember TOMDF:CommercialAgreementMember 2020-10-06 0001645260 TOMDF:BuckmanAndReidIncMember 2020-01-01 2020-12-31 0001645260 TOMDF:BuckmanAndReidIncMember 2020-10-18 2020-10-19 0001645260 TOMDF:BuckmanAndReidIncMember 2020-12-31 0001645260 TOMDF:AslanoPrivateLimitedMember TOMDF:ProspectiveBusinessMember 2020-10-07 0001645260 TOMDF:AslanoPrivateLimitedMember TOMDF:PotentialStockSwapInvestorMember 2020-10-07 0001645260 TOMDF:AslanoPrivateLimitedMember 2020-10-05 2020-10-07 0001645260 TOMDF:MarkZegalMember 2020-11-04 0001645260 TOMDF:YeshivatOrotHateshuvaLtdMember 2020-11-04 0001645260 TOMDF:BGNegevTechnologiesandApplicationsLtdandMorResearchApplicationsLtdMember TOMDF:LicenseAgreementMember 2010-04-22 0001645260 TOMDF:BGNegevTechnologiesandApplicationsLtdandMorResearchApplicationsLtdMember TOMDF:LicenseAgreementMember 2019-12-31 0001645260 TOMDF:BGNegevTechnologiesandApplicationsLtdandMorResearchApplicationsLtdMember TOMDF:LicenseAgreementMember 2020-01-01 2020-12-31 0001645260 TOMDF:BGNegevTechnologiesandApplicationsLtdandMorResearchApplicationsLtdMember TOMDF:LicenseAgreementMember 2020-05-19 2020-05-20 0001645260 TOMDF:BGNegevTechnologiesandApplicationsLtdandMorResearchApplicationsLtdMember TOMDF:LicenseAgreementMember 2020-12-31 0001645260 TOMDF:UniversityOfLeipzigMember TOMDF:LicenseAgreementMember 2018-11-06 2018-11-07 0001645260 TOMDF:UniversityOfLeipzigMember TOMDF:LicenseAgreementMember 2018-11-07 0001645260 TOMDF:UniversityOfLeipzigMember TOMDF:LicenseAgreementMember TOMDF:UponSaleOfLicensedProductMember 2018-11-07 0001645260 TOMDF:UniversityOfLeipzigMember TOMDF:LicenseAgreementMember TOMDF:FDAApprovalMember 2018-11-07 0001645260 TOMDF:UniversityOfLeipzigMember TOMDF:LicenseAgreementMember TOMDF:UpoReachingFiveMillionNetSalesMember 2018-11-07 0001645260 TOMDF:UniversityOfLeipzigMember TOMDF:LicenseAgreementMember TOMDF:AfterSevenYearsMember 2018-11-07 0001645260 TOMDF:UniversityOfLeipzigMember TOMDF:LicenseAgreementMember 2020-01-01 2020-12-31 0001645260 TOMDF:CareGBPlusLtdMember TOMDF:LeaseAgreementMember TOMDF:ILSMember 2020-11-24 2020-11-25 0001645260 TOMDF:CareGBPlusLtdMember TOMDF:LeaseAgreementMember 2020-11-25 0001645260 TOMDF:EmploymentAgreementMember TOMDF:DrWeeYueChewMember 2017-03-15 2017-03-16 0001645260 TOMDF:EmploymentAgreementMember TOMDF:DrWeeYueChewMember TOMDF:SGDMember 2017-03-15 2017-03-16 0001645260 TOMDF:CompensationPackagesForOfficersAndMembersMember srt:ChiefExecutiveOfficerMember 2020-07-26 2020-07-30 0001645260 TOMDF:CompensationPackagesForOfficersAndMembersMember srt:ChiefExecutiveOfficerMember 2020-07-26 2020-07-29 0001645260 TOMDF:CompensationPackagesForOfficersAndMembersMember srt:ChiefExecutiveOfficerMember srt:MinimumMember 2020-07-26 2020-07-29 0001645260 TOMDF:CompensationPackagesForOfficersAndMembersMember srt:ChiefExecutiveOfficerMember srt:MaximumMember 2020-07-26 2020-07-29 0001645260 TOMDF:CompensationPackagesForOfficersAndMembersMember srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockUnitsRSUMember 2020-07-26 2020-07-29 0001645260 TOMDF:CompensationPackagesForOfficersAndMembersMember TOMDF:GeneralAndAdministrativeMember srt:ChiefExecutiveOfficerMember 2020-01-01 2020-12-31 0001645260 TOMDF:CompensationPackagesForOfficersAndMembersMember srt:ChiefFinancialOfficerMember 2020-07-26 2020-07-30 0001645260 TOMDF:CompensationPackagesForCheifExecutiveOfficersAndMembersMember srt:ChiefFinancialOfficerMember 2020-07-26 2020-07-29 0001645260 TOMDF:CompensationPackagesForOfficersAndMembersMember srt:ChiefFinancialOfficerMember 2020-07-26 2020-07-29 0001645260 TOMDF:CompensationPackagesForOfficersAndMembersMember srt:ChiefFinancialOfficerMember srt:MinimumMember 2020-07-26 2020-07-29 0001645260 TOMDF:CompensationPackagesForOfficersAndMembersMember srt:MaximumMember srt:ChiefFinancialOfficerMember 2020-07-26 2020-07-29 0001645260 TOMDF:CompensationPackagesForOfficersAndMembersMember srt:ChiefFinancialOfficerMember us-gaap:RestrictedStockUnitsRSUMember 2020-07-26 2020-07-29 0001645260 TOMDF:CompensationPackagesForOfficersAndMembersMember TOMDF:GeneralAndAdministrativeMember srt:ChiefFinancialOfficerMember 2020-01-01 2020-12-31 0001645260 TOMDF:CompensationPackagesForOfficersAndMembersMember srt:BoardOfDirectorsChairmanMember 2020-07-26 2020-07-30 0001645260 TOMDF:CompensationPackagesForOfficersAndMembersMember srt:BoardOfDirectorsChairmanMember us-gaap:RestrictedStockUnitsRSUMember 2020-07-26 2020-07-30 0001645260 TOMDF:CompensationPackagesForOfficersAndMembersMember TOMDF:GeneralAndAdministrativeMember srt:BoardOfDirectorsChairmanMember 2020-01-01 2020-12-31 0001645260 TOMDF:CharitablePledgeAgreementMember 2020-01-01 2020-12-31 0001645260 TOMDF:CharitablePledgeAgreementMember 2020-12-31 0001645260 TOMDF:CollaborationAgreementMember 2020-01-01 2020-12-31 0001645260 TOMDF:CollaborationAgreementMember 2020-12-31 0001645260 TOMDF:CollaborationAgreementMember TOMDF:CompensationStructureOfTheCollaborationMember 2020-01-01 2020-12-31 0001645260 TOMDF:CollaborationAgreementMember 2020-10-01 2020-10-31 0001645260 TOMDF:OptionAgreementMember 2020-01-01 2020-12-31 0001645260 TOMDF:OptionAgreementMember 2020-09-29 2020-09-30 0001645260 TOMDF:OptionAgreementMember TOMDF:NISMember 2020-09-30 0001645260 TOMDF:OptionAgreementMember us-gaap:CallOptionMember TOMDF:StrategicInvestmentHoldingsLLCAscendaBioSciencesLLCAndProvistaDiagnosticsIncMember 2020-01-01 2020-01-31 0001645260 TOMDF:OptionAgreementMember us-gaap:CallOptionMember TOMDF:StrategicInvestmentHoldingsLLCAscendaBioSciencesLLCAndProvistaDiagnosticsIncMember 2020-04-01 2020-04-30 0001645260 TOMDF:OptionAgreementMember us-gaap:CallOptionMember TOMDF:StrategicInvestmentHoldingsLLCAscendaBioSciencesLLCAndProvistaDiagnosticsIncMember 2020-07-01 2020-07-31 0001645260 TOMDF:DistributionAgreementMember srt:MinimumMember 2020-12-31 0001645260 2012-01-01 2013-12-31 0001645260 2016-01-01 2016-12-31 0001645260 2016-12-31 0001645260 TOMDF:StrategicGlobalResearchAndDevelopmentIncMember 2020-02-12 2020-02-13 0001645260 TOMDF:StrategicGlobalResearchAndDevelopmentIncMember TOMDF:ClaimPaidOverTimePerMonthMember 2020-04-07 2020-04-08 0001645260 TOMDF:StrategicGlobalResearchAndDevelopmentIncMember 2020-04-07 2020-04-08 0001645260 TOMDF:StrategicGlobalResearchAndDevelopmentIncMember 2020-08-10 2020-08-11 0001645260 TOMDF:OrotPlusLtdMember TOMDF:ILSMember 2020-01-01 2020-12-31 0001645260 TOMDF:OrotPlusLtdMember 2020-01-01 2020-12-31 0001645260 TOMDF:OrotPlusLtdMember 2020-12-31 0001645260 TOMDF:ConsultingAgreementMember TOMDF:ExpansionMedicalLLCMember 2020-01-01 2020-12-31 0001645260 TOMDF:LeukemiaRelatedProductsMember 2020-12-31 0001645260 TOMDF:OtherProductMember 2020-12-31 0001645260 TOMDF:HoldersMember 2018-05-31 0001645260 TOMDF:ConsultantMember 2018-08-14 2018-08-15 0001645260 TOMDF:ConsultantMember TOMDF:ILSMember 2018-08-15 0001645260 TOMDF:PurchaseAgreementMember us-gaap:InvestorMember 2018-11-17 2018-11-18 0001645260 TOMDF:PurchaseAgreementMember us-gaap:InvestorMember TOMDF:ILSMember 2018-11-18 0001645260 TOMDF:PurchaseAgreementMember us-gaap:InvestorMember 2018-11-18 0001645260 TOMDF:PurchaseAgreementMember us-gaap:InvestorMember 2019-01-01 2019-12-31 0001645260 TOMDF:PurchaseAgreementMember us-gaap:InvestorMember TOMDF:ILSMember 2019-12-31 0001645260 TOMDF:PurchaseAgreementMember us-gaap:InvestorMember 2019-12-31 0001645260 srt:ChiefExecutiveOfficerMember 2019-04-13 2019-04-14 0001645260 srt:ChiefExecutiveOfficerMember TOMDF:ILSMember 2019-04-14 0001645260 TOMDF:GeneralAndAdministrativeMember 2019-04-13 2019-04-14 0001645260 TOMDF:GeneralAndAdministrativeMember 2019-04-14 0001645260 TOMDF:InvestorRelationsAgreementMember TOMDF:MDMWorldwideSolutionIncMember 2018-06-20 2018-06-21 0001645260 TOMDF:MDMWorldwideSolutionIncMember 2019-07-16 2019-07-17 0001645260 TOMDF:MDMWorldwideSolutionIncMember 2019-07-17 0001645260 TOMDF:MDMWorldwideSolutionIncMember 2019-01-01 2019-12-31 0001645260 TOMDF:MDMWorldwideSolutionIncMember TOMDF:ILSMember 2019-12-31 0001645260 us-gaap:ServiceAgreementsMember 2019-01-01 2019-12-31 0001645260 us-gaap:ServiceAgreementsMember TOMDF:ILSMember 2019-12-31 0001645260 TOMDF:MarketingExpensesMember 2019-01-01 2019-12-31 0001645260 TOMDF:GeneralAndAdministrativeMember 2019-01-01 2019-12-31 0001645260 us-gaap:ServiceAgreementsMember 2019-12-31 0001645260 TOMDF:SubscriptionAgreementsMember us-gaap:InvestorMember 2020-03-30 2020-03-31 0001645260 TOMDF:SubscriptionAgreementsMember us-gaap:InvestorMember 2020-03-31 0001645260 TOMDF:SubscriptionAgreementsMember us-gaap:InvestorMember 2020-01-01 2020-12-31 0001645260 TOMDF:ExchangeAgreementMember TOMDF:MDMWorldwideSolutionIncMember 2020-04-12 2020-04-13 0001645260 TOMDF:ExchangeAgreementMember TOMDF:MDMWorldwideSolutionIncMember 2020-04-13 0001645260 TOMDF:ExchangeAgreementMember TOMDF:MDMWorldwideSolutionIncMember 2020-05-14 0001645260 TOMDF:SettlementAgreementMember TOMDF:SRKKronengoldLawOfficeMember 2020-12-07 2020-12-08 0001645260 TOMDF:SettlementAgreementMember TOMDF:SRKKronengoldLawOfficeMember 2020-12-08 0001645260 us-gaap:ServiceAgreementsMember 2020-01-01 2020-12-31 0001645260 us-gaap:ServiceAgreementsMember TOMDF:NISMember 2020-12-31 0001645260 us-gaap:ServiceAgreementsMember us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0001645260 us-gaap:ServiceAgreementsMember us-gaap:SellingAndMarketingExpenseMember 2020-01-01 2020-12-31 0001645260 us-gaap:ServiceAgreementsMember us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-12-31 0001645260 us-gaap:ServiceAgreementsMember 2020-12-31 0001645260 TOMDF:PurchaseAgreementMember TOMDF:LincolnParkCapitalFundLLCMember 2020-08-03 2020-08-04 0001645260 TOMDF:RegistrationRightsAgreementMember TOMDF:LincolnParkCapitalFundLLCMember 2020-08-03 2020-08-04 0001645260 TOMDF:PurchaseAgreementMember TOMDF:LincolnParkCapitalFundLLCMember TOMDF:NISMember 2020-08-04 0001645260 TOMDF:RegistrationRightsAgreementMember TOMDF:LincolnParkCapitalFundLLCMember TOMDF:NISMember 2020-08-04 0001645260 TOMDF:PurchaseAgreementMember TOMDF:LincolnParkCapitalFundLLCMember 2020-01-01 2020-12-31 0001645260 TOMDF:RegistrationRightsAgreementMember TOMDF:LincolnParkCapitalFundLLCMember 2020-08-04 0001645260 TOMDF:PurchaseAgreementMember TOMDF:LincolnParkCapitalFundLLCMember 2020-08-10 2020-08-11 0001645260 TOMDF:PurchaseAgreementOneMember TOMDF:LincolnParkCapitalFundLLCMember 2020-08-10 2020-08-11 0001645260 TOMDF:PurchaseAgreementOneMember TOMDF:LincolnParkCapitalFundLLCMember 2020-12-31 0001645260 TOMDF:PurchaseAgreementOneMember TOMDF:LincolnParkCapitalFundLLCMember 2020-01-01 2020-12-31 0001645260 TOMDF:PurchaseAgreementOneMember TOMDF:LincolnParkCapitalFundLLCMember TOMDF:WarrantsExercisedMember 2020-12-30 2020-12-31 0001645260 TOMDF:RedeemablePreferredSharesMember 2021-07-26 0001645260 2021-07-26 0001645260 2021-07-25 2021-07-26 0001645260 TOMDF:SubscriptionAgreementsMember us-gaap:InvestorMember 2020-03-01 2020-03-31 0001645260 TOMDF:SubscriptionAgreementsMember us-gaap:InvestorMember 2021-01-01 2021-03-31 0001645260 TOMDF:SubscriptionAgreementsMember us-gaap:InvestorMember 2020-12-31 0001645260 TOMDF:SubscriptionAgreementsMember us-gaap:InvestorMember 2021-03-31 0001645260 TOMDF:PurchaseAgreementMember TOMDF:LincolnParkCapitalFundLLCMember 2020-08-04 0001645260 TOMDF:PurchaseAgreementMember TOMDF:LincolnParkCapitalFundLLCMember TOMDF:OrdinarySharesMember 2020-08-03 2020-08-04 0001645260 TOMDF:PurchaseAgreementOneMember TOMDF:LincolnParkCapitalFundLLCMember 2021-01-01 2021-09-30 0001645260 TOMDF:PurchaseAgreementOneMember TOMDF:LincolnParkCapitalFundLLCMember 2021-09-30 0001645260 TOMDF:OrdinarySharesMember 2021-09-30 0001645260 TOMDF:OrdinarySharesMember 2021-01-01 2021-09-30 0001645260 TOMDF:OrdinarySharesMember TOMDF:NISMember 2021-09-30 0001645260 TOMDF:SecuredConvertibleEquipmentLoanAgreementMember 2021-01-01 2021-09-30 0001645260 TOMDF:SecuredConvertibleEquipmentLoanAgreementMember TOMDF:NISMember 2021-09-30 0001645260 TOMDF:SeveralServiceAgreementsMember 2021-01-01 2021-09-30 0001645260 TOMDF:SeveralServiceAgreementsMember TOMDF:NISMember 2021-09-30 0001645260 TOMDF:SeveralServiceAgreementsMember us-gaap:SellingAndMarketingExpenseMember 2021-01-01 2021-09-30 0001645260 TOMDF:SeveralServiceAgreementsMember us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-09-30 0001645260 TOMDF:TwoThousandFifteenIsraeliShareOptionPlanMember srt:MaximumMember 2016-01-10 2016-01-11 0001645260 TOMDF:EmployeesDirectorsAndNonEmployeesMember 2020-01-01 2020-12-31 0001645260 TOMDF:EmployeesDirectorsAndNonEmployeesMember TOMDF:OrdinarySharesMember 2020-01-01 2020-12-31 0001645260 TOMDF:EmployeesDirectorsAndNonEmployeesMember 2019-01-01 2019-12-31 0001645260 TOMDF:EmployeesDirectorsAndNonEmployeesMember TOMDF:OrdinarySharesMember 2019-01-01 2019-12-31 0001645260 TOMDF:TwoOfficersMember us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-09-30 0001645260 srt:ChiefFinancialOfficerMember us-gaap:DeferredBonusMember 2021-03-09 2021-03-10 0001645260 2020-03-24 2020-03-25 0001645260 TOMDF:PerformanceMilestoneMember 2020-03-24 2020-03-25 0001645260 TOMDF:TwoOfficersMember 2020-07-26 2020-07-29 0001645260 TOMDF:TwoOfficersMember 2020-07-29 0001645260 TOMDF:TwoOfficersMember us-gaap:GeneralAndAdministrativeExpenseMember 2020-07-26 2020-07-29 0001645260 TOMDF:PublicOfferingMember us-gaap:RestrictedStockMember 2020-07-25 2020-07-29 0001645260 TOMDF:TwoOfficersMember us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-12-31 0001645260 us-gaap:RestrictedStockMember 2020-07-26 2020-07-29 0001645260 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-12-31 0001645260 us-gaap:MeasurementInputExpectedDividendRateMember 2020-07-29 0001645260 us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-07-29 0001645260 TOMDF:MeasurementInputRateVolatilityMember 2020-07-29 0001645260 TOMDF:PublicOfferingMember us-gaap:RestrictedStockMember 2020-07-26 2020-07-29 0001645260 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-09-30 0001645260 srt:ChiefExecutiveOfficerMember 2021-03-09 2021-03-10 0001645260 srt:ChiefExecutiveOfficerMember TOMDF:OneTimeBonusMember 2021-03-09 2021-03-10 0001645260 srt:ChiefExecutiveOfficerMember us-gaap:DeferredBonusMember 2021-03-09 2021-03-10 0001645260 srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockMember 2021-03-09 2021-03-10 0001645260 srt:ChiefFinancialOfficerMember 2021-03-09 2021-03-10 0001645260 srt:ChiefFinancialOfficerMember TOMDF:OneTimeBonusMember 2021-03-09 2021-03-10 0001645260 srt:ChiefFinancialOfficerMember us-gaap:RestrictedStockMember 2021-03-09 2021-03-10 0001645260 srt:DirectorMember 2021-03-09 2021-03-10 0001645260 srt:BoardOfDirectorsChairmanMember 2021-03-09 2021-03-10 0001645260 TOMDF:SalariesAndRelatedExpensesMember 2020-01-01 2020-12-31 0001645260 TOMDF:SalariesAndRelatedExpensesMember 2019-01-01 2019-12-31 0001645260 TOMDF:StockBasedCompensationMember 2020-01-01 2020-12-31 0001645260 TOMDF:StockBasedCompensationMember 2019-01-01 2019-12-31 0001645260 TOMDF:ProfessionalFeesMember 2020-01-01 2020-12-31 0001645260 TOMDF:ProfessionalFeesMember 2019-01-01 2019-12-31 0001645260 TOMDF:IPRandDAcquiredAsPartofAssetAcquisitionMember 2020-01-01 2020-12-31 0001645260 TOMDF:ImpairmentOfIntangibleIprAndDMember 2019-01-01 2019-12-31 0001645260 TOMDF:LaboratoryAndMaterialsMember 2020-01-01 2020-12-31 0001645260 TOMDF:LaboratoryAndMaterialsMember 2019-01-01 2019-12-31 0001645260 TOMDF:PatentExpensesMember 2020-01-01 2020-12-31 0001645260 TOMDF:PatentExpensesMember 2019-01-01 2019-12-31 0001645260 TOMDF:RentAndMaintenanceMember 2020-01-01 2020-12-31 0001645260 TOMDF:RentAndMaintenanceMember 2019-01-01 2019-12-31 0001645260 TOMDF:LiabilityForMinimumRoyaltyExpensesMember 2020-01-01 2020-12-31 0001645260 TOMDF:LiabilityForMinimumRoyaltyExpensesMember 2019-01-01 2019-12-31 0001645260 TOMDF:DepreciationMember 2020-01-01 2020-12-31 0001645260 TOMDF:DepreciationMember 2019-01-01 2019-12-31 0001645260 TOMDF:InsuranceAndOtherExpensesMember 2020-01-01 2020-12-31 0001645260 TOMDF:InsuranceAndOtherExpensesMember 2019-01-01 2019-12-31 0001645260 TOMDF:CommunicationAndInvestorRelationsMember 2020-01-01 2020-12-31 0001645260 TOMDF:CommunicationAndInvestorRelationsMember 2019-01-01 2019-12-31 0001645260 country:IL 2020-01-01 2020-12-31 0001645260 country:IL 2020-12-31 0001645260 country:US 2020-01-01 2020-12-31 0001645260 country:US 2020-12-31 0001645260 TOMDF:BreastCancerTestMember 2020-01-01 2020-12-31 0001645260 TOMDF:AlzheimerMember 2020-01-01 2020-12-31 0001645260 TOMDF:COVIDNineteenTestingMember 2020-01-01 2020-12-31 0001645260 TOMDF:BreastCancerTestMember 2020-12-31 0001645260 TOMDF:AlzheimerMember 2020-12-31 0001645260 TOMDF:COVIDNineteenTestingMember 2020-12-31 0001645260 TOMDF:BreastCancerTestMember 2021-01-01 2021-09-30 0001645260 TOMDF:AlzheimerMember 2021-01-01 2021-09-30 0001645260 TOMDF:COVIDNineteenTestingMember 2021-01-01 2021-09-30 0001645260 TOMDF:BreastCancerTestMember 2021-09-30 0001645260 TOMDF:AlzheimerMember 2021-09-30 0001645260 TOMDF:COVIDNineteenTestingMember 2021-09-30 0001645260 country:IL 2019-01-01 2019-12-31 0001645260 country:US 2019-01-01 2019-12-31 0001645260 country:IL 2021-01-01 2021-09-30 0001645260 country:IL 2021-07-01 2021-09-30 0001645260 country:IL 2020-01-01 2020-09-30 0001645260 country:IL 2020-07-01 2020-09-30 0001645260 country:US 2021-01-01 2021-09-30 0001645260 country:US 2021-07-01 2021-09-30 0001645260 country:US 2020-01-01 2020-09-30 0001645260 country:US 2020-07-01 2020-09-30 0001645260 country:IL 2019-12-31 0001645260 country:US 2019-12-31 0001645260 country:IL 2021-09-30 0001645260 country:US 2021-09-30 0001645260 TOMDF:OneCustomerMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2020-01-01 2020-12-31 0001645260 TOMDF:OneCustomerMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2021-01-01 2021-09-30 0001645260 us-gaap:SubsequentEventMember TOMDF:SecuritiesPurchaseAgreementMember TOMDF:YozmaGlobalGenomicFund1Member 2021-01-22 0001645260 us-gaap:SubsequentEventMember TOMDF:SecuritiesPurchaseAgreementMember TOMDF:YozmaGlobalGenomicFund1Member 2021-01-21 2021-01-22 0001645260 us-gaap:SubsequentEventMember TOMDF:SecuritiesPurchaseAgreementMember TOMDF:YozmaGlobalGenomicFund1Member srt:MaximumMember 2021-01-21 2021-01-22 0001645260 us-gaap:SubsequentEventMember TOMDF:SecuritiesPurchaseAgreementMember TOMDF:YozmaGlobalGenomicFund1Member us-gaap:WarrantMember 2021-01-22 0001645260 us-gaap:SubsequentEventMember TOMDF:SecuritiesPurchaseAgreementMember TOMDF:YozmaGlobalGenomicFund1Member TOMDF:PurchaserMember 2021-04-09 0001645260 us-gaap:SubsequentEventMember TOMDF:SecuritiesPurchaseAgreementMember TOMDF:YozmaGlobalGenomicFund1Member TOMDF:PurchaserMember 2021-04-07 2021-04-09 0001645260 us-gaap:SubsequentEventMember TOMDF:SecuritiesPurchaseAgreementMember TOMDF:YozmaGlobalGenomicFund1Member TOMDF:PurchaserMember srt:MaximumMember 2021-04-07 2021-04-09 0001645260 us-gaap:SubsequentEventMember TOMDF:SecuritiesPurchaseAgreementMember TOMDF:YozmaGlobalGenomicFund1Member us-gaap:WarrantMember TOMDF:PurchaserMember 2021-04-09 0001645260 us-gaap:SubsequentEventMember TOMDF:SecuritiesPurchaseAgreementMember TOMDF:YozmaGlobalGenomicFund1Member 2021-01-02 0001645260 us-gaap:SubsequentEventMember TOMDF:SecuritiesPurchaseAgreementMember TOMDF:YozmaGlobalGenomicFund1Member 2020-12-29 2021-01-02 0001645260 TOMDF:SettlementAgreementsMember TOMDF:IntegratedHealthLLCMember srt:ScenarioForecastMember 2021-02-09 2022-01-11 0001645260 us-gaap:SubsequentEventMember TOMDF:SettlementAgreementsMember TOMDF:IntegratedHealthLLCMember 2021-02-09 2021-02-11 0001645260 us-gaap:SubsequentEventMember TOMDF:SettlementAgreementsMember TOMDF:IntegratedHealthLLCMember 2021-02-11 0001645260 us-gaap:SubsequentEventMember TOMDF:SettlementAgreementsMember TOMDF:IntegratedHealthAndMOTOPARAMember 2021-02-09 2021-02-11 0001645260 us-gaap:SubsequentEventMember TOMDF:MutualAgreementMember TOMDF:IntegratedHealthAndMOTOPARAMember 2021-02-11 0001645260 TOMDF:SettlementAgreementsMember TOMDF:MOTOPARAFoundationIncMember srt:ScenarioForecastMember 2021-01-11 2022-01-11 0001645260 us-gaap:SubsequentEventMember TOMDF:SettlementAgreementsMember TOMDF:MOTOPARAFoundationIncMember 2021-02-09 2021-02-11 0001645260 us-gaap:SubsequentEventMember TOMDF:SettlementAgreementsMember TOMDF:MOTOPARAFoundationIncMember TOMDF:LenderMember 2021-02-28 2021-03-01 0001645260 us-gaap:SubsequentEventMember TOMDF:PlatformAccountAgreementMember TOMDF:SRAXIncMember 2021-02-03 2021-02-04 0001645260 us-gaap:SubsequentEventMember TOMDF:FirstAmendmentToSecuredConvertibleEquipmentLoanAgreementMember TOMDF:LenderMember 2021-04-29 2021-05-01 0001645260 us-gaap:SubsequentEventMember TOMDF:FirstAmendmentToSecuredConvertibleEquipmentLoanAgreementMember TOMDF:LenderMember 2021-05-01 0001645260 us-gaap:SubsequentEventMember TOMDF:FirstAmendmentToSecuredConvertibleEquipmentLoanAgreementMember TOMDF:LenderMember 2021-02-28 2021-03-31 0001645260 us-gaap:SubsequentEventMember TOMDF:FirstAmendmentToSecuredConvertibleEquipmentLoanAgreementMember TOMDF:LenderMember TOMDF:NISMember 2021-03-31 0001645260 us-gaap:SubsequentEventMember TOMDF:ClosingAgreementMember TOMDF:PurchaserMember 2021-03-03 0001645260 us-gaap:SubsequentEventMember TOMDF:ClosingAgreementMember TOMDF:PurchaserMember 2021-03-02 2021-03-03 0001645260 us-gaap:SubsequentEventMember TOMDF:SecuritiesPurchaseAgreementMember TOMDF:InstitutionalInvestorMember 2021-10-21 0001645260 us-gaap:SubsequentEventMember TOMDF:SecuritiesPurchaseAgreementMember TOMDF:InstitutionalInvestorMember 2021-10-20 2021-10-21 0001645260 us-gaap:SubsequentEventMember TOMDF:SecuritiesPurchaseAgreementMember TOMDF:InstitutionalInvestorMember us-gaap:WarrantMember srt:MaximumMember 2021-10-21 0001645260 us-gaap:SubsequentEventMember TOMDF:SecuritiesPurchaseAgreementMember TOMDF:InstitutionalInvestorMember us-gaap:WarrantMember 2021-10-21 0001645260 us-gaap:SubsequentEventMember TOMDF:SecuritiesPurchaseAgreementMember 2021-11-21 2021-11-22 0001645260 TOMDF:MonteCarloSimulationModelMember 2021-01-01 2021-09-30 0001645260 TOMDF:MonteCarloSimulationsModelMember 2021-01-01 2021-09-30 0001645260 TOMDF:MonteCarloSimulationModelMember TOMDF:OptionalOrMaturityConversionMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-04-19 0001645260 TOMDF:MonteCarloSimulationModelMember TOMDF:OptionalOrMaturityConversionMember us-gaap:MeasurementInputExpectedTermMember 2021-04-14 2021-04-19 0001645260 TOMDF:MonteCarloSimulationModelMember TOMDF:OptionalOrMaturityConversionMember us-gaap:MeasurementInputPriceVolatilityMember 2021-04-19 0001645260 TOMDF:MonteCarloSimulationModelMember TOMDF:OptionalOrMaturityConversionMember us-gaap:MeasurementInputSharePriceMember 2021-04-19 0001645260 TOMDF:MonteCarloSimulationModelMember TOMDF:OptionalOrMaturityConversionMember us-gaap:MeasurementInputConversionPriceMember 2021-04-19 0001645260 TOMDF:MonteCarloSimulationModelMember TOMDF:OptionalOrMaturityConversionMember 2021-04-19 0001645260 TOMDF:MonteCarloSimulationModelMember TOMDF:MandatoryConversionMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-04-19 0001645260 TOMDF:MonteCarloSimulationModelMember TOMDF:MandatoryConversionMember us-gaap:MeasurementInputExpectedTermMember 2021-04-14 2021-04-19 0001645260 TOMDF:MonteCarloSimulationModelMember TOMDF:MandatoryConversionMember us-gaap:MeasurementInputPriceVolatilityMember 2021-04-19 0001645260 TOMDF:MonteCarloSimulationModelMember TOMDF:MandatoryConversionMember us-gaap:MeasurementInputSharePriceMember 2021-04-19 0001645260 TOMDF:MonteCarloSimulationModelMember TOMDF:MandatoryConversionMember us-gaap:MeasurementInputConversionPriceMember 2021-04-19 0001645260 TOMDF:MonteCarloSimulationModelMember TOMDF:MandatoryConversionMember 2021-04-19 0001645260 TOMDF:MonteCarloSimulationModelMember TOMDF:MandatoryConversionMember 2021-04-14 2021-04-19 0001645260 TOMDF:MonteCarloSimulationModelMember TOMDF:OptionalOrMaturityConversionMember 2021-04-14 2021-04-19 0001645260 TOMDF:SecuredConvertibleEquipmentLoanAgreementMember 2021-07-01 2021-09-30 0001645260 TOMDF:SecuritiesPurchaseAgreementMember 2021-07-01 2021-09-30 0001645260 TOMDF:SecuritiesPurchaseAgreementMember TOMDF:YozmaGlobalGenomicFund1Member 2021-01-22 0001645260 TOMDF:SecuritiesPurchaseAgreementMember TOMDF:YozmaGlobalGenomicFund1Member 2021-01-01 2021-01-22 0001645260 TOMDF:SecuritiesPurchaseAgreementMember TOMDF:YozmaGlobalGenomicFund1Member srt:MaximumMember 2021-01-01 2021-01-22 0001645260 TOMDF:SecuritiesPurchaseAgreementMember TOMDF:YozmaGlobalGenomicFund1Member us-gaap:WarrantMember 2021-01-22 0001645260 TOMDF:SecuritiesPurchaseAgreementMember TOMDF:YozmaGlobalGenomicFund1Member us-gaap:WarrantMember 2021-01-01 2021-01-22 0001645260 TOMDF:SecuritiesPurchaseAgreementMember TOMDF:YozmaGlobalGenomicFund1Member us-gaap:WarrantMember TOMDF:ConvertibleBridgeLoanMember 2021-01-01 2021-09-30 0001645260 TOMDF:SecuritiesPurchaseAgreementMember TOMDF:YozmaGlobalGenomicFund1Member us-gaap:WarrantMember TOMDF:ConvertibleBridgeLoanMember 2021-07-01 2021-09-30 0001645260 TOMDF:AslanoPrivateLimitedMember 2021-09-30 0001645260 TOMDF:SecuritiesPurchaseAgreementMember TOMDF:YozmaGlobalGenomicFund1Member us-gaap:WarrantMember 2021-01-01 2021-09-30 0001645260 TOMDF:LoanAgreementMember 2021-01-01 2021-09-30 0001645260 TOMDF:FirstAmendmentToSecuredConvertibleEquipmentLoanAgreementMember TOMDF:LenderMember 2021-04-28 2021-05-01 0001645260 TOMDF:FirstAmendmentToSecuredConvertibleEquipmentLoanAgreementMember TOMDF:LenderMember 2021-05-01 0001645260 TOMDF:FirstAmendmentToSecuredConvertibleEquipmentLoanAgreementMember TOMDF:LenderMember 2021-01-01 2021-09-30 0001645260 TOMDF:FirstAmendmentToSecuredConvertibleEquipmentLoanAgreementMember TOMDF:LenderMember TOMDF:NISMember 2021-09-30 0001645260 TOMDF:ClosingAgreementMember TOMDF:PurchaserMember 2021-09-30 0001645260 TOMDF:ClosingAgreementMember TOMDF:PurchaserMember 2021-01-01 2021-09-30 0001645260 TOMDF:SecuritiesPurchaseAgreementMember 2021-09-30 0001645260 TOMDF:SecuritiesPurchaseAgreementMember 2021-08-27 2021-09-30 0001645260 TOMDF:ConvertibleBridgeLoanMember 2021-01-01 2021-09-30 0001645260 TOMDF:ConvertibleBridgeLoanMember 2021-07-01 2021-09-30 0001645260 TOMDF:AssignmentOfReceivableAgreementsMember 2021-01-01 2021-09-30 0001645260 TOMDF:SecuritiesPurchaseAgreementMember TOMDF:FamilyOfficeInvestorMember 2021-04-09 0001645260 TOMDF:SecuritiesPurchaseAgreementMember TOMDF:FamilyOfficeInvestorMember 2021-04-08 2021-04-09 0001645260 TOMDF:SecuritiesPurchaseAgreementMember TOMDF:FamilyOfficeInvestorMember us-gaap:WarrantMember srt:MaximumMember 2021-04-09 0001645260 TOMDF:SecuritiesPurchaseAgreementMember TOMDF:FamilyOfficeInvestorMember us-gaap:WarrantMember 2021-04-09 0001645260 TOMDF:SecuritiesPurchaseAgreementMember TOMDF:FamilyOfficeInvestorMember TOMDF:PurchaserMember 2021-04-09 0001645260 TOMDF:SecuritiesPurchaseAgreementMember TOMDF:FamilyOfficeInvestorMember TOMDF:PurchaserMember 2021-04-07 2021-04-09 0001645260 TOMDF:SecuritiesPurchaseAgreementMember TOMDF:FamilyOfficeInvestorMember us-gaap:WarrantMember TOMDF:PurchaserMember 2021-04-09 0001645260 TOMDF:FamilyOfficeInvestorMember TOMDF:SecuritiesPurchaseAgreementMember 2021-04-06 2021-04-09 0001645260 TOMDF:SecuritiesPurchaseAgreementMember TOMDF:FamilyOfficeInvestorMember us-gaap:WarrantMember 2021-04-06 2021-04-09 0001645260 2021-04-06 2021-04-09 0001645260 TOMDF:SecuritiesPurchaseAgreementMember TOMDF:FamilyOfficeInvestorMember 2021-01-01 2021-09-30 0001645260 TOMDF:SecuritiesPurchaseAgreementMember TOMDF:FamilyOfficeInvestorMember 2021-07-01 2021-09-30 0001645260 TOMDF:SecuritiesPurchaseAgreementMember TOMDF:YozmaGlobalGenomicFund1Member 2021-04-27 0001645260 TOMDF:SecuritiesPurchaseAgreementMember TOMDF:YozmaGlobalGenomicFund1Member 2021-04-26 2021-04-27 0001645260 TOMDF:SecuritiesPurchaseAgreementMember TOMDF:YozmaGlobalGenomicFund1Member srt:MaximumMember us-gaap:WarrantMember 2021-04-27 0001645260 TOMDF:SecuritiesPurchaseAgreementMember TOMDF:YozmaGlobalGenomicFund1Member us-gaap:WarrantMember 2021-04-27 0001645260 TOMDF:YozmaGlobalGenomicFund1Member TOMDF:SecuritiesPurchaseAgreementMember 2021-04-26 2021-04-27 0001645260 TOMDF:SecuritiesPurchaseAgreementMember TOMDF:YozmaGlobalGenomicFund1Member us-gaap:WarrantMember 2021-04-06 2021-04-09 0001645260 TOMDF:DetachableWarrantsMember 2021-04-27 0001645260 TOMDF:FinanaceExpensesMember 2021-01-01 2021-09-30 0001645260 TOMDF:FinanaceExpensesMember 2021-07-01 2021-09-30 0001645260 TOMDF:SecuritiesPurchaseAgreementMember TOMDF:FirstAndSecondTranchesMember 2021-05-12 2021-05-13 0001645260 TOMDF:SecuritiesPurchaseAgreementMember TOMDF:PromissoeryConvertibleNoteMember 2021-07-07 0001645260 TOMDF:SecuritiesPurchaseAgreementMember TOMDF:PromissoeryConvertibleNoteMember 2021-07-06 2021-07-07 0001645260 TOMDF:SecuritiesPurchaseAgreementMember 2021-07-06 2021-07-07 0001645260 TOMDF:SecuritiesPurchaseAgreementMember TOMDF:PromissoeryConvertibleNoteMember 2021-09-23 0001645260 TOMDF:SecuritiesPurchaseAgreementMember TOMDF:PromissoeryConvertibleNoteMember 2021-09-22 2021-09-23 0001645260 TOMDF:SecuritiesPurchaseAgreementMember 2021-09-22 2021-09-23 0001645260 2021-07-19 0001645260 2021-07-18 2021-07-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure TOMDF:Integer

 

As filed with the Securities and Exchange Commission on February 2, 2022

 

Registration No. 333-256053

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM S-1/A

(Amendment No. 2

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

 

Todos Medical Ltd.

(Exact name of registrant as specified in its charter)

 

Israel

(State or other jurisdiction of incorporation or organization)

 

2835

(Primary Standard Industrial Classification Code Number)

 

N/A

(I.R.S. Employer Identification Number)

 

121 Derech Menachem Begin, 30th Floor, Tel Aviv, 6701203 Israel, +972 (52) 642-0126

(Address, including zip code, and telephone number,

including area code, of registrant’s principal executive offices)

 

Puglisi & Associates

850 Library Avenue, Suite 204

Newark, Delaware 19711

302-738-6680

(Name, address, including zip code, and telephone number,

including area code, of agent for service)

 

Copies of all Correspondence to:

 

Carl M. Sherer

Rimon PC

100 Park Ave, 16th floor

New York, NY 10017

Telephone No. (800) 930-7271

Facsimile No.: (617)997-0098

 

Jeffrey J. Fessler

Sheppard, Mullin, Richter &

Hampton LLP

30 Rockefeller Plaza

New York, NY 10112

Telephone No. (212) 634-3067

Facsimile No.: (917) 438-6133

 

As soon as practicable after the effective date of this Registration Statement.

 

 

(Approximate date of commencement of proposed sale to the public)

 

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box: ☒

 

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

 

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

 

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐   Accelerated filer ☐
Non-accelerated filer   Smaller reporting company
    Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

 

Calculation of Registration Fee

 

Title of each class of securities to be registered

 

Amount

to be Registered (1)

   Proposed Maximum Offering Price Per Share (2)  

Proposed Maximum Aggregate

Offering Price

  

Amount of

Registration Fee

 
                 
Ordinary shares, par value NIS 0.01, issuable upon exercise of Warrants   

137,980,949

   $.064   $8,830,781   $

818.61

 
                     
Ordinary Shares, par value NIS 0.01, issuable upon conversion of Convertible Notes   

123,086,088

   $

.064

    

7,877,510

   $

730.25

 
TOTAL   

261,067,037

       $

16,708,291

   $

1,548.86

(3)

 

(1) Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), the ordinary shares issuable upon the exercise of warrants, and ordinary shares issuable upon conversion of Convertible Notes being registered hereunder include such indeterminate number of ordinary shares as may be issuable as a result of share splits, share dividends or similar transactions.
   
(2) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457 (c) under the Securities Act of 1933, as amended. Calculated based upon the closing bid price for the Company’s shares on the OTCQB Venture Market on January 13, 2022.
   
(3) Previously paid

 

The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.

 

 

 

 
 

 

The information in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission becomes effective. This preliminary prospectus is not an offer to sell nor does it seek an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.

 

Preliminary Prospectus Subject to Completion. Dated: February 2, 2022

 

 

TODOS MEDICAL LTD.

261,067,037 Ordinary Shares

 

This prospectus relates to the resale by the selling shareholders named herein, from time to time, of up to (i) 123,086,088 ordinary shares, (the “Convertible Note Shares”), issuable upon the exercise of outstanding convertible notes (the “Convertible Notes”), (ii) 78,332,201 ordinary shares, (the “Purchaser Warrant Shares”), issuable upon exercise of outstanding warrants (the “2021 Warrants”), and (iii) 59,648,748 ordinary shares (the “Prior Warrant Shares”) issuable upon the exercise of outstanding warrants (the “2020 Warrants”). The Convertible Notes and the 2021 Warrants were initially issued by us in a private placement (the “Private Placement”), pursuant to nine securities purchase agreements, dated as of July 6, 2021, July 7, 2021, August 9, 2021, September 15, 2021, October 18, 2021, November 2, 2021, November 24, 2021, December 14, 2021, and December 21, 2021 between us and certain selling shareholders. The 2020 Warrants were initially issued by us in a series of private placements to fifteen purchasers between November 1, 2019, and July 8, 2020. The Purchaser Warrant Shares, the Prior Warrant Shares and the Convertible Note Shares are referred to herein as the “Ordinary Shares” or the “Securities.” We are not registering the resale of the Convertible Notes, the 2021 Warrants or the 2020 Warrants.

 

The conversion price for the Convertible Notes is subject to adjustment downwards under certain circumstances. All share numbers in this prospectus assume that such conversion price will not be adjusted. The maximum adjustment of the conversion price under the Convertible Notes is 20%.

 

We will not receive any proceeds from the sale of Securities by the selling shareholders. We will, however, receive the proceeds of any Warrants exercised for cash in the future, which will total up to approximately $13,506,515, based on the Warrants’ respective exercise prices. See “Use of Proceeds” in this prospectus.

 

The selling shareholders may offer and sell the Securities from time to time at varying prices and in a number of different ways as each selling shareholder may determine through public or private transactions or through other means described under “Plan of Distribution.” Each selling shareholder may also sell shares under Rule 144 under the Securities Act of 1933, as amended, to the extent available pursuant to the restrictions thereunder, rather than under this prospectus.

 

The selling shareholders will bear all commissions, discounts and concessions, if any, attributable to the sale or disposition of the Securities. Other than in connection with our indemnification obligations with respect to the selling shareholders, we will bear only the costs, expenses and fees in connection with the registration of the Securities. We will not be paying any underwriting commissions or discounts in offerings under this prospectus. For more information, see “Plan of Distribution.”

 

Our ordinary shares are traded on the OTCQB under the symbol “TOMDF.” The last reported sales price of our ordinary shares on the OTCQB on January 13, 2022 was $.064 per ordinary share.

 

INVESTING IN OUR SECURITIES INVOLVES A HIGH DEGREE OF RISK. SEE “RISK FACTORS” IN THIS PROSPECTUS.

 

None of the Securities and Exchange Commission, the Israel Securities Authority or any state securities commission has approved or disapproved of the securities being offered by this prospectus, or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

 

The date of this prospectus is February 2, 2022

 

 

 

 

TABLE OF CONTENTS

 

About This Prospectus 1
Cautionary Statement Regarding Forward-Looking Statements 2
Prospectus Summary 3
The Offering 12
Risk Factors 13
Use of Proceeds 36
Management’s Discussion and Analysis of Financial Condition and Results of Operations 37
Business 48
Description of Our Securities 66
Market Price and Dividend Policy 74
Properties 75
Legal Proceedings 76
Directors, Officers and Corporate Governance 77
Executive and Director Compensation 83
Security Ownership of Certain Beneficial Owners and Management 86
Certain Relationships and Related Party Transactions, and director independence 87
Selling Shareholders 88
Plan of Distribution 89
Material Tax Considerations and Government Programs 91
Legal Matters 101
Experts 101
Where You Can Find More Information 102

 

i

 

 

ABOUT THIS PROSPECTUS

 

This prospectus relates to the resale from time to time by selling shareholders of up to (i) 123,086,088 ordinary shares, (the “Convertible Note Shares”), issuable upon the exercise of outstanding convertible notes (the “Convertible Notes”), (ii) 78,332,201 ordinary shares, (the “Purchaser Warrant Shares”), issuable upon exercise of outstanding warrants (the “2021 Warrants”), and (iii) 59,648,748 ordinary shares (the “Prior Warrant Shares”) issuable upon the exercise of outstanding warrants (the “2020 Warrants”). Before buying any of the ordinary shares that the selling shareholders are offering, we urge you to read this prospectus carefully. These documents contain important information that you should consider when making your investment decision.

 

We have not authorized anyone to provide you with information that is different from that contained in this prospectus, any amendment or supplement to this prospectus, or in any free writing prospectus we may authorize to be delivered or made available to you. We do not take responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. The selling shareholders are offering to sell our ordinary shares and seeking offers to purchase our ordinary shares only in jurisdictions where offers and sales are permitted. The information contained in this prospectus is accurate only as of the date on the front of this prospectus, regardless of the time of delivery of this prospectus or any sale of our ordinary shares. Our business, financial condition, results of operations and prospects may have changed since the date on the front cover of this prospectus.

 

For investors outside the United States: We have not done anything that would permit offerings under this prospectus, or possession or distribution of this prospectus, in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the ordinary shares and the distribution of this prospectus outside of the United States.

 

Unless the context clearly indicates otherwise, references in this prospectus to “we,” “our,” “ours,” “us,” “the Company” and “Todos” refer to Todos Medical Ltd. and its subsidiaries.

 

1

 

 

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

 

In addition to historical information, this prospectus contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933 (the “Securities Act”), and Section 21E of the U.S. Securities Exchange Act of 1934 (the “Exchange Act”). Such forward-looking statements may include projections regarding the Company’s future performance and other statements that are not statements of historical fact and, in some cases, may be identified by words like “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “future,” “will,” “should,” “would,” “seek” and similar terms or phrases.

 

These forward-looking statements are based on our management’s current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict, and many of which are outside of our control. Important factors that could cause our actual resu0lts to differ materially from those indicated in the forward-looking statements include, among others, the factors discussed under the heading “Risk Factors.”

 

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur.

 

Any forward-looking statements made in this prospectus speak only as of the date of the particular statement. Factors or events that could cause the Company’s actual results to differ from the statements contained herein or therein may emerge from time to time, and it is not possible for the Company to predict all of them. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

 

2

 

 

PROSPECTUS SUMMARY

 

This summary highlights information contained elsewhere in this prospectus. It may not contain all of the information that you should consider before investing in our securities. You should read this entire prospectus carefully, including the “Risk Factors”, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections, and the financial statements and related notes included herein. This prospectus includes forward-looking statements that involve risks and uncertainties. See “Forward-Looking Statements.”

 

Overview

 

  Todos Medical Ltd. (“Todos Medical,” “Todos,” the “Company,” “we,” “our,” “us”), is a comprehensive medical diagnostics and related solutions company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and immune resisting supplements, and on developing blood tests for the early detection of cancer and Alzheimer’s disease.
     
  Todos has entered into distribution agreements with companies to distribute certain novel coronavirus (COVID-19) test kits. The agreements cover multiple international suppliers of PCR testing kits and related materials and supplies, as well as antibody testing kits from multiple manufacturers after completing validation of said testing kits and supplies in its partner CLIA/CAP certified laboratory in the United States. Todos has combined the PCR testing kits with automated lab equipment to create lab workflows capable of performing up to 40,000 PCR tests per day. Todos has entered into supply agreements with CLIA/CAP certified laboratories in the United States to deploy these PCR workflows. Todos has formed strategic partnerships with Meridian Health and other strategic partners to deploy COVID-19 antigen and antibody testing in the United States. Additionally, the Company is developing a lab-based COVID-19 3CL protease test to determine whether a COVID-19 positive patient remains contagious after quarantine is complete and is further developing point-of-care-based embodiments of the lab test for use in screening programs worldwide.
     
  In December 2020, Todos announced the commercial launch of its proprietary 3CL protease inhibitor dietary supplement Tollovid™ at The Alchemist’s Kitchen in the SoHo district in Manhattan, New York. Tollovid, a mix of botanical extracts, is being targeted to support healthy immune function against circulating coronaviruses. Tollovid’s mechanism of action is to inhibit the activity of the 3CL protease, a key protease required for the intracellular replication of coronaviruses. Tollovid was granted a Certificate of Free Sale by the US Food & Drug Administration in August 2020, allowing its commercial sale anywhere in the United States. Tollovid has begun online sales through Amazon, Shopify and other online marketplaces.
     
  Additionally, the Company’s patented Todos Biochemical Infrared Analyses (TBIA) is a cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer’s influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos’ two internally developed cancer-screening tests, TMB-1 and TMB-2 have received a CE mark in Europe. In April 2021, Todos completed the acquisition of U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab and Provista’s proprietary commercial-stage Videssa® breast cancer blood test.
     
  Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer’s disease.
     
  In July 2020, Todos completed the acquisition of Breakthrough Diagnostics, Inc., the owner of the LymPro Test intellectual property, from Amarantus Bioscience Holdings, Inc.
     
  In July 2021, Todos completed the acquisition of Provista Diagnostics Inc. (“Provista”), a CLIA laboratory performing COVID testing for the general population as well as other scientific functions.
     
  At our annual general meeting of shareholders held on July 26, 2021, our shareholders voted to approve a reverse share split of the Company’s Ordinary Shares within a range of 2:1 to 500:1, to be effective at the ratio and on a date to be determined by the Board of Directors of the Company (the “Reverse Split”). Although our shareholders approved the Reverse Split, all per share amounts and calculations in this prospectus and the accompanying consolidated financial statements do not reflect the effects of the Reverse Split, as the Board of Directors has not determined the final ratio or the effective date of the Reverse Split.

 

3

 

 

Recent Developments

 

On January 22, 2021, we entered into a Securities Purchase Agreement (the “SPA”) with Yozma Global Genomic Fund (the “Purchaser”) pursuant to which on January 29, 2021, the Company issued a promissory convertible note (the “Note”) to the Purchaser in the principal amount of $4,857,142.86 for proceeds of $3,400,000 (the “Transaction”). The Note has a maturity date of one year from the date of issuance and pays interest at a rate of 4% per annum. The Note is convertible into Ordinary Shares of the Company (the “Conversion Shares”) at a conversion price of $0.0599 (the “Conversion Price). In addition, the Purchaser received a warrant (the “Warrant”) to purchase up to 16,956,929 Ordinary Shares (the “Warrant Shares”) of the Company with an exercise price equal to $0.107415 per share. The Warrant is exercisable for 5 years from the date of issuance. In the event that the Company effectuates a reverse split of its ordinary shares for a ratio in excess of 20:1, the resulting adjusted Warrant Shares and Exercise Price are limited to a 20:1 ratio.

 

This registration statement registers for resale the Warrant Shares. Subsequent to the effective date of such Registration Statement, if the closing sale price of the Ordinary Shares averages less than the then Conversion Price over a period of ten (10) consecutive trading days, the Conversion Price shall reset to such average price. If the 10 day volume weighted average price of the Ordinary Shares continues to be less than the Conversion Price, then the Conversion Price should reset to such 10-day average price. The maximum discount from the initial Conversion Price under the Note is 20%.

 

The Company and Leviston Resources LLC, a Delaware limited liability company (the “Purchaser”) are parties to that certain Securities Purchase Agreement, dated as of July 9, 2020 (the “Purchase Agreement”), pursuant to which the Purchaser purchased an aggregate principal amount of $850,000 of convertible notes (the “July 2020 Convertible Notes”) from the Company. On March 3, 2021, the Company and the Purchaser entered into a Closing Agreement (the “Closing Agreement”) pursuant to which the Purchaser exercised its right to invest an additional $847,570 into the Company of July 2020 Convertible Notes (the “Tranche 2 Securities”).

 

This registration statement registers for resale the Ordinary Shares underlying the Tranche 2 Securities.

 

During the first quarter of 2021, the Company’s contractual agreement to supply Covid-19 testing kits to NOAH Laboratories, Inc., a significant customer expired. At the customer’s request, the Company continued to supply Covid-19 testing kits until such time as the customer requested that the Company stop doing so. The customer has not yet paid for some of the Covid-19 testing kits so supplied and has not yet renewed its agreement with the Company. On November 15, 2021, Todos USA sent a demand letter (the “Demand Letter”) to the significant customer with which our contractual agreement to supply Covid-19 testing kits expired. The Demand Letter seeks (a) payment for testing kits that Todos USA supplied for which it was not paid, in the amount of $3,465,000, (b) the return of Todos USA’s equipment, title to which remains with Todos USA unless and until the significant customer meets a minimum purchase requirement, and (c) payment of damages as a result of the significant customer’s unlawful retention of Todos USA’s equipment, in an amount anticipated to be $2 million. The Company and Todos USA are negotiating a settlement with NOAH Laboratories, Inc., which the Company believes will result in most of the Company’s demands being met.

 

4

 

 

On April 8, 2021, the Company entered into a Securities Purchase Agreement (the “SPA”) with Kips Bay Select LP (the “Purchaser”) pursuant to which the Company agreed to issue a promissory convertible note (the “Note”) to the Purchaser in the principal amount of $4,285,714.29 for proceeds of $3,000,000 (the “Transaction”). The closing occurred on April 12, 2021 (the “Closing Date”). The Note has a maturity date of one year from the date of issuance and pays interest at a rate of 4% per annum. The Note is convertible into Ordinary Shares (the “Conversion Shares”) at a conversion price of $0.0599 (the “Conversion Price). In addition, the Purchaser received a warrant (the “Warrant”) to purchase up to 16,000,000 Ordinary Shares (the “Warrant Shares”) of the Company with an exercise price equal to $0.107415 per share. The Warrant is exercisable for 5 years from the date of issuance. In the event that the Company effectuates a reverse split of its Ordinary shares for a ratio in excess of 20:1, the resulting adjusted Warrant Shares and Exercise Price are limited to a 20:1 ratio. The Company used the net proceeds from this Note to initiate the Phase 2 for Tollovir™ clinical trial in COVID-19 patients, complete the acquisition of Provista Diagnostics, Inc. and for general corporate purposes.

 

This registration statement registers for resale the Warrant Shares. Subsequent to the effective date of such registration statement, if the closing sale price of our Ordinary Shares averages less than the then Conversion Price over a period of ten (10) consecutive trading days, the Conversion Price shall reset to such average price. If the 10 day volume weighted average price of our Ordinary Shares continues to be less than the Conversion Price then the Conversion Price should reset to such 10-day average price with a maximum of a 20% discount from the initial Conversion Price.

 

The Purchaser has the option to purchase an additional Note in the principal amount of $5,285,714.20 for proceeds of $3,700,000 and an additional Warrant to purchase 16,000,000 Ordinary Shares within 90 days of the effective date of the registration statement on Form S-1 described in the previous paragraph.

 

On April 8, 2021, the Company received a notice of allowance (‘Letter of Intent to Grant a Patent’) from the European Patent Office covering the use of the Company’s proprietary Total Biochemical Infrared Analysis (‘TBIA’) method that uses blood (plasma and/or peripheral blood mononuclear cells ‘PBMCs’) to distinguish between patients with benign tumors vs. malignant tumors vs. no tumors (healthy controls).

 

The patent application specifically covers methods for capturing consistent data from infrared spectroscopy readers, as well as the application of various artificial intelligence algorithm development methods to the data. The ability of TBIA to make a diagnosis of cancer has first been applied to the detection of breast and colon cancers, where Todos has received CE Marks in Europe paving the way for commercialization initially focused on TMB-2 (dense breast / inconclusive mammogram secondary screening) and TMB-1 (general breast cancer screening) cancer detection tests.

 

On April 19, 2021, the Company entered into an Agreement to Purchase Provista Diagnostics, Inc. (“Agreement to Purchase”) with Strategic Investment Holdings, LLC (“SIH”), Ascenda BioSciences LLC (“Ascenda”) and Provista Diagnostics, Inc. (“Provista”). Ascenda was the sole owner of the outstanding securities of Provista and SIH is the sole owner of all the outstanding securities of Ascenda.

 

Pursuant to the Agreement to Purchase, the Company acquired Provista from Ascenda and SIH for an aggregate purchase price of $7.5 million consisting of an initial cash payment of $1.25 million, the issuance of $1.5 million in Ordinary Shares priced at $0.0512 per share, the issuance to SIH of a $3.5 million convertible promissory note dated April 19, 2021 (the “Note”) and the payment on for before July 1, 2021 of $1.25 million in cash (the “July Payment”), which payment the Company had the right to, and did, extend to July 15, 2021. The Provista shares acquired by the Company remained in an escrow account until the July Payment was made.

 

5

 

 

The Note has a maturity date of April 8, 2025, and is convertible beginning on October 20, 2021, into Ordinary Shares of the Company at a conversion price equal to the lesser of $0.05 or the volume weighted average price of the last 20 trading days for the Ordinary Shares prior to the date of conversion. In the event SIH delivers a Notice of Conversion to the Company at a per share price less than $0.05 ($0.05), the Company has the right to immediately notify SIH of its intention to pay the conversion amount in cash within three (3) business days of receipt of the Notice of Conversion (i.e., before SIH would take possession of shares converted under the Notice of Conversion). If, at any time between October 20, 2021 and April 20, 2022, the average of the lowest bid and closing sale price at 4:00:00 p.m., New York time (or such other time as such market publicly announces is the official close of trading) is below ($0.05), the Company has the option to buy out all or any portion of the Note (the “Buyback Option”). In the event the Company exercises the Buyback Option for an amount equal to or greater than one million, one hundred seventy thousand dollars ($1,170,000) (the “Buyback Amount”), SIH may not submit any conversions below five cents ($0.05) for ninety (90) days from receipt of the Buyback Amount (“90 Day Period”).

 

In the event that the Company uplists its Ordinary Shares to a national securities exchange, the Note shall automatically be exchanged into Series B preferred stock with a conversion price equal to the lesser of (a) $0.05, (b) the opening price on the day of the uplisting provides there is no transaction associated with the uplisting or (c) the deal price of an uplisting transaction.

 

As of the date of this prospectus, SIH has not submitted a Conversion Notice.

 

On July 7, 2021, the Company entered into a Securities Purchase Agreement (the “SPA”) with Kips Bay Select LP (the “Purchaser”) pursuant to which the Company agreed to issue a promissory convertible note (the “Note”) to the Purchaser in the principal amount of $1,535,714 for proceeds of $1,075,000 (the “Transaction”). The closing occurred on July 7, 2021 (the “Closing Date”). The Note has a maturity date of one year from the date of issuance and pays interest at a rate of 4% per annum. The Note is convertible into Ordinary Shares of the Company (the “Conversion Shares”) at a conversion price of $0.0599 (the “Conversion Price). In addition, the Purchaser received a warrant (the “Warrant”) to purchase up to 3,440,000 Ordinary Shares (the “Warrant Shares”) of the Company with an exercise price equal to $0.107415 per share. The Warrant is exercisable for 5 years from the date of issuance. From the Closing Date until 180 days thereafter, the Company shall be restricted from issuing or entering into any agreement to issue any Ordinary Shares, except under certain circumstances, including an uplisting. This provision shall no longer be in effect if the closing sale price of the Ordinary shares exceeds $0.10. The Company intends to use the net proceeds for general corporate purposes.

 

This registration statement registers for resale the Warrant Shares. Subsequent to the effective date of such registration statement, if the closing sale price of the Ordinary Shares averages less than the then Conversion Price over a period of ten (10) consecutive trading days, the Conversion Price shall reset to such average price. If the 10-day volume weighted average price of the Ordinary Shares continues to be less than the Conversion Price then the Conversion Price should reset to such 10-day average price with a maximum of a 20% discount from the initial Conversion Price.

 

On September 23, 2021, the Company completed the conditions precedent required to enter into a Securities Purchase Agreement (the “SPA”) with Mercer Street Global Opportunity Fund, LLC (the “Purchaser”) pursuant to which the Company issued a promissory convertible note (the “Note”) to the Purchaser in the principal amount of $2,285,142.86 for proceeds of $2,000,000 (the “Transaction”). The Note has a maturity date of one year from the date of issuance and pays interest at a rate of 4% per annum. The Note is convertible into Ordinary Shares of the Company (the “Conversion Shares”) at a conversion price of $0.0599 (the “Conversion Price). In addition, the Purchaser received a warrant (the “Warrant”) to purchase up to 11,924,636 Ordinary Shares (the “Warrant Shares”) of the Company with an exercise price equal to $0.107415 per share. The Warrant is exercisable for 5 years from the date of issuance. The Company intends to use the net proceeds from this Note to initiate Phase 2/3 trials for Tollovir™ COVID-19 patients, initiate digital marketing for its dietary supplement Tollovid®, increase sales & marketing for Provista Diagnostics, and for general corporate purposes.

 

6

 

 

Univest Securities, LLC acted as placement agent for the offering.

 

This registration statement registers for resale the Conversion Shares and the Warrant Shares. Subsequent to the effective date of the registration statement, if the closing sale price of the Ordinary shares averages less than the then Conversion Price over a period of ten (10) consecutive trading days, the Conversion Price shall reset to such average price. If the 10 day volume weighted average price of the Ordinary shares continues to be less than the Conversion Price then the Conversion Price should reset to such 10-day average price with a maximum of a 20% discount from the initial Conversion Price.

 

On July 22, 2021, the US Food & Drug Administration (FDA) granted a new Certificate of Free Sale for Tollovid Daily™, the newest member of the Company’s Tollovid™ dietary supplement product line.

 

The Certificate of Free Sale is for a twice-daily dosing regimen and, critically, a 3CL protease inhibitor claim. Each 60-pill bottle of Tollovid Daily can help support and maintain healthy immune function for 30 days. The Company intends to establish a monthly subscription model as part of its marketing launch campaign for Tollovid Daily immune system support. Tollovid™ and Tollovid Daily are both 3CL protease inhibitor products developed under a joint venture with NLC Pharma.

 

On November 15, 2021, Todos USA sent a demand letter (the “Demand Letter”) to a significant customer with which our contractual agreement to supply Covid-19 testing kits expired. The Demand Letter seeks (a) payment for testing kits that Todos USA supplied for which it was not paid, in the amount of $3,465,000, (b) the return of Todos USA’s equipment, title to which remains with Todos USA unless and until the significant customer meets a minimum purchase requirement, and (c) payment of damages as a result of the significant customer’s unlawful retention of Todos USA’s equipment, in an amount anticipated to be $2 million. Todos USA has yet to receive a response to the Demand Letter.

 

On November 18, 2021, Todos entered into a license agreement (the “License Agreement”) with T-Cell Protect Hellas S.A. (“T-Cell Protect”) pursuant to which the Company will license the European manufacturing and distribution rights to a product based on the Company’s Tollovid® and Tollovid Daily™ 3CL protease inhibitor and immune support dietary supplements to T-Cell Protect (the “Product”). The License Agreement became effective on November 22, 2021 when the Company received a purchase order for 50,000 bottles of Tollovid Daily, per the terms of the License Agreement. The Product is expected to be marketed under the T-Cell Protect brand in Europe. In addition, the Company will grant to T-Cell Protect an exclusive license to manufacture, sell and distribute the Product in Greece. The License Agreement provides for royalty in the low double digits to the Company and a minimum of 500,000 bottles in sales over the 18 months after the date of the License Agreement. In the event T-Cell Protect establishes its own manufacturing of the Product in the European market, the 500,000 bottle minimum referred to in the previous sentence will become a minimum sales requirement. In the License Agreement, T-Cell Protect acknowledged that the Company intends to assign the License Agreement to a subsidiary being formed by the Company to focus on the development of 3CL protease biology called 3CL Sciences, Inc. (“3CL Sciences”).

 

On November 22, 2021, the Company entered into a Securities Purchase Agreement (the “SPA”) with T-Cell pursuant to which the Company issued a promissory convertible note (the “Note”) to T-Cell Protect in the principal amount of €1,000,000 (the “Transaction”). The Note has a maturity date of one year from the date of issuance and pays interest at a rate of 10% per annum. The Note is convertible into ordinary shares (the “Conversion Shares”) at a conversion price of $0.0599 (the “Conversion Price). At any time prior to the Company uplisting its ordinary shares to a national securities exchange, T-Cell Protect may exchange the Note into either (a) a direct equity investment in 3CL Sciences at the same terms as a financing round of at least $5,000,000 (the “Sub”) or (b) into a note in the Sub, bearing 10% interest that converts into direct equity in the Sub at the same terms as a financing round of at least $5,000,000. The proceeds from this Transaction are intended to be used for the clinical development of Tollovir, the Company’s therapeutic candidate for hospitalized COVID-19 patients.

 

7

 

 

On November 24, 2021, the Company entered into a binding letter of intent (the “LOI”) with NLC Pharma Ltd. (“NLC”) pursuant to which 3CL Sciences will purchase all therapeutic, diagnostic, dietary supplement and pharmaceutical assets from NLC that relate to 3CL protease biology in exchange for a 40% equity interest in 3CL Sciences that NLC will own, single digit royalties and Company ordinary shares. Promptly following execution of the LOI, the Company will deliver $325,000 to pay outstanding invoices related to the interim analysis of the ongoing clinical trial of Tollovir. The Company shall be responsible for providing or assisting in the raising of a total of $10 million into 3CL Sciences over a period of 7 months from execution of the LOI. The Company and NLC agree to identify a seasoned biopharmaceutical CEO to run 3CL Sciences going forward. The board of directors of 3CL Sciences will be made up of five (5) individuals: two (2) appointed by the Company, two (2) appointed by NLC and one (1) to be mutually agreed upon by the Company and NLC. In addition, NLC will be granted one (1) seat on the Company’s Board of Directors.

 

The Company has agreed to file a registration statement with the Securities and Exchange Commission registering for resale the Conversion Shares (the “Registration Statement).

 

Summary of Risk Factors

 

Our business is subject to significant risks and uncertainties that make an investment in us speculative and risky. Below we summarize what we believe are the principal risk factors, but these risks are not the only ones we face, and you should carefully review and consider the full discussion of our risk factors in the section titled “Risk Factors”, together with the other information in this prospectus. If any of the following risks actually occurs (or if any of those listed elsewhere in this prospectus occur), our business, reputation, financial condition, results of operations, revenue, and future prospects could be seriously harmed. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that adversely affect our business.

 

8

 

 

We have a history of losses, may incur future losses and may not achieve profitability.

 

We have a need for substantial additional financing and will have to significantly delay, curtail or cease operations if we are unable to secure such financing.

 

The report of our former independent registered public accounting firm expresses substantial doubt about our ability to continue as a going concern.

 

There can be no assurance of market acceptance for our COVID-19 antibody test.

 

We rely on a third party to manufacture the COVID-19 antibody tests for us, and if such third party refuses or is unable to supply us with the COVID-19 test kits, our business will be materially harmed.

 

We may not succeed in completing the development of our cancer detection products, commercializing our products or generating significant revenues.

 

We are currently in the process of improving our technology and adapting to the high throughput methodology.

 

We will require additional funding in order to commercialize our cancer detection kits and to develop and commercialize any future products.

 

We may not successfully maintain our existing license agreement with BGU and Soroka, and we are currently not in compliance with the repayment terms of the license agreement, which could adversely affect our ability to develop and commercialize our product candidates.

 

If we are unable to protect our intellectual property rights, our competitive position could be harmed.

 

Because the medical device industry is litigious, we are susceptible to intellectual property suits that could cause us to incur substantial costs or pay substantial damages or prohibit us from selling our cancer detection kits.

 

If we or our future distributors do not obtain and maintain the necessary regulatory clearances or approvals in a specific country or region, we will not be able to market and sell our cancer detection kits or future products in that country or region.

 

If we are unable to successfully complete clinical trials with respect to our cancer detection kits, we may be unable to receive regulatory approvals or clearances for our cancer detection kits and/or our ability to achieve market acceptance of our cancer detection kits will be harmed.

 

Conditions in Israel could materially and adversely affect our business

 

Your rights and responsibilities as a shareholder will be governed by Israeli law which differs in some material respects from the rights and responsibilities of shareholders of U.S. companies.

 

It may be difficult to enforce a judgment of a U.S. court against us, or against our officers and directors in Israel, or to assert U.S. securities laws claims in Israel or to serve process on our officers and directors in Israel.

 

The sale or issuance of our Ordinary Shares to Lincoln Park Capital may cause dilution and the sale of the Ordinary Shares acquired by Lincoln Park, or the perception that such sales may occur, could cause the price of our Ordinary Shares to fall.

 

We may not have access to the full amount available under the Purchase Agreement with Lincoln Park.

 

An active trading market for our Ordinary Shares may not develop and our shareholders may not be able to resell their Ordinary Shares.

 

9

 

 

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur.

 

Any forward-looking statements made in this prospectus speak only as of the date of the particular statement. Factors or events that could cause the Company’s actual results to differ from the statements contained herein or therein may emerge from time to time, and it is not possible for the Company to predict all of them. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

 

Corporate Information

 

We were incorporated in the State of Israel in April 2010, and are subject to the Israel Companies Law, 5760-1999 (the “Companies Law”). Since March 7, 2017, our Ordinary Shares have been quoted on the OTCQB under the symbol TOMDF.

 

In January 2016, we incorporated our wholly owned subsidiary, Todos (Singapore) Pte. Ltd. In March 2016, Todos (Singapore) Pte. Ltd. changed its name to Todos Medical Singapore Pte. Ltd., or Todos Singapore. Todos Singapore has not yet commenced its business operations.

 

In January 2020, we incorporated Todos Medical USA, a Nevada corporation (“Todos US”), for the purpose of conducting business as a medical importer and distributor focused on the distribution the Company’s testing products and services to customers in North America and Latin America. In addition, in March 2020, Todos US formed a subsidiary, Corona Diagnostics, LLC, in the State of Nevada, for the purpose of marketing COVID-19 related products in the United States. In July 2020, we completed the acquisition of Breakthrough Diagnostics, Inc, which is now a wholly owned subsidiary of Todos. In July 2021, we completed the acquisition of Provista Diagnostics, Inc., which is now a wholly owned subsidiary of Todos.

 

10

 

 

The current corporate organizational structure of the Company and how we have operated substantially for the past year appears below.

 

 

Our principal executive office is located at 121 Derech Menachem Begin, 30th Floor, Tel Aviv, 6701203 Israel, and our telephone number in Israel is +972-52-642-0126. Our web address is www.todosmedical.com. The information contained on our website or available through our website is not incorporated by reference into and should not be considered a part of this prospectus, and the reference to our website in this prospectus is an inactive textual reference only. Puglisi & Associates is our agent in the United States, and its address is 850 Library Avenue, Suite 204 Newark, Delaware 19711.

 

All per share amounts and calculations in this prospectus and the accompanying financial statements do not reflect the effects of the Reverse Split discussed elsewhere in this prospectus.

 

Shares offered for sale in this prospectus

 

The shares offered in this prospectus relate to the resale by selling shareholders of an aggregate of (i) 123,086,088 ordinary shares issuable upon the conversion of eight convertible notes (the “2021 Convertible Notes”) which were issued in private placements to six institutional investors, (ii) 78,332,201 ordinary shares, (the “Purchaser Warrant Shares”), issuable upon exercise of outstanding warrants (the “2021 Warrants”), and (iii) 59,648,748 ordinary shares (the “Prior Warrant Shares”) issuable upon the exercise of outstanding warrants (the “2020 Warrants”). We sold the 2021 Convertible Notes and the 2021 Warrants pursuant to nine securities purchase agreements between us and the respective investors party thereto, dated July 6, 2021, July 7, 2021, August 9, 2021, September 15, 2021, October 18, 2021, November 2, 2021, November 24, 2021, December 14, 2021, and December 21, 2021, respectively (the “2021 Purchase Agreements”). The 2020 Warrants were initially issued by us in a series of private placements to fifteen purchasers between November 1, 2019 and July 8, 2020.

 

The 2021 Convertible Notes include:

 

 

nine convertible notes issued to seven different investors in the original principal amounts ranging from $142,857 to $2,857,143 respectively, which may be converted to purchase up to 123,086,088 ordinary shares at a conversion price of $0.0599 per share, which were issued to certain of the Selling Shareholders pursuant to the 2021 Purchase Agreements. The conversion price for the Convertible Notes is subject to adjustment downwards under certain circumstances. All share numbers in this prospectus assume that such conversion price will not be adjusted. The maximum adjustment of the conversion price under the Convertible Notes is 20%. One convertible note did not include warrants.

 

The 2021 Warrants include:

 

 

fourteen warrants issued to eight different investors to purchase between 266,667 and 16,956,929 ordinary shares respectively, at an exercise price of $0.10741, which were issued to certain of the Selling Shareholders pursuant to the 2021 Purchase Agreements.

 

The 2020 Warrants include:

 

 

twenty-one warrants issued to fifteen different investors to purchase up to an aggregate of 59,648,748 ordinary shares (ranging from 446,428 to 8,000,000 ordinary shares) at exercise prices ranging from $0.04 to $0.10 per ordinary share, which were issued to certain of the Selling Shareholders in a series of private placements between November 2019 and July 2020.

 

All of the 2021 Convertible Notes, 2021 Warrants and 2020 Warrants were issued pursuant to the exemption from the registration requirements in Section 4(a)(2) of the Securities Act of 1933, as amended, and/or Regulation D thereunder. We are filing the registration statement on Form S-1, of which this prospectus is a part, to enable the holders of the 2021 Convertible Notes to resell the underlying ordinary shares upon converting the convertible notes to ordinary shares, and the holders of the 2021 Warrants and the 2020 Warrants to resell the underlying ordinary shares after exercising the warrants for cash.

 

11

 

 

The Offering

 

Securities offered by the selling shareholders  

123,086,088 ordinary shares issuable upon the conversion of the 2021 Convertible Notes, 78,332,201 ordinary shares issuable upon exercise of the outstanding 2021 Warrants, and 59,648,748 ordinary shares issuable upon exercise of the outstanding 2020 Warrants.

     
Ordinary shares outstanding before this offering   977,144,432 ordinary shares, based on the number of shares outstanding as of January 13, 2022
     
Ordinary shares to be outstanding after this offering  

1,505,466,119 ordinary shares (assuming (a) the conversion of all of the Convertible Notes, (b) the exercise of all the outstanding 2021 Warrants, (c) the exercise of all of the outstanding 2020 Warrants, and the resale of all underlying ordinary shares by the selling shareholders in offerings under this prospectus, (d) the conversion by Yozma Global Genomic Fund 1 of $9,571,429 in principal amount of convertible notes into 166,181,732 ordinary shares, and (e) the conversion by Kips Bay Select LP of an additional $5,821,428 in principal amount of convertible notes into 101,072,918 ordinary shares). The conversion price for the Convertible Notes is subject to adjustment downwards under certain circumstances. All share numbers in this prospectus assume that such conversion price will not be adjusted. The maximum adjustment of the conversion price under the Convertible Notes is 20%.

     
Use of proceeds   We will not receive any proceeds from the sale of ordinary shares issuable upon conversion of the 2021 Convertible Notes by the selling shareholders. We will, however, receive the proceeds of any Warrants exercised for cash in the future. Such net proceeds will be up to approximately $13,506,515, based on the 2020 Warrants’ and the 2021 Warrants’ respective exercise prices. See “Use of Proceeds” in this prospectus.
     
Dividend policy   We have never declared or paid any cash dividends on our ordinary shares. We do not anticipate paying any cash dividends in the foreseeable future.
     
Risk factors   You should carefully consider the risk factors described in the section of this prospectus entitled “Risk Factors,” together with all of the other information included in this prospectus, before deciding to purchase our ordinary shares.

 

12

 

 

RISK FACTORS

 

An investment in our Ordinary Shares involves a high degree of risk. You should carefully consider the following factors and other information in this prospectus before deciding to invest in us. If any of the following risks actually occur, our business, financial condition, results of operations and prospects for growth would likely suffer. As a result, you could lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may materially and adversely affect our business, financial condition and results of operations.

 

Risks Related to Our Business

 

We have a history of losses, may incur future losses and may not achieve profitability.

 

Until March 2020, we were solely a clinical-stage medical diagnostics company with a limited operating history. We have incurred net losses in each fiscal year since we commenced operations in 2010. We incurred net losses of $11,904,000 and $11,814,515 in the fiscal years ended December 31, 2020, and 2019, respectively, and we may incur a net loss in 2021. As of September 30, 2021, our accumulated deficit was $71,827,000. Our losses could continue for the foreseeable future, as we continue our investment in research and development and clinical trials to complete the development of our technology and to attain regulatory approvals, begin the commercialization efforts for our cancer detection kits, increase our marketing and selling expenses, and incur additional costs as a result of being a publicly reporting company in the United States. The extent of our future operating losses and the timing of becoming profitable are highly uncertain, and we may never achieve or sustain profitability.

 

We have a need for substantial additional financing and will have to significantly delay, curtail or cease operations if we are unable to secure such financing.

 

The Company requires substantial additional financing to fund its operations. As of September 30, 2021, we had cash and cash equivalents of $166,000. We will need to raise additional funds prior to commercializing our cancer detection products. Additional financing may not be available to us on a timely basis on terms acceptable to us, or at all. In addition, any additional financing may be dilutive to our shareholders or may require us to grant a lender a security interest in our assets.

 

The report of our independent registered public accounting firm expresses substantial doubt about our ability to continue as a going concern.

 

Our former independent registered public accounting firm indicated in its report on our financial statements for the year ended December 31, 2020, included elsewhere in this prospectus, that conditions exist that raise substantial doubt about our ability to continue as a going concern. A going concern paragraph included in our independent registered public accounting firm’s report on our financial statements, could color investor perceptions and impair our ability to finance our operations through the sale of equity, incurring debt, or other financing alternatives. Our ability to continue as a going concern will depend upon many factors beyond our control including the availability and terms of future funding and the demand for COVID-19 tests. If we are unable to achieve our goals and raise the necessary funds to finance our operations, our business would be jeopardized, and we may not be able to continue. If we ceased operations, it is likely that all of our investors would lose their investment.

 

13

 

 

Risks Related to our COVID-19 Antibody Test

 

In connection with the marketing and sale of our COVID-19 antibody test, we are relying on FDA policies and guidance provisions that have recently changed and may continue to change. If we misinterpret this guidance or the guidance changes unexpectedly and/or materially, potential sales of our COVID-19 antibody test could be impacted.

 

The FDA issued non-binding guidance for manufacturers relating to the pathway to enable FDA notification following confirmed validation for devices related to testing for COVID-19 under the Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency. Following the issuance of the guidance published on March 16, 2020, revised guidance specific to COVID-19 ‘antibody tests’ was issued. Newer guidance was published on May 4, 2020 further describing the requirements for serology tests to continue to be marketed under an Emergency Use Authorization. If our interpretation of the newly revised guidance is incorrect or specifics around the guidance change, sales of our COVID-19 antibody test could be materially impacted.

 

There can be no assurance of market acceptance for our COVID-19 antibody test.

 

The commercial success of our COVID-19 antibody test will depend upon its acceptance as medically useful and cost-effective by physicians and other members of the medical community, patients and third-party payers. Broad market acceptance can be achieved only with substantial education about the benefits and limitations of such tests, as well as resolution of concerns about their appropriate use. Our reputation and the public image of our COVID-19 antibody test kits may be impaired if they fail to perform as expected or are perceived as difficult to use. Despite quality control testing, defects or errors could occur with the tests. Thus, there can be no assurance our COVID-19 antibody test will gain market acceptance on a timely basis, if at all, and purchasers of such tests could choose to purchase competitors’ tests instead. Failure to achieve market acceptance and/or the impact of strong competition will have a material adverse effect on our business, financial condition and results of operations.

 

We rely on a third party to manufacture the COVID-19 antibody tests for us, and if such third party refuses or is unable to supply us with the COVID-19 test kits, our business will be materially harmed.

 

We rely on a third party to manufacture the COVID-19 antibody tests. If any issues arise with respect to the manufacturer’s ability to manufacture and deliver to us the COVID-19 tests, our business could be materially harmed. In addition, the manufacturer may be unable to provide us with an adequate supply of COVID-19 antibody tests for various reasons, including, among others, if it becomes insolvent, if a United States regulatory authority or other governments block the import or sale of the COVID-19 tests or if it fails to maintain its rights to manufacture the COVID-19 test. If we are unable to keep up with demand for the COVID-19 antibody test kits, our revenue growth could be impaired, market acceptance for the test could be adversely affected, and our customers might instead purchase our competitors’ diagnostic tests.

 

We have relied and expect to continue to rely on third parties to conduct studies of the COVID-19 diagnostic tests that will be required by the FDA or other regulatory authorities, and those third parties may not perform satisfactorily.

 

Although we are selling our COVID-19 antibody test kits by virtue of recent FDA guidance allowing for reduced product clinical and analytical studies, we have relied on third parties, such as independent testing laboratories and hospitals, to conduct such studies. Our reliance on these third parties will reduce our control over these activities. These third-party contractors may not complete activities on schedule or conduct studies in accordance with regulatory requirements or our study design. We cannot control whether they devote sufficient time, skill and resources to our studies. Our reliance on third parties that we do not control will not relieve us of any applicable requirement to prepare, and ensure compliance with, various procedures required under good clinical practices. If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, if the third parties need to be replaced or if the quality or accuracy of the data they obtain is compromised due to their failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our studies may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory approval for additional diagnostic tests.

 

14

 

 

We may not succeed in completing the development of our cancer detection products, commercializing our products or generating significant revenues.

 

From the commencement of our operations until March 2020, we have focused on the research and development and limited clinical trials of our cancer detection kits. Our ability to generate revenues and achieve profitability in the long run depends on our ability to successfully complete the development of our products, obtain market approval and generate significant revenues. The future success of our business cannot be determined at this time, and we do not anticipate generating revenues from cancer detection product sales for the foreseeable future. At the same time, we recognize that the recent development of several vaccines for COVID-19 may make our COVID-19 tests less valuable. In addition, we face a number of challenges with respect to our future commercialization efforts of our products that do not relate to COVID-19, including, among others, that:

 

  we may not have adequate financial or other resources to complete the development of our products;
     
  we may not be able to manufacture our products in commercial quantities, at an adequate quality or at an acceptable cost;
     
  we may not be able to meet the timing schedule for (a) completing successful clinical trials in the U.S.; and (b) receiving U.S. Food and Drug Administration, or FDA, approval within our goal of approximately two to four years;
     
  we may not be able to maintain our CE mark due to the regulatory changes;
     
  we may never receive FDA approval, for our intended development plan;
     
  we may not be able to establish adequate sales, marketing and distribution channels;
     
  healthcare professionals and patients may not accept our cancer detection kits;
     
  technological breakthroughs in cancer detection, treatment and prevention may reduce the demand for our products;
     
  changes in the market for cancer detection, new alliances between existing market participants and the entrance of new market participants may interfere with our market penetration efforts;
     
  third-party payors may not agree to reimburse patients for any or all of the purchase price of our products, which may adversely affect patients’ willingness to purchase our cancer detection kits;
     
  uncertainty as to market demand may result in inefficient pricing of our cancer detection kits;
     
  we may face third-party claims of intellectual property infringement;
     
  we may fail to obtain or maintain regulatory approvals for our cancer detection kits in our target markets or may face adverse regulatory or legal actions relating to our cancer detection kits even if regulatory approval is obtained; and
     
  we are dependent upon the results of ongoing clinical studies relating to our cancer detection kits and the products of our competitors. We may fail in obtaining positive results.

 

If we are unable to meet any one or more of these challenges successfully, our ability to effectively commercialize our cancer detection kits could be limited, which in turn could have a material adverse effect on our business, financial condition and results of operations.

 

We are currently in the process of improving our technology and adapting to the high throughput methodology.

 

We believe our existing protocols and measurement instruments are sufficient to support the initial commercial launch in Israel and Europe. However, we plan to change our protocol and measurement instrument as well as our sample handling in order to adapt it to new high throughput methodology once we have successfully commercialized and have begun research activities on this second-generation protocols and measurement instruments. The changes we plan to implement in the second-generation protocol and measurement instrument are significant. The new protocol aims to be more robust, reproducible, fast and easy to handle, however, this transformation from the older manual protocol to the new protocol incurs several risks. To our management’s knowledge, the new protocol will not impact the previously obtained European Conformity, or CE, mark of approval of the TBIA test. The results may not be as promising as the former version and although some procedures may be more reproducible, these procedures will unfortunately damage some molecules, which were part of the diagnostic features in the previous protocol.

 

15

 

 

The previous tests we performed were preliminary or limited un-blinded studies.

 

We consider the tests conducted by us, as of the current date, under our method, to be preliminary or limited, as they include a relatively small number of test subjects. Thus, there is a risk in having less sufficient sensitivity and/or specificity in the trials we plan on conducting with larger populations, in comparison to the preliminary data we have gathered thus far. Increasing the population can increase the variance in the medical condition of the control patients as well as the cancer patients, thus affecting our test performances with regard to cancer detection.

 

If healthcare professionals do not recommend our product to their patients, our cancer detection kits may not achieve market acceptance and we may not become profitable.

 

Cancer detection candidates are generally referred to a specified device by their healthcare professional and detection technologies are purchased by prescription. If healthcare professionals, including physicians, do not recommend or prescribe our product to their patients, our cancer detection kits may not achieve market acceptance and we may not become profitable. In addition, physicians have historically been slow to change their medical diagnostic and treatment practices because of perceived liability risks arising from the use of new products. Delayed adoption of our cancer detection kits by healthcare professionals could lead to a delayed adoption by patients and third-party payors. Healthcare professionals may not recommend or prescribe our cancer detection kits until certain conditions have been satisfied, including, among others:

 

  sufficient long-term clinical evidence to convince them to supplement their existing detection methods and device recommendations;
     
  recommendations from other prominent physicians, educators and/or associations that our cancer detection kits are safe and effective;
     
  obtainment of favorable data from clinical studies for our cancer detection kits; and
     
  availability of reimbursement or insurance coverage from third-party payors.

 

We cannot predict when, if ever, healthcare professionals and patients may adopt the use of our cancer detection kits. Even if favorable data is obtained from clinical studies for our cancer detection kits, there can be no assurance that physicians would endorse it or that future clinical studies will continue to produce favorable data regarding our cancer detection kits. In addition, prolonged market exposure may also be a pre-requisite to reimbursement or insurance coverage from third-party payors. If our cancer detection kits do not achieve an adequate level of acceptance by patients, healthcare professionals and third-party payors, we may not generate significant product revenues and we may not become profitable.

 

Our reliance on limited source suppliers could harm our ability to meet demand for our product in a timely manner or within budget.

 

We currently depend on a limited number of source suppliers for some of the components necessary for the production of our product. Our current suppliers have been able to supply the required quantities of such components to date. However, if the supply of these components is disrupted or terminated or if our current suppliers are unable to supply required quantities of components, we may not be able to find alternative sources for these key components in a timely manner. Although we are planning to maintain strategic inventory of key components, the inventory may not be sufficient to satisfy the demand for our products if such supply is interrupted or otherwise affected by catastrophic events such as a fire at our storage facility. As a result, we may be unable to meet the demand for our testing kits, which could harm our ability to generate revenues, lead to customer dissatisfaction and damage our reputation. If we are required to change the manufacturer of any of these key components, there may be a significant delay in locating a suitable alternative manufacturer. The delays associated with the identification of a new manufacturer could delay our ability to manufacture our testing kits in a timely manner or within budget. Furthermore, in the event that the manufacturer of a key component of our testing kits ceases operations or otherwise ceases to do business with us, we may not have access to the information necessary to enable another supplier to manufacture the component. The occurrence of any of these events could harm our ability to meet demand for our testing kits in a timely manner or within budget.

 

16

 

 

We have sent a demand letter to a significant customer, which has not yet paid for some of the Covid-19 testing kits that we supplied to it.

 

During the first quarter of 2021, the Company’s contractual agreement to supply Covid-19 testing kits to NOAH Laboratories, Inc., a significant customer, expired. At the customer’s request, the Company continued to supply Covid-19 testing kits until such time as the customer requested that the Company stop doing so. The customer has not yet paid for some of the Covid-19 testing kits so supplied, and has not renewed its agreement with the Company. On November 15, 2021, Todos USA sent a demand letter (the “Demand Letter”) to a significant customer with which our contractual agreement to supply Covid-19 testing kits expired. The Demand Letter seeks (a) payment for testing kits that Todos USA supplied for which it was not paid, in the amount of $3,465,000, (b) the return of Todos USA’s equipment, title to which remains with Todos USA unless and until the significant customer meets a minimum purchase requirement, and (c) payment of damages as a result of the significant customer’s unlawful retention of Todos USA’s equipment, in an amount anticipated to be $2 million. The Company and Todos USA are negotiating a settlement with NOAH Laboratories, Inc., which the Company believes will result in most of the Company’s demands being met. The Company believes that ultimately the customer will pay for the Covid-19 testing kits so supplied. Should the customer not make payment in full of all amounts owed to the Company, it could have a material adverse effect on the Company’s revenues from the sale of Covid-19 testing kits.

 

The use of any of our products could result in product liability or similar claims that could have an adverse effect on our business, financial condition, results of operations and our reputation.

 

Our business exposes us to an inherent risk of potential product liability or similar claims related to the manufacturing, marketing and sale of medical devices. The medical device industry has historically been litigious, and we face financial exposure to product liability or similar claims if the use of our kits were to cause or contribute to injury or death, including, without limitation, harm to the body caused by the procedure or inaccurate diagnoses from the procedure that could affect treatment options. There is also the possibility that defects in the design or manufacture of any of these products might necessitate a product recall. Although we plan to maintain product liability insurance, the coverage limits of these policies may not be adequate to cover future claims. In the future, we may be unable to maintain product liability insurance on acceptable terms or at reasonable costs and such insurance may not provide us with adequate coverage against potential liabilities. A product liability claim, regardless of merit or ultimate outcome, or any product recall could result in substantial costs to us, damage to our reputation, customer dissatisfaction and frustration, and a substantial diversion of management attention. A successful claim brought against us in excess of, or outside of, our insurance coverage could have a material adverse effect on our business, financial condition, results of operations and our reputation.

 

We will require additional funding in order to commercialize our cancer detection kits and to develop and commercialize any future products.

 

Assuming we are successful in raising additional capital, we will continue our efforts to commercialize our cancer detection kits.

 

In order to market and sell our products in Israel, we require the approval of the Ministry of Health. To the best of our knowledge, approval of our products by the Ministry of Health requires us to comply with CE mark approval and International Organization for Standardization (ISO) 13485 (both of which we have already obtained). We were previously approved to sell our products in Israel, and we have restarted the regulatory approval process in Israel and expect the regulatory approval process in Israel to take until the end of the second quarter of 2022, although there may be delays due to the backlog from the Coronavirus pandemic.

 

17

 

 

Furthermore, if adequate additional financing on acceptable terms is not available, we may not be able to develop our cancer detection kits at the rate or to the stage we desire, and we may have to delay or abandon the commercialization of our cancer detection kits. Alternatively, we may be required to prematurely license to third parties the rights to further develop or to commercialize our cancer detection kits on terms that are not favorable to us. Any of these factors could materially adversely affect our business, financial condition and results of operations.

 

We are entering a potentially highly competitive market.

 

Early detection is vital to the treatment of cancer, which is also the focus area of our products. The diagnostic, pharmaceutical and biopharmaceutical industries are characterized by intense competition and rapid, significant technological changes. Many companies, research institutions and universities are conducting research and development in a number of areas similar to those that we focus on that could lead to the development of new products which could possibly compete with our own. Most of the companies against which we will compete have substantially greater financial, technical, manufacturing, marketing, distribution and other resources. A number of these companies may have or may develop technologies for developing products for detecting various cancers that could prove to be the same or even superior to ours. We expect technological developments in the diagnostic, pharmaceutical, biopharmaceutical and related fields to occur at a rapid rate, and we believe competition will intensify as advances in these fields are made.

 

Our future success depends in part on our ability to retain our executive officers and to attract, retain and motivate other qualified personnel.

 

We are highly dependent on the principal members of our management, research and development team and scientific staff. In order to implement our business strategy, we will need to attract and retain key personnel with expertise in the areas of research and development, clinical testing, government regulation, manufacturing, finance, marketing and sales. The inability to recruit and retain qualified personnel, or the loss of the services of our executive officers, without proper replacement, may impede the progress of our development and commercialization objectives.

 

There are future financial risks associated with funding our business operations with loans.

 

It is highly likely that we will find it necessary to borrow funds from banks or other financial institutions. In particular, despite the fact that we have repurchased a significant portion of our convertible debt, we may still need to borrow money in order to repurchase additional convertible debt that we have issued to finance our operations, the conversion of which may have a depressant effect on our stock price. No assurances can be given that, at the time we desire to borrow funds, banks or other financial institutions will be willing to loan funds to us or that, if willing, they will do so on terms acceptable to our management. If we cannot borrow sufficient funds for our operations, that might have a material adverse effect on our business, financial condition or operating results.

 

We may become involved in legal proceedings.

 

From time to time, we may become involved in various lawsuits and legal proceedings, including securities class action litigation. In the past, biotechnology and pharmaceutical companies have experienced significant share price volatility, particularly when associated with binary events such as clinical trials and product approvals. If we face such litigation, it could result in substantial costs and a diversion of management’s attention and resources, which could harm our business and result in a decline in the market price of our Ordinary Shares.

 

We may face tax exposure as a result of the Provista transaction.

 

On April 19, 2021, the Company entered into an Agreement to Purchase Provista Diagnostics, Inc. (“Agreement to Purchase”) with Strategic Investment Holdings, LLC (“SIH”), Ascenda BioSciences LLC (“Ascenda”) and Provista Diagnostics, Inc. (“Provista”). Ascenda was the sole owner of the outstanding securities of Provista and SIH is the sole owner of all the outstanding securities of Ascenda.

 

18

 

 

Pursuant to the Agreement to Purchase, the Company acquired Provista from Ascenda and SIH for an aggregate purchase price of $7.5 million consisting of an initial cash payment of $1.25 million, the issuance of $1.5 million in Ordinary Shares of the Company priced at $0.0512 per share, the issuance of a $3.5 million convertible promissory note dated April 19, 2021 (the “Note”) and the payment on for before July 1, 2021 of $1.25 million in cash (the “July Payment”), which payment the Company had the right to, and did, extend to July 15, 2021. The Provista shares acquired by the Company remained in an escrow account until the July Payment was made. The Note has a maturity date of April 8, 2025, and is convertible beginning on October 20, 2021, into Ordinary Shares of the Company at a conversion price equal to the lesser of $0.05 or the volume weighted average price of the last 20 trading days for the Ordinary Shares prior to the date of conversion. In the event SIH delivers a Notice of Conversion to the Company at a per share price less than $0.05 ($0.05), the Company has the right to immediately notify SIH of its intention to pay the conversion amount in cash within three (3) business days of receipt of the Notice of Conversion (i.e., before SIH would take possession of shares converted under the Notice of Conversion). If, at any time between October 20, 2021 and April 20, 2022, the average of the lowest bid and closing sale price at 4:00:00 p.m., New York time (or such other time as such market publicly announces is the official close of trading) is below ($0.05), the Company has the option to buy out all or any portion of the Note (the “Buyback Option”). In the event the Company exercises the Buyback Option for an amount equal to or greater than one million, one hundred seventy thousand dollars ($1,170,000) (the “Buyback Amount”), SIH may not submit any conversions below five cents ($0.05) for ninety (90) days from receipt of the Buyback Amount (“90 Day Period”).

 

In the event that the Company uplists its Ordinary Shares to a national securities exchange, the Note shall automatically be exchanged into Series B preferred stock with a conversion price equal to the lesser of (a) $0.05, (b) the opening price on the day of the uplisting provides there is no transaction associated with the uplisting or (c) the deal price of an uplisting transaction.

 

As of the date of this prospectus, SIH has not submitted a Conversion Notice.

 

To the extent that the value of the assets transferred to us in the transaction are not comparable to the value of our Ordinary Shares issued to SIH pursuant to the Option Agreement, we may face tax exposure in both Israel and the United States.

 

We may face tax liability as a result of the Amarantus transaction.

 

On February 27, 2019, we entered into a joint venture agreement with Amarantus Bioscience Holdings, Inc. (“Amarantus”) pursuant to which we issued Ordinary Shares representing 19.99% of the then-issued and outstanding Ordinary Shares of our Company to Amarantus, in exchange for Amarantus transferring to us 19.99% of Breakthrough, which was then a wholly-owned subsidiary of Amarantus, and for Amarantus assigning its amended and restated license agreement with the University of Leipzig for an exclusive license to develop and commercialize the LymPro Test®, an immune-based neurodiagnostic blood test for the detection of Alzheimer’s disease (the “License”). On April 14, 2019, we notified Amarantus of the Company’s decision to exercise its option to acquire the remaining 80.01% of Breakthrough held by Amarantus in exchange for the issuance to Amarantus of Ordinary Shares of the Company representing an additional thirty percent (30%) of the Company’s then-issued and outstanding share capital, such that the Company would own 100% of Breakthrough, and Amarantus would own 49.99% of the Company. At the annual meeting of shareholders of the Company held on April 29, 2019, the Company’s shareholders voted on a resolution approving the Company’s exercise of this option. On July 28, 2020, the Company entered into Amendment No. 1 to the Binding Joint Venture Agreement with Amarantus pursuant to which the parties agreed that the Company would issue 49.9% of its Ordinary Shares as of December 31, 2019 to Amarantus in exchange for the 80.01% equity interest it does not own of Breakthrough Diagnostics, Inc. In addition, Amarantus will receive a 10% royalty on LymPro intellectual property. On July 28, 2020, the Company exercised this option and issued an additional 67,599,796 Ordinary Shares to Amarantus. To the extent that the value of the assets transferred to us in the transaction is not comparable to the value of our Ordinary Shares issued to Amarantus in this transaction, we may face a tax exposure in both Israel and the United States.

 

19

 

 

Our U.S. Holders may suffer adverse tax consequences if we were to be characterized as a passive foreign investment company, or PFIC.

 

Generally, if for any taxable year 75% or more of our gross income is passive income, or at least 50% of our assets are held for the production of, or produce, passive income, we would be characterized as a passive foreign investment company, or PFIC, for U.S. federal income tax purposes. There can be no assurance that we will not be classified as a PFIC in any year. If we were to be characterized as a PFIC for U.S. federal income tax purposes in any taxable year during which a U.S. Holder, as defined in “Taxation— U.S. Tax Considerations”, owns Ordinary Shares, such U.S. Holder could face adverse U.S. federal income tax consequences, including having gains realized on the sale of our Ordinary Shares classified as ordinary income, rather than as capital gains, a loss of the preferential rate applicable to dividends received on our Ordinary Shares by individuals who are U.S. Holders and having interest charges apply to distributions by us and the proceeds of share sales. Certain elections exist that may alleviate some of the adverse consequences of PFIC status and would result in an alternative treatment (such as mark-to-market treatment) of our Ordinary Shares; however, we do not intend to provide the information necessary for U.S. Holders to make “qualified electing fund elections”, or QEF elections, if we are classified as a PFIC, and, accordingly, such elections would not be available to U.S. Holders. See “Taxation — U.S. Tax Considerations”.

 

Our business may be adversely affected by the ongoing Coronavirus pandemic.

 

The outbreak of the novel Coronavirus (COVID-19) has evolved into a global pandemic. The Coronavirus has spread to many regions of the world. The extent to which the Coronavirus impacts our business and operating results will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning the Coronavirus and the actions to contain the Coronavirus or treat its impact, among others.

 

As a result of the continuing spread of the Coronavirus, certain aspects of our cancer testing business operations may be delayed. Specifically, as a result of shelter-in-place orders and other mandated local travel restrictions, among other things, the research and development activities of certain of our partners may be affected, resulting in delays to our clinical trials, and we can provide no assurance as to when such trials will resume at this time.

 

Furthermore, site initiation, participant recruitment and enrollment, participant dosing, distribution of clinical trial materials, study monitoring, and data analysis may be paused or delayed due to changes in hospital or university policies, federal, state or local or foreign regulations, prioritization of hospital resources toward pandemic efforts, or other reasons related to the pandemic. If the Coronavirus continues to spread, some participants and clinical investigators may not be able to comply with clinical trial protocols. For example, quarantines or other travel limitations (whether voluntary or required) may impede participant movement, affect sponsor access to study sites, or interrupt healthcare services, and we may be unable to conduct our clinical trials. Further, if the spread of the Coronavirus pandemic continues and our operations are adversely impacted, we risk a delay, default and/or non-performance under existing agreements which may increase our costs. These cost increases may not be fully recoverable or adequately covered by insurance.

 

Infections and deaths related to the pandemic may disrupt the United States’ or other countries’ healthcare and healthcare regulatory systems. Such disruptions could divert healthcare resources away from, or materially delay FDA or foreign regulatory agency review and/or approval with respect to, our clinical trials. It is unknown how long these disruptions could continue, were they to occur. Any elongation or de-prioritization of our clinical trials or delay in regulatory review resulting from such disruptions could materially affect the development and study of our product candidates.

 

We currently utilize third parties to, among other things, manufacture raw materials. If any third-party party in the supply chain for materials used in the production of our product candidates is adversely impacted by restrictions resulting from the Coronavirus outbreak, our supply chain may be disrupted, limiting our ability to manufacture our product candidates for our clinical trials and research and development operations.

 

On the other hand, we have produced revenue as a result of the Coronavirus pandemic through our testing products and our Tollovid nutritional supplement. If the Coronavirus pandemic were to end completely, these revenues will disappear. Notwithstanding the development of several vaccines against the Coronavirus, it appears that for now, at least, the Coronavirus pandemic is not ending in many countries, and we expect to continue to produce revenue from our Coronavirus testing and from Tollovid (as well as from Tollovir if it is commercialized) for at least the next 12 months.

 

The spread of the Coronavirus, which has caused a broad impact globally, including restrictions on travel and quarantine policies put into place by businesses and governments, may have a material economic effect on our business. While the potential economic impact brought by and the duration of the pandemic may be difficult to assess or predict, it has already caused, and is likely to result in further, significant disruption of global financial markets, which may reduce our ability to access capital either at all or on favorable terms. In addition, a recession, depression or other sustained adverse market event resulting from the spread of the Coronavirus could materially and adversely affect our business and the value of our Ordinary Shares.

 

20

 

 

The ultimate impact of the current pandemic, or any other health epidemic, is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole. However, these effects could have a material impact on our operations, and we will continue to monitor the situation closely.

 

Risks Related to Our Intellectual Property

 

We may not successfully maintain our existing license agreement with BGU and Soroka, and we are currently not in compliance with the repayment terms of the license agreement, which could adversely affect our ability to develop and commercialize our product candidates.

 

We rely on our existing License Agreement with BGU and Soroka with respect to the development of our core cancer technology, TBIA. Our failure to maintain our existing license could adversely affect our ability to develop and commercialize our product candidates and could adversely affect our business prospects, financial condition or ability to develop and commercialize our product candidates.

 

We may not be able to further establish or maintain such licensing and collaboration arrangements necessary to develop and commercialize our product candidates. Even if we are able to maintain or establish licensing or collaboration arrangements, these arrangements may not be on favorable terms and may contain provisions that will restrict our ability to develop, test and market our product candidates. Any failure to maintain or establish licensing or collaboration arrangements on favorable terms could adversely affect our business prospects, financial condition or ability to develop and commercialize our product candidates.

 

Our license agreement contains provisions that could give rise to disputes regarding the rights and obligations of the parties. These and other possible disagreements could lead to termination of the agreement or delays in collaborative research, development, supply, or commercialization of certain product candidates, or could require or result in litigation or arbitration. Moreover, disagreements could arise with our collaborators over rights to intellectual property or our rights to share in any of the future revenues of products developed by our collaborators. These kinds of disagreements could result in costly and time-consuming litigation. Any such conflicts with our collaborators could reduce our ability to obtain future collaboration agreements and could have a negative impact on our relationship with existing collaborators.

 

If we are unable to protect our intellectual property rights, our competitive position could be harmed.

 

Our success and ability to compete depends in large part upon our ability to protect our intellectual property. We face several risks and uncertainties in connection with our intellectual property rights, including, among others:

 

  pending and future patent applications may not result in the issuance of patents or, if issued, may not be issued in a form that will be advantageous to us;
     
  our issued patents may be challenged, invalidated or legally circumvented by third parties;
     
  our patents may not be upheld as valid and enforceable or prevent the development of competitive products;
     
  the eligibility of certain inventions related to diagnostic medicine, more specifically diagnostic methods and processes, for patent protection in the United States has been limited recently which may affect our ability to enforce our issued patents in the United States or may make it difficult to obtain broad patent protection going forward in the United States;
     
  for a variety of reasons, we may decide not to file for patent protection on various improvements or additional features; and
     
  intellectual property protection and/or enforcement may be unavailable or limited in some countries where laws or law enforcement practices may not protect our proprietary rights to the same extent as the laws of the United States, the European Union, or Israel.

 

21

 

 

Consequently, our competitors could develop, manufacture and sell products that directly compete with our products, which could decrease our sales and diminish our ability to compete. In addition, competitors could attempt to develop their own competitive technologies that fall outside of our intellectual property rights. If our intellectual property does not adequately protect us from our competitors’ products and methods, our competitive position could be materially adversely affected.

 

Because the medical device industry is litigious, we are susceptible to intellectual property suits that could cause us to incur substantial costs or pay substantial damages or prohibit us from selling our cancer detection kits.

 

There is a substantial amount of litigation over patent and other intellectual property rights in the medical device industry. Whether or not a product infringes a patent involves complex legal and factual considerations, the determination of which is often uncertain. Our management is presently unaware of any other parties’ valid patents and proprietary rights which our evolving product designs would infringe. Searches typically performed to identify potentially infringed patents of third parties are often not conclusive and, because patent applications can take many years to issue, there may be applications now pending, which may later result in issued patents which our current or future products may infringe. In addition, our competitors or other parties may assert that our cancer detection kits, and the methods employed may be covered by patents held by them. If any of our products infringes a valid patent, we could be prevented from manufacturing or selling such product unless we are able to obtain a license or able to redesign the product in such a manner as to avoid infringement. A license may not always be available or may require us to pay substantial royalties. We also may not be successful in any attempt to redesign our product to avoid infringement. Infringement and other intellectual property claims, with or without merit, can be expensive and time-consuming to litigate and could divert our management’s attention from operating our business.

 

The steps we have taken to protect our intellectual property may not be adequate, which could have a material adverse effect on our ability to compete in the market.

 

In addition to filing patent applications, we rely on confidentiality, non-compete, non-disclosure and assignment of inventions provisions, as appropriate, in our agreements with our employees, consultants, and service providers, to protect and otherwise seek to control access to, and distribution of, our proprietary information. These measures may not be adequate to protect our intellectual property from unauthorized disclosure, third-party infringement or misappropriation, for the following reasons:

 

  the agreements may be breached, may not provide the scope of protection we believe they provide or may be determined to be unenforceable;
     
  we may have inadequate remedies for any breach;
     
  proprietary information could be disclosed to our competitors; or
     
  others may independently develop substantially equivalent or superior proprietary information and techniques or otherwise gain access to our trade secrets or disclose such technologies.

 

Specifically, with respect to non-compete agreements, we may be unable to enforce these agreements, in whole or in part, and it may be difficult for us to restrict our competitors from gaining the expertise that our former employees gained while working for us. If our intellectual property is disclosed or misappropriated, it could harm our ability to protect our rights and could have a material adverse effect on our business, financial condition and results of operations.

 

22

 

 

We may need to initiate lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive and, if we lose, could cause us to lose some of our intellectual property rights, which would harm our ability to compete in the market.

 

We rely on patents to protect a portion of our intellectual property and our competitive position. Patent law relating to the scope of claims in the technology fields in which we operate is still evolving and, consequently, patent positions in the medical device industry are generally uncertain. In order to protect or enforce our patent rights, we may initiate patent and related litigation against third parties, such as infringement suits or interference proceedings. Any lawsuits that we initiate could be expensive, take significant time and divert our management’s attention from other business concerns and the outcome of litigation to enforce our intellectual property rights in patents, copyrights, trade secrets or trademarks is highly unpredictable. Litigation also puts our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing. In addition, we may provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, including attorney fees, if any, may not be commercially valuable. The occurrence of any of these events could have a material adverse effect on our business, financial condition and results of operations.

 

Risks Related to Regulations

 

If we or our future distributors do not obtain and maintain the necessary regulatory clearances or approvals in a specific country or region, we will not be able to market and sell our cancer detection kits or future products in that country or region.

 

We intend to market our cancer detection kits in a number of international markets. To be able to market and sell our cancer detection kits in a specific country or region, we or our distributors must comply with the regulations of that country or region. While the regulations of some countries do not impose barriers to marketing and selling part or all of our products or only require notification, others require that we or our distributors obtain the approval of a specified regulatory authority. These regulations, including the requirements for approvals and the time required for regulatory review, vary from country to country. Obtaining regulatory approvals is expensive and time-consuming, and we cannot be certain that we or our distributors will receive regulatory approvals for our cancer detection kits or any future products in each country or region in which we plan to market such products. If we modify our cancer detection kits or any future products, we or our distributors may need to apply for new regulatory approvals or regulatory authorities may need to review the planned changes before we are permitted to sell them.

 

We obtained approval to use the European CE mark on December 9, 2013 with the receipt of a Certificate of Conformance from our regulatory authorized representative in Europe. The European regulatory demands regarding IVD have recently been revised and major changes need to be made in order to keep our CE Mark. These changes will need to be made by 2022. We may not meet the quality and safety standards required to maintain any authorizations we receive in the future or maintain the CE Certificate of Conformance that we have already received. If we or our distributors are unable to maintain our authorizations or CE Certificate of Conformance in a particular country or region, we will no longer be able to sell our cancer detection kits or any future products in that country or region, and our ability to generate revenues will be materially and adversely affected.

 

If we are unable to successfully complete clinical trials with respect to our cancer detection kits, we may be unable to receive regulatory approvals or clearances for our cancer detection kits and/or our ability to achieve market acceptance of our cancer detection kits will be harmed.

 

The development of cancer diagnostics typically includes pre-clinical studies. Certain other devices require the submission of data generated from clinical trials, which can be a long, expensive and uncertain process, subject to delays and failure at any stage. The data obtained from the studies and trials may be inadequate to support regulatory clearances or approvals, or to obtain third country approval equivalent to the European CE mark of approval, or to allow market acceptance of the products being studied. Our cancer detection kits are currently undergoing clinical development.

 

We conducted clinical studies in cooperation with leading hospitals in Israel. A study with Soroka (along with BGU) formed the basis of our methodology. We then conducted studies, with both Rabin Medical Center, or Rabin, and Kaplan Medical Center, or Kaplan, which focused on breast and colorectal cancers.

 

23

 

 

As for the FDA, our products’ intended use or other specifications that are under development today may not be accepted by the FDA. Under such circumstances, we may be required to change the intended use or specifications of our products, and be required to perform additional trials and provide new supportive material to the FDA.

 

We are an IVD company, developing proprietary technology which will analyze a blood sample to detect the presence of various cancers. Since we are not developing a drug, we believe that we will not need to submit an investigational new drug application to the FDA prior to conducting clinical trials in the U.S. We believe that we will only need institutional review board, or IRB, approval prior to conducting clinical trials in the U.S.

 

We expect that obtaining FDA approval for the marketing and selling of our products in the U.S. will take anywhere between two to four years and will cost us approximately $10 million to $15 million. As we do not have this amount of money, we would need to raise additional funds to perform clinical trials in the U.S. in order to receive FDA approval. If we are unable to raise such funds, we will not be able proceed with our efforts to obtain FDA approval. Inability to obtain FDA approval would significantly harm our viability as a company.

 

We estimate that we will need a “small pilot” clinical trial (less than 100 patients) to enable us to approach the FDA with the results and begin a dialogue with the FDA to seek the FDA’s recommendation (not their approval) as to trial size and the protocols for future U.S. clinical trials. We plan to submit a formal application to the FDA for approval of the TBIA method after we have completed our clinical trials in the U.S.

 

Upon the closing of the Provista transaction, we acquired a Clinical Laboratory Improvement Amendments laboratory, or CLIA laboratory, and retain our product as a Laboratory Developed Test, or LDT, which are assays developed in the laboratory for internal use, in parallel to the FDA evaluation.

 

Further, any regulatory authority whose approval we will require in order to market and sell our products in any territory may require us to submit data on a greater number of patients than we originally anticipated and/or for a longer follow-up period, or may change the data collection requirements or data analysis applicable to our clinical trials.

 

The commencement or completion of any of our clinical studies or trials may be delayed or halted, or be inadequate to support regulatory clearance, approval or product acceptance, or to obtain local regulatory approvals in any country that we wish to sell our products, for numerous reasons, including, among others:

 

  patients do not enroll in the clinical trial at the rate we expect;
     
  patients do not comply with trial protocols;
     
  patient follow-up is not at the rate we expect;
     
  patients experience adverse side effects;
     
  patients die during a clinical trial, even though their death may be unrelated to our product;
     
  regulatory authorities do not approve a clinical trial protocol or a clinical trial, or place a clinical trial on hold;
     
  IRBs, Ethics Committees and third-party clinical investigators may delay or reject our trial protocol and Informed Consent Form;
     
  third-party clinical investigators decline to participate in a study or trial or do not perform a study or trial on our anticipated schedule or consistent with the investigator agreements, study or trial protocol, good clinical practices or FDA, IRBs, Ethics Committees, or other applicable requirements;
     
  third-party organizations such as the Contract Research Organization, do not perform data collection, monitoring and analysis in a timely or accurate manner or consistent with the study or trial protocol or investigational or statistical plans;

 

24

 

 

  regulatory inspections of our studies, trials or manufacturing facilities may require us to, among other things, undertake corrective action or suspend or terminate our studies or clinical trials;
     
  changes in governmental regulations or administrative actions;
     
  the interim or final results of the study or clinical trial are inconclusive or unfavorable as to safety or efficacy; and
     
  a regulatory agency or our notified body concludes that our trial design is or was inadequate to demonstrate different parameters of the assay.

 

The results of pre-clinical and clinical studies do not necessarily predict future clinical trial results, and predecessor clinical trial results may not be repeated in subsequent clinical trials. Additionally, any regulatory authority whose approval we will require in order to market and sell our products in any territory may disagree with our interpretation of the data from our pre-clinical studies and clinical trials, or may find the clinical trial design, conduct or results inadequate to demonstrate safety or efficacy, and may require us to pursue additional pre-clinical studies or clinical trials, which could further delay the clearance or approval of the sale of our products. The data we collect from our non-clinical testing, our pre-clinical studies and other clinical trials may not be sufficient to support regulatory approval.

 

If the third parties on which we rely to conduct our clinical trials and clinical development do not perform as contractually required or expected, we may not be able to obtain regulatory clearance or approval for, or commercialize, our cancer detection kits or future products.

 

We do not have the ability to independently conduct our clinical trials for our cancer detection kits and we must rely on third parties, such as contract research organizations, medical institutions, clinical investigators and contract laboratories to conduct such trials. If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, if these third parties need to be replaced, or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our pre-clinical development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory clearance for, or successfully commercialize, our cancer detection kits or future products on a timely basis, if at all, and our business, operating results and prospects may be adversely affected. Furthermore, our third-party clinical trial investigators may be delayed in conducting our clinical trials for reasons outside of their control.

 

The results of our clinical trials may not support our product claims or may result in the discovery of adverse side effects.

 

Even if our clinical trials are completed as planned, we cannot be certain that their results will support our product claims or that any regulatory authority whose approval we will require in order to market and sell our products in any territory will agree with our conclusions regarding them. Success in pre-clinical studies and early clinical trials does not ensure that later clinical trials will be successful, and we cannot be sure that clinical trials will replicate the results of prior trials and pre-clinical studies. The clinical trial process may fail to demonstrate that our cancer detection kits, or any future products, are safe and effective for the proposed indicated uses, which could cause us to abandon a product and may delay development of others. Any delay or termination of our clinical trials will delay the filing of our product submissions and, ultimately, our ability to commercialize our cancer detection kits, or any future products, and generate revenues. It is also possible that patients enrolled in clinical trials will experience adverse side effects that are not currently part of the product candidate’s profile.

 

25

 

 

Our cancer detection kits may in the future be subject to product recalls that could harm our reputation, business and financial results.

 

The FDA and similar foreign governmental authorities have the authority to require the recall of commercialized products in the event of material deficiencies or defects in design or manufacture. In the case of the FDA, the authority to require a recall must be based on an FDA finding that there is a reasonable probability that the device would cause serious injury or death. In addition, foreign governmental bodies have the authority to require the recall of our products in the event of material deficiencies or defects in design or manufacture. Manufacturers may, under their own initiative, recall a product if any material deficiency in a device is found. A government-mandated or voluntary recall by us or one of our distributors could occur as a result of component failures, manufacturing errors, design or labeling defects or other deficiencies and issues. Once marketed, recalls of any of our products, including our cancer detection kits, would divert managerial and financial resources and have an adverse effect on our business, financial condition and results of operations. The FDA requires that certain classifications of recalls be reported to the FDA within 10 working days after the recall is initiated. Companies are required to maintain certain records of recalls, even if they are not reportable to the FDA. We may initiate voluntary recalls involving our products in the future that we determine do not require us to notify the FDA. If the FDA disagrees with our determinations, they could require us to report those actions as recalls. A future recall announcement could harm our reputation with customers and negatively affect our sales. In addition, the FDA could take enforcement action against us based on our failure to report the recalls when they were conducted.

 

If we are unable to achieve reimbursement and coverage from third-party payors for laboratory tests using our cancer detection kits, or if reimbursement is insufficient to create an economic benefit for purchasing or using our cancer detection kits when compared to alternative tests, demand for our products may not grow at the rate we expect.

 

The demand for our cancer detection kits will depend significantly on the eligibility of the tests performed using our cancer detection kits for reimbursement through government-sponsored healthcare payment systems and private third-party payors. Reimbursement practices vary significantly from country to country and within some countries, by region, and we must obtain reimbursement approvals on a country-by-country and/or region-by-region basis. In general, the process of obtaining reimbursement and coverage approvals has been longer outside of the United States. We may not be able to obtain reimbursement approvals in a timely manner or at all and existing reimbursement and coverage policies may be revised from time to time by third-party payors. If physicians, hospitals and other healthcare providers are unable to obtain sufficient coverage and reimbursement from third-party payors for tests using our cancer detection kits, if reimbursement is, or is perceived by our customers to be, insufficient to create an economic incentive for purchasing or using our cancer detection kits, or if such reimbursement does not adequately compensate physicians and health care providers compared to the other tests they offer, demand for our products may not grow at the rate we expect.

 

Federal and state privacy laws, and equivalent laws of third countries, may increase our costs of operation and expose us to civil and criminal sanctions.

 

The Health Insurance Portability and Accountability Act of 1996, as amended, and the regulations that have been issued under it, or collectively HIPAA, and similar laws outside the United States, contain substantial restrictions and requirements with respect to the use and disclosure of individuals’ protected health information. The HIPAA privacy rules prohibit “covered entities,” such as healthcare providers and health plans, from using or disclosing an individual’s protected health information, unless the use or disclosure is authorized by the individual or is specifically required or permitted under the privacy rules. Under the HIPAA security rules, covered entities must establish administrative, physical and technical safeguards to protect the confidentiality, integrity and availability of electronic protected health information maintained or transmitted by them or by others on their behalf. While we do not believe that we will be a covered entity under HIPAA, we believe many of our customers will be covered entities subject to HIPAA. Such customers may require us to enter into business associate agreements, which will obligate us to safeguard certain health information we obtain in the course of our relationship with them, restrict the manner in which we use and disclose such information and impose liability on us for failure to meet our contractual obligations.

 

In addition, under The Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, certain of HIPAA’s privacy and security requirements are now also directly applicable to “business associates” of covered entities and subject them to direct governmental enforcement for failure to comply with these requirements. We may be deemed as a “business associate” of some of our customers. As a result, we may be subject to civil and criminal penalties for failure to comply with applicable privacy and security rule requirements. Moreover, HITECH created a new requirement obligating “business associates” to report any breach of unsecured, individually identifiable health information to their covered entity customers and imposes penalties for failing to do so.

 

26

 

 

In addition to HIPAA, most U.S. states have enacted patient confidentiality laws that protect against the disclosure of confidential medical information, and many U.S. states have adopted or are considering adopting further legislation in this area, including privacy safeguards, security standards, and data security breach notification requirements. These U.S. state laws, which may be even more stringent than the HIPAA requirements, are not preempted by the federal requirements, and we are therefore required to comply with them to the extent they are applicable to our operations.

 

These and other possible changes to HIPAA or other U.S. federal or state laws or regulations, or comparable laws and regulations in countries where we conduct business, could affect our business and the costs of compliance could be significant. Failure by us to comply with any of the standards regarding patient privacy, identity theft prevention and detection, and data security may subject us to penalties, including civil monetary penalties and in some circumstances, criminal penalties. In addition, such failure may damage our reputation and adversely affect our ability to retain customers and attract new customers.

 

The protection of personal data, particularly patient data, is subject to strict laws and regulations in many countries. The collection and use of personal health data in the EU are governed by the provisions of the General Data Protection Regulation (GDPR). GDPR carries provisions that require businesses to protect the personal data and privacy of EU citizens for transactions that occur within EU member states. The GDPR also regulates the exportation of personal data outside the EU. The GDPR will levy harsh fines against those who violate its privacy and security standards, with penalties reaching into the tens of millions of euros. The GDPR defines several roles that are responsible for ensuring compliance: data controller (defines how personal data is processed and the purposes for which it is processed), data processor (liable for breaches or non-compliance) and the data protection officer (liable to process, store and monitor large amounts of EU and Non-EU citizen data). Under the GDPR, health data is considered a special category of personal data, demanding even further steps for its protection than other, regular types of personal data. To lawfully process special category data, both a legal basis and a separate condition for processing must be identified. The GDPR also requires that upon processing special category data, you must keep records and include documenting the categories of the data you process. The GDPR doesn’t explicitly state how long an organization is allowed to hold on to personal data, however healthcare organizations should ensure that the information relating to health data is not kept for longer than needed. For that reason, retention periods must be clearly established and communicated to data subjects, such as patients. Additionally, the GDPR requires that before processing data that is likely to be high risk to the rights and freedoms of data subjects, a Data Protection Impact Assessment is to be conducted in order to identify the potential risks that could be faced.

 

The GDPR also imposes strict rules on the transfer of personal data out of the EU. Failure to comply with the requirements of the GDPR may result in fines and other administrative penalties and harm our business. We may incur extensive costs in ensuring compliance with these laws and regulations, particularly if we are considered to be a data controller within the meaning of the GDPR.

 

Once we commercialize our product, if ever, security breaches, loss of data and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation.

 

Once we commercialize our product, in the ordinary course of our business, it is highly likely that we and our third-party providers will collect and store sensitive data, including legally protected health information and personally identifiable information about patients, our healthcare provider customers and payors. We also may store sensitive intellectual property and other proprietary business information, including that of our customers and payors. We plan to manage and maintain our data utilizing a combination of on-site systems and cloud-based data center systems. This data will encompass a wide variety of business-critical information, including research and development information, commercial information and business and financial information.

 

We face four primary risks relative to protecting this critical information: loss of access risk, inappropriate disclosure risk, inappropriate modification risk and the risk of our being unable to identify and audit our controls over the first three risks.

 

27

 

 

We will be highly dependent on information technology networks and systems, including the Internet, to securely process, transmit and store this critical information. Security breaches of this infrastructure, including physical or electronic break-ins, computer viruses, attacks by hackers and similar breaches, can create system disruptions, shutdowns or unauthorized disclosure or modification of confidential information. The secure processing, storage, maintenance and transmission of this critical information will be vital to our operations and business strategy, and we plan to devote significant resources to protecting such information. Although we will take measures to protect sensitive information from unauthorized access or disclosure, our information technology and infrastructure, and that of our third-party providers, may be vulnerable to attacks by hackers or viruses or breached due to employee error, malfeasance or other disruptions.

 

A security breach or privacy violation that leads to disclosure or modification of or prevents access to consumer information (including personally identifiable information or protected health information) could harm our reputation, compel us to comply with disparate state breach notification laws, require us to verify the correctness of database contents and otherwise subject us to liability under laws that protect personal data, resulting in increased costs or loss of revenue. If we are unable to prevent such security breaches or privacy violations or implement satisfactory remedial measures, our operations could be disrupted, and we may suffer loss of reputation, financial loss and other regulatory penalties because of lost or misappropriated information, including sensitive consumer data. In addition, these breaches and other inappropriate access can be difficult to detect, and any delay in identifying them may lead to increased harm of the type described above.

 

Any such breach or interruption could compromise our networks or those of our third-party providers, and the information stored there could be inaccessible or could be accessed by unauthorized parties, publicly disclosed, lost or stolen. Any such interruption in access, improper access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, such as HIPAA, and regulatory penalties. Unauthorized access, loss or dissemination could also disrupt our operations, including our ability to perform tests, provide test results, bill payers or patients, process claims and appeals, provide customer assistance services, conduct research and development activities, collect, process and prepare company financial information, provide information about our current and future products and other patient and clinician education and outreach efforts through our website, and manage the administrative aspects of our business and damage our reputation, any of which could adversely affect our business. Any such breach could also result in the compromise of our trade secrets and other proprietary information, which could adversely affect our competitive position.

 

In addition, the interpretation and application of consumer, health-related, privacy and data protection laws in the U.S., the EU and elsewhere are often uncertain, contradictory and in flux. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices. If so, this could result in government-imposed fines or orders requiring that we change our practices, which could adversely affect our business. Complying with these various laws could cause us to incur substantial costs or require us to change our business practices and compliance procedures in a manner adverse to our business.

 

If we fail to comply with the U.S. federal Anti-Kickback Statute and similar state and third country laws, we could be subject to criminal and civil penalties and exclusion from federally funded healthcare programs including the Medicare and Medicaid programs and equivalent third country programs, which would have a material adverse effect on our business and results of operations.

 

A provision of the Social Security Act, commonly referred to as the federal Anti-Kickback Statute, prohibits the knowing and willful offer, payment, solicitation or receipt of any form of remuneration, directly or indirectly, in cash or in kind, to induce or reward the referring, ordering, leasing, purchasing or arranging for, or recommending the ordering, purchasing or leasing of, items or services payable, in whole or in part, by Medicare, Medicaid or any other federal healthcare program. Although there are a number of statutory exemptions and regulatory safe harbors to the federal Anti-Kickback Statute protecting certain common business arrangements and activities from prosecution or regulatory sanctions, the exemptions and safe harbors are drawn narrowly, and practices that do not fit squarely within an exemption or safe harbor may be subject to scrutiny. The federal Anti-Kickback Statute is very broad in scope and many of its provisions have not been uniformly or definitively interpreted by existing case law or regulations. In addition, most of the states have adopted laws similar to the federal Anti-Kickback Statute, and some of these laws are even broader than the federal Anti- Kickback Statute in that their prohibitions may apply to items or services reimbursed under Medicaid and other state programs or, in several states, apply regardless of the source of payment. Violations of the federal Anti-Kickback Statute may result in substantial criminal, civil or administrative penalties, damages, fines and exclusion from participation in federal healthcare programs.

 

28

 

 

All of our future financial relationships with U.S. healthcare providers, purchasers, formulary managers, and others who provide products or services to federal healthcare program beneficiaries will potentially be governed by the federal Anti-Kickback Statute and similar state laws. We believe our operations will be in compliance with the federal Anti-Kickback Statute and similar state laws. However, we cannot be certain that we will not be subject to investigations or litigation alleging violations of these laws, which could be time-consuming and costly to us and could divert management’s attention from operating our business, which in turn could have a material adverse effect on our business. In addition, if our arrangements were found to violate the federal Anti-Kickback Statute or similar state laws, the consequences of such violations would likely have a material adverse effect on our business, results of operations and financial condition.

 

There are other federal and state laws that may affect our ability to operate, including the federal civil False Claims Act, which prohibits, among other things, individuals or entities from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment of government funds or knowingly making, using or causing to be made or used, a false record or statement material to an obligation to pay money to the government or knowingly concealing or knowingly and improperly avoiding, decreasing, or concealing an obligation to pay money to the federal government. Moreover, we may be subject to other federal false claim laws, including, among others, federal criminal healthcare fraud and false statement statutes that extend to non-government health benefit programs. Moreover, there are analogous state laws. Violations of these laws can result in substantial criminal, civil or administrative penalties, damages, fines and exclusion from participation in federal healthcare programs.

 

Similar restrictions are imposed by the national legislation of many third countries in which our medical devices will be marketed. Moreover, the provisions of the Foreign Corrupt Practices Act of 1997 and other similar anti-bribery laws in other jurisdictions generally prohibit companies and their intermediaries from providing money or anything of value to officials of foreign governments, foreign political parties, or international organizations with the intent to obtain or retain business or seek a business advantage. Recently, there has been a substantial increase in anti-bribery law enforcement activity by U.S. regulators, with more aggressive and frequent investigations and enforcement by both the SEC and the Department of Justice. A determination that our operations or activities violated U.S. or foreign laws or regulations could result in imposition of substantial fines, interruption of business, loss of supplier, vendor or other third-party relationships, termination of necessary licenses and permits, and other legal or equitable sanctions. In addition, lawsuits brought by private litigants may also follow as a consequence.

 

Risks Related to Our Operations in Israel

 

Conditions in Israel could materially and adversely affect our business.

 

Many of Todos’ employees and consultants, including its Chief Financial Officer and Chief Business Officer, are residents of Israel. Accordingly, political, economic, and military conditions in Israel and the surrounding region may directly affect Todos’ business and operations. In recent years, Israel has been engaged in sporadic armed conflicts with Hamas, an Islamist terrorist group that controls the Gaza Strip, with Hezbollah, an Islamist terrorist group that controls large portions of southern Lebanon, and with Iranian-backed military forces in Syria. In addition, Iran has threatened to attack Israel and may be developing nuclear weapons. Some of these hostilities were accompanied by missiles being fired from the Gaza Strip against civilian targets in various parts of Israel, including areas in which Todos’ employees are located, and negatively affected business conditions in Israel. Any hostilities involving Israel or the interruption or curtailment of trade between Israel and its trading partners could adversely affect our operations and results of operations.

 

Todos’ commercial insurance does not cover losses that may occur as a result of events associated with war and terrorism. Although the Israeli government currently covers the reinstatement value of direct damages that are caused by terrorist attacks or acts of war, Todos cannot assure you that this government coverage will be maintained or that it will sufficiently cover Todos’ potential damages. Any losses or damages incurred by Todos could have a material adverse effect on its business. Any armed conflicts or political instability in the region would likely negatively affect business conditions and could harm our results of operations.

 

29

 

 

Further, in the past, the State of Israel and Israeli companies have been subjected to economic boycotts. Several countries still restrict business with the State of Israel and with Israeli companies. These restrictive laws and policies may have an adverse impact on Todos’ results of operations, financial condition or the expansion of its business. A campaign of boycotts, divestment, and sanctions has been undertaken against Israel, which could also adversely affect Todos’ business. Actual or perceived political instability in Israel or any negative changes in the political environment, may individually or in the aggregate adversely affect the Israeli economy and, in turn, Todos’ business, financial condition, results of operations, and prospects.

 

In addition, many Israeli citizens are obligated to perform several weeks of annual military reserve duty each year until they reach the age of 40 (or older, for reservists who are military officers or who have certain occupations) and, in the event of a military conflict, may be called to active duty. In response to increases in terrorist activity, there have been periods of significant call-ups of military reservists. It is possible that there will be military reserve duty call-ups in the future. Todos’ operations could be disrupted by such call-ups, which may include the call-up of members of its management. Such disruption could materially adversely affect its business, prospects, financial condition, and results of operations.

 

Your rights and responsibilities as a shareholder will be governed by Israeli law which differs in some material respects from the rights and responsibilities of shareholders of U.S. companies.

 

The rights and responsibilities of the holders of our Ordinary Shares are governed by our articles of association, as amended (the “Amended Articles”), and by Israeli law. These rights and responsibilities differ in some material respects from the rights and responsibilities of shareholders in U.S.-based corporations. For instance, a shareholder of an Israeli company has a duty to act in good faith and in a customary manner in exercising its rights and performing its obligations towards the company and other shareholders, and to refrain from abusing its power in the company, including, among other things, in voting at a general meeting of shareholders on matters such as amendments to a company’s articles of association, increases in a company’s authorized share capital, mergers and acquisitions and related party transactions requiring shareholder approval. In addition, a shareholder who is aware that it possesses the power to determine the outcome of a shareholder vote or to appoint or prevent the appointment of a director or executive officer in the company has a duty of fairness toward the company. There is limited case law available to assist us in understanding the nature of this duty or the implications of these provisions. These provisions may be interpreted to impose additional obligations and liabilities on holders of our Ordinary Shares that are not typically imposed on shareholders of U.S. corporations.

 

It may be difficult to enforce a judgment of a U.S. court against us, or against our officers and directors in Israel, or to assert U.S. securities laws claims in Israel or to serve process on our officers and directors in Israel.

 

We were incorporated in Israel. A majority of our executive officers and directors reside outside of the United States, and some of our assets and most of the assets of these persons are located outside the United States. Therefore, a judgment obtained against us, or any of these persons, including a judgment based on the civil liability provisions of the U.S. federal securities laws, may not be collectible in the U.S. and may not necessarily be enforced by an Israeli court. It also may be difficult to affect service of process on these persons in the United States or to assert U.S. securities law claims in original actions instituted in Israel. Additionally, it may be difficult for an investor, or any other person or entity, to initiate an action with respect to U.S. securities laws in Israel. Israeli courts may refuse to hear a claim based on an alleged violation of U.S. securities laws reasoning that Israel is not the most appropriate forum in which to bring such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proven as a fact by expert witnesses, which can be a time consuming and costly process. Certain matters of procedure will also be governed by Israeli law. There is little binding case law in Israel that addresses the matters described above. As a result of the difficulty associated with enforcing a judgment against us in Israel, you may not be able to collect any damages awarded by either a U.S. or foreign court.

 

30

 

 

Provisions of Israeli law and our Amended Articles may delay, prevent or otherwise impede a merger with, or an acquisition of, us, even when the terms of such a transaction are favorable to us and our shareholders.

 

Israeli corporate law regulates mergers, requires tender offers for acquisitions of shares above specified thresholds, requires special approvals for transactions involving directors, officers or significant shareholders and regulates other matters that may be relevant to such types of transactions. For example, a tender offer for all of a company’s issued and outstanding shares can only be completed if the acquirer receives positive responses from the holders of at least 95% of the issued share capital and the approval of a majority of the offerees that do not have a personal interest in the tender offer, unless at least 98% of the company’s outstanding shares are tendered. Furthermore, the shareholders, including those who indicated their acceptance of the tender offer (unless the acquirer stipulated in its tender offer that a shareholder that accepts the offer may not seek appraisal rights), may, at any time within six months following the completion of the tender offer, petition an Israeli court to alter the consideration for the acquisition. In addition, a merger may not be consummated unless at least 50 days have passed from the date on which a proposal for approval of the merger was filed by each party with the Israeli Registrar of Companies and at least 30 days have passed from the date on which the merger was approved by the shareholders of each party. See “Provisions Restricting Change in Control in our Company” for additional information.

 

Furthermore, Israeli tax considerations may make potential transactions unappealing to us or to our shareholders whose country of residence does not have a tax treaty with Israel exempting such shareholders from Israeli tax. For example, Israeli tax law does not recognize tax-free share exchanges to the same extent as U.S. tax law. With respect to mergers, Israeli tax law allows for tax deferral in certain circumstances but makes the deferral contingent on the fulfillment of a number of conditions, including, in some cases, a holding period of two years from the date of the transaction during which sales and dispositions of shares of the participating companies are subject to certain restrictions. Moreover, with respect to certain share swap transactions, the tax deferral is limited in time, and when such time expires, the tax becomes payable even if no disposition of the shares has occurred.

 

We received Israeli government grants for certain of our research and development activities. The terms of those grants may require us to pay royalties and to satisfy specified conditions in order to manufacture products and transfer technologies outside of Israel. We may be required to pay penalties in addition to repayment of the grants.

 

From inception through December 31, 2020, we have been awarded an aggregate of $272,237 in the form of grants from Israel Innovation Authority, or the IIA, formerly known as Israel’s Office of the Chief Scientist of the Ministry of Economy. The requirements and restrictions for such grants are found in the Israeli Encouragement of Research and Development Law, 5744-1984 and the regulations thereunder (the “Research Law”). Under the Research Law, royalties of 3% to 5% on the revenues derived from sales of products or services developed in whole or in part using these IIA grants are payable to the Israeli government. We developed our technologies, at least in part, with funds from these grants, and accordingly we would be obligated to pay these royalties on sales of any of our product candidates that achieve regulatory approval. The maximum aggregate royalties paid generally cannot exceed 100% of the grants made to us, plus annual interest equal to the 12-month LIBOR applicable to dollar deposits, as published on the first business day of each calendar year. As of December 31, 2020, we had not paid any royalties to the IIA. In 2020, we did not receive a grant from the IIA. When a company develops know-how, technology or products using IIA grants, the terms of these grants and the Research Law restrict the transfer of such know-how, and the transfer of manufacturing or manufacturing rights of such products, technologies or know-how outside of Israel, without the prior approval of the IIA. Therefore, the discretionary approval of an IIA committee would be required for any transfer to third parties inside or outside of Israel of know-how or manufacturing or manufacturing rights related to those aspects of such technologies. We may not receive those approvals. Furthermore, the IIA may impose certain conditions on any arrangement under which it permits us to transfer technology or development out of Israel, including an increased royalty rate.

 

The transfer of IIA-supported technology or know-how outside of Israel may involve the payment of significant amounts, depending upon the value of the transferred technology or know-how, our research and development expenses, the amount of IIA support, the time of completion of the IIA-supported research project and other factors. These restrictions and requirements for payment may impair our ability to sell or otherwise transfer our technology assets outside of Israel or to outsource or transfer development or manufacturing activities with respect to any product or technology outside of Israel. Furthermore, the consideration available to our shareholders in a transaction involving the transfer outside of Israel of technology or know-how developed with IIA funding (such as a merger or similar transaction) may be reduced by any amounts that we are required to pay to the IIA.

 

These restrictions will continue to apply even after we have repaid the full amount of royalties on the grants. For the years ended December 31, 2020 and 2019, we did not apply for or receive any grants from the IIA.

 

31

 

 

Risks Related to Our Ordinary Shares

 

The sale or issuance of our Ordinary Shares to Lincoln Park may cause dilution and the sale of the Ordinary Shares acquired by Lincoln Park, or the perception that such sales may occur, could cause the price of our Ordinary Shares to fall.

 

On August 4, 2020, we entered into a Purchase Agreement with Lincoln Park Capital, pursuant to which Lincoln Park has committed to purchase up to $10,000,000 of our Ordinary Shares. Upon the execution of the Purchase Agreement, we issued 5,812,500 Commitment Shares to Lincoln Park, and Lincoln Park purchased 3,437,500 Initial Purchase Shares. The remaining 40,750,000 Ordinary Shares that may be issued under the Purchase Agreement may be sold by us to Lincoln Park at our discretion from time to time over a 36-month period commencing after the satisfaction of certain conditions set forth in the Purchase Agreement, including the SEC declaring effective a registration statement that includes the shares included in the Purchase Agreement, which registration statement was declared effective on August 18, 2020. The purchase price for the Ordinary Shares that we may sell to Lincoln Park under the Purchase Agreement will fluctuate based on the price of our Ordinary Shares. Depending on market liquidity at the time, sales of such shares may cause the trading price of our Ordinary Shares to fall.

 

We generally have the right to control the timing and amount of any future sales of our shares to Lincoln Park. Sales of our Ordinary Shares, if any, to Lincoln Park will depend upon market conditions and other factors to be determined by us. We may ultimately decide to sell to Lincoln Park all, some or none of the additional Ordinary Shares that may be available for us to sell pursuant to the Purchase Agreement. If and when we do sell shares to Lincoln Park, after Lincoln Park has acquired the shares, Lincoln Park may resell all, some or none of those shares at any time or from time to time in its discretion. Therefore, sales to Lincoln Park by us could result in substantial dilution to the interests of other holders of our Ordinary Shares. Additionally, the sale of a substantial number of our Ordinary Shares to Lincoln Park, or the anticipation of such sales, could make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish to effect sales.

 

We may not have access to the full amount available under the Purchase Agreement with Lincoln Park.

 

Under our Purchase Agreement with Lincoln Park, we may, at our discretion from time to time over a 24-month period commencing after the satisfaction of certain conditions set forth in the Purchase Agreement, on any single business day on which the closing price of our Ordinary Shares is above $.02 per share (subject to adjustment for any reorganization, recapitalization, non-cash dividend, share split, or other similar transaction as provided in the Purchase Agreement), direct Lincoln Park to purchase our Ordinary Shares in amounts up to 500,000 shares, which amounts may be increased to up to 1,000,000 shares depending on the market price of our Ordinary Shares at the time of sale and subject to a maximum commitment by Lincoln Park of $500,000 per single regular purchase.

 

Depending on the market prices of our Ordinary Shares at the time we elect to issue and sell shares to Lincoln Park under the Purchase Agreement, we may need to register for resale under the Securities Act additional Ordinary Shares in order to receive aggregate gross proceeds equal to the $10,000,000 total commitment available to us under the Purchase Agreement. Assuming a purchase price of $0.064 per share (the closing sale price of the Ordinary Shares on January 13, 2022), total gross proceeds to us would only be $2,608,000. As of January 13, 2022, we had issued an aggregate of 37,977,388 Ordinary Shares to Lincoln Park, at prices ranging from $0.038 to $0.115 per shares for total gross proceeds of approximately $2,593,725.

 

The extent we rely on Lincoln Park as a source of funding will depend on a number of factors, including the prevailing market price of our Ordinary Shares and the extent to which we are able to secure working capital from other sources. If obtaining sufficient funding from Lincoln Park were to prove unavailable or prohibitively dilutive, we will need to secure another source of funding in order to satisfy our working capital needs. If we elect to issue and sell more than 50,000,000 shares, which we have the right, but not the obligation, to do, we must first register for resale under the Securities Act any such additional shares, which could cause additional substantial dilution to our shareholders. Even if we sell all $10,000,000 under the Purchase Agreement to Lincoln Park, we may still need additional capital to fully implement our business, operating and development plans. Should the financing we require to sustain our working capital needs be unavailable or prohibitively expensive when we require it, the consequences could be a material adverse effect on our business, operating results, financial condition and prospects.

 

32

 

 

Future issuance of our Ordinary Shares could dilute the interests of existing shareholders.

 

We may issue additional Ordinary Shares in the future. The issuance of a substantial number of Ordinary Shares could have the effect of substantially diluting the interests of our shareholders. In addition, the sale of a substantial amount of Ordinary Shares in the public market, in the initial issuance, in a situation in which we acquire a company, and the acquired company receives Ordinary Shares as consideration and the acquired company subsequently sells its Ordinary Shares, or by investors who acquired such Ordinary Shares in a private placement, could have an adverse effect on the market price of our Ordinary Shares.

 

Sales of a substantial number of our Ordinary Shares in the public market by our existing shareholders could cause our share price to fall.

 

Sales of a substantial number of shares of our Ordinary Shares in the public market, or the perception that these sales might occur, could depress the market price of our Ordinary Shares and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect that sales may have on the prevailing market price of our Ordinary Shares. Sales of shares by these shareholders could have a material adverse effect on the trading price of our Ordinary Shares. We intend to register the offering, issuance, and sale of all Ordinary Shares that we may issue under our equity compensation plans. Once we register these shares, they can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates and any lock-up agreements. Also, we are required to register the shares that would result from (a) the conversion of certain convertible notes we issued in 2021, and (b) the exercise of certain warrants we issued alongside convertible notes in 2020 and 2021. The sales of a significant number of those shares could have a depressant effect on our share price.

 

Until December 31, 2021, we were an Emerging Growth Company, which may have reduced the amount of information available to investors.

 

Until December 31, 2021, we were an Emerging Growth Company. The Jumpstart Our Business Start-ups Act, or the JOBS Act, allowed us to postpone the date by which we must comply with some of the laws and regulations intended to protect investors and to reduce the amount of information we provided in our reports filed with the SEC, which could have adversely undermined investor confidence in our company and adversely affected the market price of our Ordinary Shares. Because we have not yet filed a periodic report since our Emerging Growth Company status expired, we have not yet complied with the above-mentioned laws and regulations.

 

For as long as we remained an “emerging growth company” as defined in the JOBS Act, we took advantage of certain exemptions from various requirements that are applicable to public companies that are not emerging growth companies including:

 

  the provisions of the Sarbanes-Oxley Act requiring that our independent registered public accounting firm provide an attestation report on the effectiveness of our internal control over financial reporting;
     
  Section 107 of the JOBS Act, which provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, or the Securities Act, for complying with new or revised accounting standards. This means that an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We may elect to delay such adoption of new or revised accounting standards. As a result of this adoption, our financial statements may not be comparable to companies that comply with the public company effective date; and
     
  any rules that may be adopted by the Public Company Accounting Oversight Board requiring mandatory audit firm rotation or a supplement to the auditor’s report on the financial statements.

 

We took advantage of these exemptions until we were no longer an “emerging growth company.” We were an emerging growth company until the last day of the fiscal year ending on December 31, 2021.

 

33

 

 

We have never paid cash dividends on our Ordinary Shares, and we do not anticipate paying any dividends in the foreseeable future. Consequently, any gains from an investment in our Ordinary Shares will likely depend on whether the price of our Ordinary Shares increases, which may not occur.

 

We have not paid cash dividends on any of our share capital to date and we currently intend to retain our future earnings, if any, to fund the development and growth of our business. In addition, the Companies Law imposes restrictions on our ability to declare and pay dividends. As a result, capital appreciation, if any, of our Ordinary Shares will be your sole source of gain for the foreseeable future. Consequently, in the foreseeable future, you will likely only experience a gain from your investment in our Ordinary Shares if the price of our Ordinary Shares increases beyond the price in which you originally acquired the Ordinary Shares.

 

The potential future application of the SEC’s “penny stock” rules to our Ordinary Shares could limit trading activity in the market, and our shareholders may find it more difficult to sell their shares.

 

If our Ordinary Shares trade at less than $5.00 per share we will be subject to the SEC’s penny stock rules. Rule 15g-9 under the Exchange Act establishes the definition of a “penny stock,” for the purposes relevant to us, as any equity security that has a market price of less than $5.00 per share or with an exercise price of less than $5.00 per share, subject to certain exceptions. For any transaction involving a penny stock, unless exempt, the rules require: (a) that a broker or dealer approve a person’s account for transactions in penny stocks; and (b) the broker or dealer receive from the investor a written agreement to the transaction, setting forth the identity and quantity of the penny stock to be purchased.

 

In order to approve a person’s account for transactions in penny stocks, the broker or dealer must: (a) obtain financial information and investment experience objectives of the person and (b) make a reasonable determination that the transactions in penny stocks are suitable for that person and the person has sufficient knowledge and experience in financial matters to be capable of evaluating the risks of transactions in penny stocks.

 

The broker or dealer must also deliver, prior to any transaction in a penny stock, a disclosure schedule prescribed by the SEC relating to the penny stock market, which, in highlight form: (a) sets forth the basis on which the broker or dealer made the suitability determination; and (b) confirms that the broker or dealer received a signed, written agreement from the investor prior to the transaction. Generally, brokers may be less willing to execute transactions in securities subject to the “penny stock” rules. This may make it more difficult for investors to dispose of our Ordinary Shares and cause a decline in the market value of our Ordinary Shares.

 

Disclosure also has to be made about the risks of investing in penny stocks in both public offerings and in secondary trading and about the commissions payable to both the broker or dealer and the registered representative, current quotations for the securities and the rights and remedies available to an investor in cases of fraud in penny stock transactions. Finally, monthly statements have to be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stocks.

 

The market price of our Ordinary Shares may be volatile.

 

The market price of our Ordinary Shares may be highly volatile. Some of the factors that may materially affect the market price of our Ordinary Shares are beyond our control, such as changes in financial estimates by industry and securities analysts, conditions or trends in the industry in which we operate or sales of our Ordinary Shares. These factors may materially adversely affect the market price of our Ordinary Shares, regardless of our performance. In addition, the public stock markets have experienced extreme price and trading volume volatility. This volatility has significantly affected the market prices of securities of many companies for reasons frequently unrelated to the operating performance of the specific companies. These broad market fluctuations may adversely affect the market price of our Ordinary Shares.

 

34

 

 

Our executive officers, directors and principal shareholders will maintain the ability to exert significant control over matters submitted to our shareholders for approval.

 

Our executive officers, directors and principal shareholders who own more than 5% of our outstanding Ordinary Shares beneficially own shares representing approximately 17.63% of our share capital. As a result, if these shareholders were to act together, they would be able to control all matters submitted to our shareholders for approval, as well as our management and affairs. For example, these persons, if they act together, could control the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration of voting power could delay or prevent an acquisition of our company on terms that other shareholders may desire or may result in management of our company being appointed despite our other shareholders’ disapproval.

 

If securities or industry analysts do not publish or cease publishing research or reports about us, our business or our market, or if they adversely change their recommendations or publish negative reports regarding our business or our shares, our share price and trading volume could decline.

 

The trading market for our Ordinary Shares will be influenced by the research and reports that industry or securities analysts may publish about us, our business, our market or our competitors. We do not have any control over these analysts, and we cannot provide any assurance that analysts will cover us or provide favorable coverage. If any of the analysts who may cover us adversely change their recommendation regarding our shares, or provide more favorable relative recommendations about our competitors, our share price would likely decline. If any analyst who may cover us were to cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause our share price or trading volume to decline.

 

35

 

 

USE OF PROCEEDS

 

This prospectus relates to our ordinary shares that may be offered and sold from time to time by the selling shareholders. We will receive no proceeds from the sale of ordinary shares by the selling shareholders in this offering. However, we may receive the proceeds of any exercise by certain of the selling shareholders of warrants owned by them.

 

We intend to use the net proceeds for research and development of our cancer detection kits, and for general corporate purposes, including working capital needs. We may also use such proceeds for potential acquisitions in complementary businesses, although we do not currently have any agreement or understanding with respect to an acquisition in which we plan to invest such proceeds.

 

We will not be paying any underwriting discounts or commissions in offerings under this prospectus. The selling shareholders will bear discounts or commissions, if any, attributable to their sale or disposition of the ordinary shares. Other than in connection with our indemnification obligations with respect to the selling shareholders, we will bear all costs, expenses and fees in connection with the registration of the shares (which do not include the fees and expenses of any selling shareholder counsel).

 

36

 

 

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND

RESULTS OF OPERATIONS

 

The following discussion and analysis should be read in conjunction with our financial statements and related notes, which have been publicly filed with the Securities Exchange Commission and are included with this prospectus. This discussion and other parts of this offering memorandum contain forward-looking statements based upon current expectations that involve risks and uncertainties. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth under “Risk Factors” and elsewhere in this offering memorandum. We report financial information under US GAAP and our financial statements were prepared in accordance with generally accepted accounting principles in the United States.

 

Overview

 

Todos Medical is an in-vitro-diagnostic (“IVD”) firm engaging in the development and commercialization of a series of patient-friendly blood tests that enable screening of a variety of cancers. Detecting cancer at an early stage may lead to more effective treatment and possible better survival rate. Our goal is to establish our name in the cancer detection industry worldwide. Our cancer tests are still in the development phase, have not yet been approved by the FDA and are not yet being marketed.

 

Screening tests for cancer, specifically breast, colon and lung cancers, have compliance shortcomings due to their scientific limitations, invasive procedures, and expensive nature of more accurate diagnostic methods. More importantly, many of the most effective diagnostic methods remain too expensive for adoption as screening tests for all those at risk are used too rarely and not quickly enough to allow for the most effective treatment. Blood based tests are the future of cancer screening.

 

Our Provista Diagnostics Laboratory serves as a hub for our diagnostic development programs, including our flagship Videssa blood test, as well as support for our automation solutions customers.

 

Diagnostic testing helps health care providers screen for or monitor specific diseases or conditions. It also helps assess patient health to make clinical decisions for patient care. Our Provista Diagnostics Laboratory is approved under the Clinical Laboratory Improvement Amendments (CLIA). The Clinical Laboratory Improvement Amendments (CLIA) regulate laboratory testing and require clinical laboratories to be certified by the Center for Medicare and Medicaid Services (CMS) before they can accept human samples for diagnostic testing. Laboratories can obtain multiple types of CLIA certificates, based on the kinds of diagnostic tests they conduct.

 

We have also focused our COVID-19 diagnostic testing efforts at Provista to prioritize delivering diagnostic services, including PCR and neutralizing antibody testing, becoming a direct provider to healthcare professionals.

 

This expansion into testing services allows us to diversify our business into higher margin revenue in the COVID-19 space, as well as help us to expand our business development opportunities with the labs we work with by providing reference lab testing services as we increase Provista’s automated testing capabilities. The Company intends to build Provista into a highly automated lab capable of running multiple platforms in parallel in order to offer clients comprehensive testing solutions that meet their needs, especially in cancer, infectious disease, immune monitoring and Alzheimer’s disease.

 

The Company is also a developer and distributor of immune support products and antivirals that target the inhibition of 3CL protease for the treatment of Covid-19. Todos has acquired exclusive distribution rights to the dietary supplement Tollovid™. Tollovid is a powerful proprietary blend of plant extracts that help support healthy immune function for today’s challenges.

 

Todos is also developing a more concentrated version of Tollovid for COVID-19 infected patients, using a proprietary blend of botanical extracts with an active chemical ingredient that limits replication of coronaviruses. Todos is currently supporting randomized, placebo-controlled clinical trials managed by joint venture partner NLC Pharma in Israel. Tollovir is the result of over 15 years of development and an investment of over $18 million to date.

 

37

 

 

Videssa Breast

 

Current methods of breast cancer detection have known limitations, particularly in women with abnormal or difficult-to-interpret imaging findings. While clinical examination and imaging technologies are critical elements for detecting breast cancer, the high rate of false positive and false negative results from these approaches can significantly impact patient care. In an effort to improve the accuracy of early breast cancer detection, complementary blood-based approaches are being developed to help address the current limitations of breast imaging. By utilizing new detection strategies, healthcare providers will be able to improve the accuracy of breast cancer detection and minimize the consequences of false positive and false negative results. To help address the diagnostic challenges in breast cancer, we developed Videssa Breast—the first blood test of its kind to detect the presence or absence of breast cancer in women with abnormal or difficult-to-interpret imaging findings. When combined with imaging, Videssa Breast improves diagnostic accuracy and provides greater confidence and clarity when clinical assessment is challenging.

 

Videssa Breast was developed to provide physicians with actionable information regarding breast cancer risk in women following an inconclusive mammogram result (BI-RADS III or IV), which primarily occurs in women with dense breasts. The data provided from the test, which has demonstrated specificity of ~99% in both women over and under 50 years of age, arms physicians with a powerful tool to help guide decisions of whether to continue to monitor a low-risk patient intermittently, or whether to advance an at-risk patient immediately into a more expensive and invasive diagnostic assessment that likely includes a breast biopsy. With Videssa as the proprietary centerpiece of our cancer diagnostic strategy, we will be looking to offer highly advanced, comprehensive cancer testing solutions to OB-GYNs, general practitioners and other stakeholders in the medical community who will ultimately be managing patients likely to be strong candidates for Videssa.

 

Videssa Breast combines multiple Serum Protein Biomarkers (SPBs) and Tumor-Associated Autoantibodies (TAAbs), along with patient clinical data, to generate a unique protein signature for breast cancer. As these protein biomarkers are released into the bloodstream, they act as biological cues for the presence of a malignancy, providing a snapshot of what’s going on inside of a woman’s body to complement the anatomical features visible on imaging. Unlike genetic testing which determines the future risk of developing breast cancer, Videssa Breast is designed to detect real-time disease status. By identifying early biochemical warning signals of breast cancer in the bloodstream, such as “protein biomarkers,” Videssa Breast provides information not detectable through imaging technologies, allowing for a more comprehensive assessment.

 

LymPro Test™:

 

The Lymphocyte Proliferation (LymPro) Test™ measures markers of immune cells present in the blood as a surrogate for loss of nerve cell function and the toxic accumulation of beta-amyloid plaques in the brain, which is a hallmark of Alzheimer’s disease. Based on differences observed in the response of cells from patients with Alzheimer’s disease as compared with age-matched controls and patients with other dementias, it appears that the test has high potential as an adjunctive diagnostic for Alzheimer’s disease. LymPro exploits the fact that abnormalities in replication (or the cell cycle) seem to extend to immune cells in the blood. The test specifically measures the alterations in cell cycle activity in blood lymphocytes (a type of immune cell) as a biomarker of neuronal damage, for the early identification and screening of Alzheimer’s. Areas for deployment include initial Investigational Use Only (“IUO”) testing followed by full diagnostic testing for patients with mild cognitive impairment (“MCI”) and dementia for differential diagnosis. Todos owns the exclusive worldwide rights to this Alzheimer’s blood test as a result of its acquisition of Breakthrough from Amarantus as follows. On February 27, 2019, we entered into a joint venture agreement with Amarantus, pursuant to which we issued Ordinary Share representing 19.99% of our then outstanding Ordinary Shares to Amarantus, in exchange for Amarantus transferring to us 19.99% of Breakthrough, then a wholly-owned subsidiary of Amarantus, and for Amarantus assigning the license for the LymPro test to Breakthrough. As part of the transaction, we agreed to provide working capital to Breakthrough to support Breakthrough’s operations. As part of the Breakthrough joint venture, we were granted an exclusive option to acquire the remaining 80.01% of Breakthrough from Amarantus. At our 2019 annual meeting of shareholders, our shareholders approved a resolution authorizing us to exercise our option to acquire the remaining 80.01% of Breakthrough from Amarantus in exchange for an additional 30% of our then issued and outstanding Ordinary Shares. We closed the acquisition of Breakthrough in July 2020.

 

38

 

 

There are a few blood-based approaches to Alzheimer’s, most of which focus on identifying canonical Alzheimer’s markers – Amyloid or Tau. The rationale for these tests is that they serve as a proxy for brain concentration Amyloid and Tau-based imaging. Given the failure of these two mechanisms to demonstrate improvement across hundreds of clinical trials, we believe that looking upstream from Amyloid and Tau is where both true diagnostic and therapeutic avenues exist. LymPro captures both Amyloid and Tau-based information by proxy. Given the expectation that the Alzheimer’s therapeutic market could reach $13.57 billion by 20271, we believe LymPro could also help drive mid-term value for Todos as progress is made. Taken together with our core patented Todos Biochemical Infrared Analyses (“TBIA”), which uses a platform based upon a highly sensitive mid infrared equipment called fourier transform infrared spectrometers (“FTIR”), we believe Todos is positioned to become a worldwide leader in the field of immune-based diagnostics.

 

COVID-19 Proprietary Lab and Distribution Business:

 

We provide advanced technologies addressing bottlenecks, whether they be scientific, technical or logistical, to enable laboratories to rapidly expand testing capacity while reducing operational costs. To forward this business, we entered into distribution agreements with multiple companies (such as 3D Biomedicine Science and Technology Col. Ltd., Meridian Health Services Network, Inc., and PCL Inc.) to gain rights to rapid IgM/IgG COVID-19 antibody test kits, RNA extraction machines, RNA extraction reagents, qPCR reagents, digital PCR reagents and automated liquid handler machines, in order to offer a comprehensive suite of solutions to laboratories worldwide. In the second quarter of 2020, we began marketing a turnkey automation services solution to laboratories seeking to expand their COVID-19 testing capabilities and started generating revenue from the distribution of products to support laboratory COVID testing through the automated machinery we provided.

 

Our Provista Diagnostics Laboratory serves as a hub for our diagnostic development programs, including our flagship Videssa blood test, as well as support for our automation solutions customers. We have focused our COVID-19 diagnostic testing efforts at Provista to prioritize delivering diagnostic services, including PCR and neutralizing antibody testing, becoming a direct provider to healthcare professionals. We have partnered with Fosun Pharma to offer the first neutralizing antibody test, cPass™ SARS-CoV-2 Neutralizing Antibody Detection Kit, which has received Emergency Use Authorization (“EUA”) from the US FDA for the detection of SARS-CoV-2 receptor binding domain (“RBD” or “neutralizing”) antibodies. We believe this test can serve as a key marker for physicians, businesses and schools to access Covid-19 immunity risk among their populations. This expansion into testing services allows us to diversify our business into higher margin revenue in the COVID-19 space, as well as help us to expand our business development opportunities with the labs we work with by providing reference lab testing services as we increase Provista’s automated testing capabilities. The Company intends to build Provista into a highly automated lab capable of running multiple platforms in parallel in order to offer clients comprehensive testing solutions that meet their needs, especially in cancer, infectious disease, immune monitoring and Alzheimer’s disease.

 

With the Delta variant posing a significant risk for breakthrough infections, we see neutralizing antibody testing becoming critical for informed decision making to assess who may be best suited for booster shots, as well as at what point someone previously infected with COVID begins to show waning immunity and may decide to receive vaccination as a result. We see a large market opportunity developing for the cPass™ SARS-CoV-2 Neutralizing Antibody Detection Kit that we believe will begin to encroach on the COVID-19 PCR testing market. The cPass test will enable individuals to take charge of their health by making data-driven decisions to protect themselves beyond vaccination, such as masking or avoiding certain higher-risk activities when armed with this crucial information. A key differentiator for this novel cPass test is that it detects neutralizing antibodies in patient samples without the use of live virus and with very fast turnaround times, as compared to the conventional method of measuring neutralizing antibodies in patient samples, which requires the use of live cells. We believe immune monitoring will be the primary driver of COVID-19 testing growth going forward. As time advances, and more individuals are several months from their initial vaccine dose, it will become increasingly important for individuals and healthcare providers to assess and monitor neutralizing antibody levels in order to make data-driven decisions with respect to booster shots and behavioral changes. We are currently in the process of automating the cPass test at our laboratory, Provista Diagnostics, to add high-capacity neutralizing antibody testing to its test menu. Provista plans to offer cPass as a testing service to other CLIA labs on a reference basis, as well as directly to the public through healthcare professionals.

 

1https://www.medgadget.com/2021/01/alzheimers-therapeutics-market-to-reach-usd-13-57-billion-by-2027-size-share-industry-

analysis-and-global-forecast-to-2027.html

 

39

 

 

We intend to focus on ways of leveraging our existing testing business and our client base to deliver actionable high value testing that will improve outcomes while lowering cost of care. We believe that our establishment of a strong commercial infrastructure is the key to unlocking the value of our intellectual property portfolio for our Company and its shareholders.

 

TBIA Platform

 

Todos Medical’s TBIA platform represents a cost effective, scalable, and patient-friendly screening method for cancer screening. Todos has developed the “Total Biochemical Infrared Analysis” (TBIA) method, a proprietary method for screening of solid tumors using peripheral blood spectroscopy analysis. The process involves observing the immune system’s response to tumor presence rather than looking for the tumor cells themselves or specific markers. TBIA analyzes the entire biochemical signatures spectrum (including proteins, lipids, nucleic acids and carbohydrates) of affected immune cells from peripheral blood, using infrared spectroscopy.

 

Advances in mid infrared spectroscopy using fourier transform infrared spectrometers (FTIR) open new diagnostic frontiers
   
Immune system changes detected in plasma and mononuclear cells via FTIR
   
Immune response acts as body’s sensor for cancer
   
FTIR allows observation of distinct immune response to breast, colorectal, lung and other cancer types

 

The test offered under our TBIA method could help reduce false positives and improve detection rate by reporting to the physician the probability of the presence/absence of cancer prior to more expensive tests. A large, underserved population of unscreened and inadequately screened patients represents a significant opportunity for a patient friendly screening test. Furthermore, traditional tests are more likely to expose patients to radiation and other risks inherent in those tests, our products offer may become a viable solution for these patients, as it is a simple blood test.

 

Each of the existing screening diagnosis methods have at least one of the following significant drawbacks:

 

- Expensive
- Low sensitivity or specificity
- Uncomfortable to use
- Not accessible to the general public
- Require specialists for results interpretation
- Possible medical side effects from radiation and invasive tests

 

Many patients who need to be checked regularly for cancer, avoid undertaking periodic examinations due to one or more of the above disadvantages. The objective of our Company is to provide a more reliable alternative to the current methods of testing and to thereby overcome patients’ fear of regular cancer checkups, leveraging our proprietary technology in TBIA.

 

40

 

 

Despite the various indications of the positive potential of our products, in order to establish our product in the market we still need to conduct larger and more focused blind trials and we need to invest in a large-scale validation blind trial on the same cancer to confirm these preliminary results.

 

Our test is for cancer screening and cannot be regarded as a final diagnosis. However, it only requires a simple blood test causing minor risk and pain (as below diagram demonstrates). Following the results of the test for positive or negative for specific cancer, the physician will refer the patient for additional screenings such as colonoscopy for further examination of cancer presence.

 

Immune Support Products and 3CL Protease Inhibiting Antivirals

 

The Company entered into a joint venture with Israeli-based biotech company, NLC Pharma, to advance a theragnostic program targeting the 3CL protease, a key enzyme required for coronaviruses to replicate and infect other cells. We have funded the development of a novel enzymatic 3CL protease diagnostic test that determines whether a coronavirus is actively replicating vs. inactively being cleared from the body by the immune system, as well as 3CL protease inhibitors that aim to slow the replication of the virus in order to be able to further support the body’s ability to be able to overcome a potential coronavirus exposure or infection.

 

Tollovir:

 

Furthermore, the partnership is in the development phase of our own antiviral, Tollovir™, a potent 3CL protease inhibitor for the treatment of hospitalized COVID-19 patients, which is currently undergoing a Phase 2 clinical trial in Israel with plans to expand the clinical development program to India.

 

In light of the emerging delta variant circulating widely worldwide, there is now a clear need for novel COVID-19 anti-viral therapies to protect the unvaccinated and those for whom authorized vaccines do not confer immunity, which includes a large portion of the elderly and those taking immune suppressants, against COVID-19 infection. In the United States, the Biden administration recently underscored this need by pledging to invest $3.2 billion into research for COVID-19 anti-viral therapies, similar to the US Government’s investments into COVID-19 vaccines in 2020 at the beginning of the pandemic. We believe this government recognition of the need for antivirals will provide a significant tailwind for the development of our Tollovir™ anti-viral that is currently undergoing a Phase 2 clinical trial in Israel with plans progressing rapidly to expand the clinical development program to India. As part of the ongoing scientific effort to further elucidate the mechanisms that have enabled Tollovir to achieve its very positive early clinical results, NLC Pharma identified an anti-inflammatory mechanism of action of Tollovir to complement its 3CL protease inhibiting mechanism. This dual mechanism of action helps explain the significant reduction in symptoms and the biomarker C Reactive Protein (CRP) that was documented in the earliest clinical COVID-19 data sets produced in Israel, which could not be explained by a reduction in viral load alone likely caused by Tollovir’s 3CL protease inhibiting mechanism. As a result of these quite complementary 3CL protease inhibiting and anti-inflammatory mechanisms, given that we are in a race with Pfizer to get to market with the first 3CL protease inhibiting COVID-19 antiviral for which therapeutic claims could be made, we believe it is critical to rapidly expand our clinical development programs to gather additional data in multiple clinical settings to demonstrate Tollovir’s ability to help patients suffering from COVID-19. As part of that effort, our Israel-based Principal Investigators have introduced us to physician clinical collaborators in India who work with a highly-respected local Clinical Research Organization (CRO) with extensive experience in running COVID-19 clinical trials. This CRO has near-immediate access to 6 clinical sites that have previously enrolled patients into clinical trials for hospitalized COVID-19 patients and 5 clinical sites that have previously enrolled patients into clinical trials for non-hospitalized COVID-19 patients. We believe this CRO relationship will allow for the rapid expansion of enrollment for Tollovir’s clinical data acquisition, and allow us to quickly prepare for a Phase 3 international clinical development program to support regulatory approval under Emergency Use Authorization.

 

Tollovid: